Module 5 — GLP-1 Backbone + Lean-Mass Preservation Stack Protocol

Stack-protocol integration view. This is the operational integration protocol for the most common real-world Module 5 multi-compound regimen: a GLP-1 RA backbone (semaglutide / tirzepatide / retatrutide) plus the CJC-1295 (without DAC; Mod-GRF 1-29) + Ipamorelin + MOTS-c lean-mass-preservation adjunct stack. The unit of analysis is the combination, not the individual compounds. Each constituent compound has its own dedicated standalone protocol covering compound-level pharmacology, screening, workup, initiation, maintenance, side-effect management, and discontinuation; this protocol covers the integration — sequencing, timing within the weight-loss arc, dose adjustments between backbone and adjunct, surveillance unique to the stacked regimen, contraindications that emerge only in combination, patient counseling for the multi-compound regimen, and the discontinuation/transition logic for the regimen as a whole.

Three backbone options framed per Anchor 4 multi-dimensional comparator. This protocol does not advocate one backbone — it presents three: semaglutide (Wegovy 2.4 mg or Wegovy HD 7.2 mg) [[Semaglutide Protocol]], tirzepatide (Zepbound 15 mg) [[Tirzepatide Protocol]], and retatrutide (12 mg per TRIUMPH-4 sponsor disclosure; pre-FDA-approval-for-marketing-claims as of 2026-05-14) [[Retatrutide Protocol]]. Backbone selection is phenotype-guided per the multi-dimensional comparator framework in §4 and §10.5.

Single adjunct stack. The lean-mass adjunct is the CJC-1295 (without DAC; Mod-GRF 1-29) + Ipamorelin + MOTS-c stack documented in [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]]. The without-DAC form is specified; the with-DAC form is a different pharmacologic profile used in different clinical contexts (§9.5 alternative discussion). All three adjunct compounds are research-state — NOT FDA-approved-for-marketing-claims for any drug indication; available through 503A compounding pharmacies under the post-2023 FDA Category 2 listing variation.

Pattern Z Anchor 5 (off-label / extrapolation transparency) is DOMINANT. The entire adjunct stack overlay on an FDA-approved-for-marketing-claims GLP-1 backbone (sema/tirz) — or on an investigational backbone (reta) — is off-label combined-regimen use. §10.6 is the largest §10 subsection. Pattern AA.marketing-claims precision throughout: the backbone is FDA-approved-for-marketing-claims for its labeled indications (Wegovy CWM; Zepbound CWM/OSA) OR pre-FDA-approval (retatrutide pending TRIUMPH Phase 3 program); the adjunct stack is research-state with no FDA-approved-for-marketing-claims version of any of the three compounds.

Sequencing question is load-bearing. When does the adjunct stack start — at GLP-1 initiation, after titration to maintenance, or only when DEXA shows lean-mass-loss fraction >25–30%? This protocol covers each clinical-decision branch in §4 (initiation) and §9 (combination operational core), with phenotype-guided branching across three phenotype categories: sarcopenic-baseline / older adult; female athletes and athletic / high-baseline-lean-mass; post-50lb-loss patients approaching maintenance.

IGF-1 surveillance is the load-bearing safety overlay. The GH-axis component of the adjunct stack (CJC-1295 + Ipamorelin) elevates IGF-1 as its intended pharmacologic effect; the question is not “does IGF-1 elevate” (yes — that is the mechanism) but “is the elevation within the upper-quartile-of-reference target (Z 0 to +1) vs supraphysiologic; what does the elevation mean for cancer surveillance and glucose tolerance in the stacked regimen.” §6.10 develops the three-pillar surveillance framework (Renehan 2004 PMID 15110491 observational signal + Child 2022 PMID 35368070 GH-replacement cohort + Boguszewski 2022 PMID 35319491 consensus statement) adapted for the stacked context where the GLP-1 backbone is the dominant weight-loss driver and the adjunct stack is the lean-mass-preservation overlay.

§9 IS the protocol. This protocol IS the combination. Section 9 is the load-bearing operational section: it codifies sequencing relative to the GLP-1 RA backbone, timing within the weight-loss arc, duration discipline for the adjunct cycles, and discontinuation pathway after lean-mass goal is achieved. Sections 1–8 set up the stack-protocol indication scope, selection criteria, workup, initiation, maintenance, side-effect management, plateau handling, and discontinuation; Section 9 codifies how the integrated regimen operates across the clinical arc.

Table of Contents

1. Indication scope and patient phenotypes
2. Selection criteria (inclusion / exclusion / contraindications)
3. Pre-treatment workup
4. Initiation protocol — backbone selection + adjunct stack sequencing
5. Maintenance protocol — stacked-regimen monitoring
6. Side-effect management — combined-regimen AE classes
7. Plateau and non-response algorithm — stacked-regimen endpoints
8. Discontinuation and tapering — sequenced discontinuation
9. Combination rules (stack-combination operational core)
10. Patient counseling beats (Pattern Z calibration-anchor-compliant)
11. Source citations
12. Clinical decision tree — phenotype-guided integration

Appendices

• A. Verification gate
• B. Pattern discipline summary
• C. Self-audit findings

Methodology cross-references

• /obsidian-peptides/Methodology/Protocol Template.md — 12-section structural authority
• /obsidian-peptides/Methodology/Synergy Editorial Framework.md — voice, framing discipline, length expectations
• /obsidian-peptides/Methodology/Voice Profile - Dr. Jeff Gross MD.md — clinician-voice calibration
• /obsidian-peptides/Methodology/AC2-26 - System Observations.md — Patterns R / R.1 / R.2 / V / V.metric-axis / W / Z / Z.injection-framing / Z.research-precision / AA / AA.marketing-claims / AB.1 / AB.2 / AB.4 / N.1
• /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md — five Pattern Z calibration anchors verbatim
• /obsidian-peptides/Protocols/Semaglutide Protocol.md — backbone option 1 canonical
• /obsidian-peptides/Protocols/Tirzepatide Protocol.md — backbone option 2 canonical
• /obsidian-peptides/Protocols/Retatrutide Protocol.md — backbone option 3 canonical (pre-FDA-approval)
• /obsidian-peptides/Protocols/CJC-1295 + Ipamorelin + MOTS-c - Lean Mass Preservation Stack Protocol.md — adjunct stack canonical

---

1. Indication scope and patient phenotypes

1.1 Purpose

This protocol covers the integrated stacked regimen — a GLP-1 RA backbone delivering the primary weight-loss effect plus a CJC-1295 (without DAC) + Ipamorelin + MOTS-c adjunct stack delivering the lean-mass-preservation overlay — for adult patients with a clinically meaningful lean-mass-preservation concern superimposed on a GLP-1-driven catabolic weight-loss arc. The clinical question this protocol answers is not “should this patient be on a GLP-1 RA” (that question is answered by the constituent backbone protocols at [[Semaglutide Protocol]] / [[Tirzepatide Protocol]] / [[Retatrutide Protocol]]) and not “what is the lean-mass adjunct stack” (that question is answered by [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] at compound-level depth). The clinical question this protocol answers is: given that a clinician is deploying both, how does the integrated regimen operate as one clinical entity — sequencing, timing, dose interaction, surveillance, contraindications-in-combination, counseling-for-the-regimen-as-a-whole, and discontinuation/transition logic.

Pattern R.1 enforcement at this section: the protocol opens with what the stacked regimen IS (an integrated weight-loss + lean-mass-preservation regimen with three backbone options and one adjunct stack) and the indication for which it is deployed (lean-mass-preservation overlay on catabolic GLP-1-driven weight loss) — not with regulatory deficits, not with the absence of Phase 3 RCT for the combined regimen, not with cautionary framing. Pattern R.2: the indication scope is locked at this section and is read through every downstream section.

Pattern AA.marketing-claims enforcement: the regulatory framing in §1 carries per-component precision. The GLP-1 backbone options are FDA-approved-for-marketing-claims for specified indications (semaglutide Wegovy for CWM 2021; Wegovy HD 7.2 mg for CWM 2026-03; tirzepatide Zepbound for CWM 2023 and OSA-with-obesity 2024) OR pre-FDA-approval-for-marketing-claims (retatrutide via TRIUMPH Phase 3 program; sponsor disclosure of −28.7% at 12 mg in TRIUMPH-4 December 2025; peer-reviewed primary publication and FDA submission pending as of 2026-05-14). The three adjunct compounds are NOT FDA-approved-for-marketing-claims for any drug indication; available through 503A compounding pharmacies under post-2023 FDA Category 2 listing variation. The integrated regimen is therefore a combination of an FDA-approved-for-marketing-claims backbone (for sema/tirz patients) or pre-FDA-approval backbone (for reta patients) with a research-state adjunct stack — Pattern AA precision applied per-component throughout.

1.2 The stacked-regimen indication — lean-mass-preservation overlay on GLP-1-driven catabolic weight loss

The single integrated indication this protocol addresses, anchored to Module 5 Protocol Template §1.2 indication categories 2 (chronic weight management) and 8 (lean mass / body composition — peptide stacks):

Indication — Lean-mass-preservation overlay on GLP-1-driven catabolic weight loss in adults with a clinically meaningful lean-mass-concern profile. Patient phenotype: an adult on or initiating a GLP-1 RA backbone (semaglutide Wegovy 2.4 mg or Wegovy HD 7.2 mg; tirzepatide Zepbound 5–15 mg; OR — under explicit informed-consent and trial-enrollment or research-protocol pathway — retatrutide 8–12 mg per Phase 2/3 evidence) plus the Tier 1 foundation (resistance training + 1.2–1.6 g/kg protein + vitamin D adequacy + monitoring) plus a clinically meaningful lean-mass-preservation concern triggering adjunct stack consideration. The lean-mass concern profile typically includes one or more of:

• Age ≥50 with sarcopenia-progression risk factors (post-menopausal, low baseline lean mass, prior sarcopenia signal on grip strength or 5-time sit-to-stand testing). The 2025 multi-society advisory (Mozaffarian D et al. Obesity (Silver Spring) 2025;33(8):1475-1503; PMID 40445127) identifies older adults and post-menopausal women as the highest-sarcopenic-risk subpopulations during GLP-1-driven weight loss.
• Documented elevated lean-mass-loss fraction on the GLP-1 backbone — DEXA at a 12-week or 24-week check shows lean-mass-loss fraction exceeding ~30% of total weight loss, above the Phase 3-pooled-DEXA expected fraction (semaglutide ~28–32%; tirzepatide ~20–25% per Look 2025 PMID 39996356 pooled STEP and SURMOUNT body-composition substudies; Beavers 2025 meta-analysis context).
• Functional measure decline — grip strength or 5-STS deterioration despite documented adherence to the Tier 1 foundation. EWGSOP2 / AWGS sarcopenia operational definitions prioritize muscle strength and physical performance over mass alone.
• High-target-weight-loss trajectory — patients with a target weight loss exceeding 15–20% of starting body weight (the upper tirzepatide Zepbound efficacy-estimand range and the SURMOUNT-1 −22.5% / Wegovy HD STEP UP −18.7% / retatrutide TRIUMPH-4 −28.7% range), where the absolute lean-mass-loss magnitude across the larger weight-loss range becomes operationally meaningful.
• Athletic / high-baseline-lean-mass phenotype — patients whose baseline body composition includes well-developed skeletal muscle that is at risk of disproportionate loss during caloric deficit, including female athletes and male athletes in non-WADA-prohibited contexts (WADA caveat: CJC-1295, Ipamorelin, and MOTS-c are all WADA-prohibited substances; competitive athletes subject to WADA testing are ineligible for the stack).
• Pre-discontinuation set-point preservation — patients approaching planned GLP-1 RA discontinuation (rare; typically cost / access / pre-conception planning / patient preference) where set-point preservation and post-discontinuation weight-regain-trajectory smoothing (STEP-4 ~two-thirds regain pattern per Rubino 2021 PMID 33755728; SURMOUNT-4 +14% regain on placebo-switch per Aronne 2024 PMID 38078870) are clinical concerns.
• Post-50lb-loss patients approaching maintenance — patients who have already lost a substantial absolute mass (≥50 lb / ~23 kg) on the GLP-1 backbone and are approaching their target weight or maintenance phase, where preserving the lean-mass that remains is the dominant body-composition concern as catabolic pressure eases.

The protocol does not advocate adding the adjunct stack to every GLP-1 RA prescription. It develops the integration framework — mechanism rationale for the combined regimen, evidence-state framing (per-component vs combined-regimen RCT evidence), screening discipline for the stacked phenotype, dosing protocol for the combined regimen, monitoring approach (IGF-1 + glucose + body-composition + cancer-surveillance overlay), side-effect management for the combined regimen, sequencing and timing rules, and patient-counseling discipline for clinicians who choose to offer the integrated regimen to patients where it is clinically appropriate.

1.3 Why this is a stack protocol and not a “GLP-1 + peptides” hand-wave

The stacked regimen is mechanism-class-integrated, not mechanism-redundant. The GLP-1 RA backbone and the adjunct stack engage distinct receptor systems via distinct signaling cascades and converge on a single body-composition outcome where the backbone delivers the catabolic-pressure–driven weight loss (predominantly fat mass, with an obligatory lean-mass-loss fraction in the ~20–32% range across Phase 3 trial-program pooled DEXA data) and the adjunct stack delivers the anabolic-counterpressure–driven lean-mass-preservation overlay (predominantly via GH-pulse–mediated IGF-1 trajectory and mitochondrial AMPK-pathway / myostatin-pathway engagement).

Backbone mechanism axis — GLP-1R / GIPR / GCGR engagement (varies by backbone selection).

• Semaglutide is a single GLP-1R agonist; ~7-day half-life; effect-size envelope at Wegovy 2.4 mg ~14.9% (STEP-1 PMID 33567185, 68 weeks, non-diabetic obesity, treatment-policy estimand). Wegovy HD 7.2 mg ~18.7% (STEP UP PMID 40961952; FDA-approved 2026-03-19 for CWM).
• Tirzepatide is a dual GLP-1R / GIPR agonist; ~5-day half-life; effect-size envelope at Zepbound 15 mg ~20.9% treatment-regimen / ~22.5% efficacy estimand (SURMOUNT-1 PMID 35658024). Head-to-head vs semaglutide at obesity doses: tirzepatide −20.2% vs semaglutide −13.7% (SURMOUNT-5 PMID 40353578).
• Retatrutide is a triple GLP-1R / GIPR / GCGR agonist; ~6-day half-life; Phase 2 obesity effect-size up to −24.2% at 12 mg / 48 weeks (Jastreboff 2023 NEJM PMID 37366315); TRIUMPH-4 Phase 3 sponsor topline December 2025: −28.7% at 12 mg / 68 weeks (peer-reviewed publication and FDA submission pending as of 2026-05-14).

Each backbone produces appetite suppression + glucose-improvement + variable secondary effects (CV-event reduction for semaglutide per SELECT PMID 37952131; OSA reduction for tirzepatide per SURMOUNT-OSA PMID 38912654; visceral-fat reduction and hepatic-fat reduction for retatrutide per Phase 2a MASLD substudy Sanyal 2024 PMID 38858523). The backbone delivers the catabolic pressure; the lean-mass-loss fraction within that catabolic pressure is the body-composition cost the adjunct stack is deployed to attenuate.

Adjunct stack mechanism axes — GH-axis (CJC-1295 + Ipamorelin) + mitochondrial AMPK / myostatin pathway (MOTS-c).

• Axis 1 — CJC-1295 (without DAC; Mod-GRF 1-29). GHRH analog; binds GHRH-R on anterior pituitary somatotrophs; half-life ~30 minutes; preserves pulsatile (not tonic) GH release. Jette 2005 Endocrinology PMID 15817669 foundational mechanism paper.
• Axis 2 — Ipamorelin. Selective GHS-R1a (ghrelin receptor) agonist — the first selective growth hormone secretagogue (Raun 1998 Eur J Endocrinol PMID 9849822) without cortisol / prolactin / ACTH elevation. Pentapeptide; half-life ~2 hours.
• Combined Axis 1 + Axis 2 — synergistic dual-pathway GH pulse. Co-administration produces a supra-additive GH pulse approximately 7–10× greater amplitude than either alone in the human PK/PD literature (Teichman 2006 JCEM PMID 16352683; Ionescu & Bhatt 2006 JCEM PMID 17018654). Downstream cascade: GH pulse → hepatic IGF-1 → IGF-1 receptor engagement in skeletal muscle → PI3K/AKT/mTOR anabolic signaling → protein synthesis pathway.
• Axis 3 — MOTS-c. 16-amino-acid mitochondrial-derived peptide encoded in the mitochondrial 12S rRNA gene (Lee 2015 Cell Metab PMID 25738459). Four mechanism sub-axes: (a) AMPK activation via folate-cycle inhibition → AICAR accumulation → AMPK; (b) mitochondria-to-nucleus retrograde signaling (Kim 2018 Cell Metab PMID 29983246); (c) myostatin inhibition via CK2-PTEN-mTORC2-AKT-FOXO1 (Kong 2021 Cell Rep PMID 33554779); (d) exercise mimesis (Reynolds 2021 Nat Commun PMID 33473109).

Integration mechanism — non-redundant convergence on the body-composition endpoint. The GLP-1 RA backbone engages incretin-receptor pathways (GLP-1R / GIPR / GCGR depending on backbone selection) producing appetite suppression + glucose improvement. The adjunct GH-axis stack engages pituitary GHRH-R + GHS-R1a producing anabolic GH-pulse / IGF-1 signaling. The mitochondrial-peptide adjunct (MOTS-c) engages mitochondrial-encoded retrograde signaling + AMPK + myostatin pathways. The three mechanism families are non-redundant; they converge on the body-composition outcome where the backbone drives total weight reduction and the adjunct stack attenuates the lean-mass fraction of that weight loss. No Phase 3 RCT tests the combined regimen specifically for lean-mass preservation during GLP-1-driven weight loss. Practitioner-observation data from multi-peptide weight-management practice suggests the lean-mass-loss fraction can be reduced from the Phase 3-pooled-DEXA expectation (~25–32%) toward ~15–20% with the combined regimen plus Tier 1 foundation in adherent patients; this is practitioner observation, not RCT evidence, and §10.6 counseling beats frame the expectation at that resolution (Pattern Z Anchor 5 — DOMINANT).

1.4 Phenotype-targeting taxonomy applied to the stacked regimen

The Module 5 phenotype taxonomy applies with stacked-regimen-specific calibrations:

• Metabolic phenotype. Insulin-resistant vs insulin-sensitive obesity. The GLP-1 backbone delivers insulin-sensitization (additive across all three backbone options); MOTS-c additionally insulin-sensitizes; the GH-axis adjunct (CJC-Ipamorelin) at supraphysiologic GH levels antagonizes insulin sensitivity — at physiologic-range dosing (CJC-1295 100 mcg + Ipamorelin 200 mcg producing upper-quartile-of-reference IGF-1 Z 0 to +1), the net glucose-tolerance directional pressure on the stacked regimen is typically maintained-or-improved against pre-stack on-GLP-1 baseline. §5 + §6.10 monitoring discipline.

• Adiposity distribution. Visceral-dominant vs subcutaneous-dominant. The backbone delivers visceral and subcutaneous fat reduction (retatrutide has the largest hepatic-fat-reduction magnitude per the Phase 2a MASLD substudy ~82% MRI-PDFF reduction at 12 mg). The GH-axis adjunct adds modest GH-mediated lipolysis; visceral-fat-specific targeting is more commonly addressed with tesamorelin (M5.5 separate protocol; FDA-approved-for-marketing-claims for HIV-lipodystrophy) rather than CJC-1295.

• Appetite phenotype. Backbone addresses; adjunct does not. Ipamorelin engages GHS-R1a (the ghrelin receptor) but at the selective-binding profile and the 200 mcg SubQ dose does not produce the appetite-stimulating effect of GHRP-6.

• Energy-expenditure phenotype. Low-REE-for-mass vs normal-REE; adaptive-thermogenesis-prone vs adaptive-thermogenesis-naive. The adjunct stack attenuates the lean-mass-loss-driven RMR reduction; combined with retatrutide’s GCGR-mediated thermogenesis-via-futile-substrate-cycling component (preclinical mechanism), the energy-expenditure-phenotype targeting is research-state-active.

• Comorbidity load. Monocondition vs polycondition. The stacked regimen is most commonly considered in CWM-monocondition phenotypes plus selected polycondition phenotypes (T2D + CWM; CV + CWM); T2D phenotypes with elevated baseline IGF-1 or advanced diabetic retinopathy require enhanced surveillance (§2.3, §3.5, §6.10).

• Pharmacologic history. Prior GLP-1 RA exposure with documented response (the patient is on or has been on a GLP-1 RA at adequate dose and duration); prior adjunct-stack exposure (rare; most patients are stack-naive); prior tesamorelin exposure (uncommon outside HIV-lipodystrophy patients); prior tirzepatide intolerance is a Pattern V signal for retatrutide backbone selection (the GIPR-agonism overlap is research-state-incomplete for tolerability cross-class).

• Life-stage modifier. Reproductive-age female (pregnancy planning is a discontinuation trigger for BOTH backbone and adjunct — §8.4 sequenced washout arithmetic), post-menopausal female (highest sarcopenic risk per 2025 multi-society advisory; relatively favored stacked-regimen candidate on lean-mass-preservation grounds, with breast-cancer-context IGF-1 monitoring relevant), older adult ≥65 (sarcopenia-risk-elevated; favored stacked-regimen candidate with enhanced cancer-surveillance and glucose-tolerance monitoring), adolescent (not a stacked-regimen candidate population — pediatric GH-axis manipulation is a separate clinical context; semaglutide and tirzepatide have adolescent CWM indications but the adjunct stack is not deployed in pediatric populations).

1.5 Three phenotype branches — sequencing decision differs

The protocol covers three operational phenotype branches that differ in when the adjunct stack is initiated relative to the GLP-1 backbone:

Branch A — Sarcopenic baseline / older adult phenotype. Patient has documented sarcopenic risk at GLP-1 initiation (age ≥65, post-menopausal with low baseline lean mass, prior sarcopenia signal on grip strength, OR documented baseline DEXA lean-mass below age/sex-specific population median). Sequencing decision: adjunct stack initiated at or shortly after GLP-1 RA target dose attainment (typically Month 3 on GLP-1 target dose), without waiting for documented lean-mass-loss fraction. Rationale: the baseline sarcopenic risk is high enough that anticipatory adjunct deployment is mechanism-class-favorable; waiting for documented lean-mass loss exposes the patient to preventable lean-mass reduction during the first months of the catabolic arc.

Branch B — Female athletes / athletic / high-baseline-lean-mass phenotype. Patient has well-developed baseline skeletal muscle (above age/sex-specific population median lean mass; documented baseline grip strength and 5-STS in favorable percentiles; athletic / strength-training history). Sequencing decision: adjunct stack initiated at or shortly after GLP-1 RA target dose attainment (typically Month 3 on GLP-1 target dose), again without waiting for documented lean-mass-loss fraction. Rationale: the absolute lean-mass at risk is large; the high-baseline-lean-mass phenotype is more visible to relative lean-mass loss than a low-baseline patient and the absolute lean-mass-loss magnitude across the planned target weight-loss range (typically >15%) is operationally meaningful. WADA caveat: CJC-1295, Ipamorelin, and MOTS-c are all WADA-prohibited substances; competitive athletes subject to WADA testing are ineligible for the stack regardless of phenotype-targeting; non-competitive athletes and competitive athletes outside WADA-tested contexts are eligible per the standard inclusion criteria.

Branch C — Post-50lb-loss / mid-trajectory / DEXA-triggered phenotype. Patient is mid-trajectory on the GLP-1 RA backbone (typically 6–12 months in, 8–20% weight loss already achieved), with a 12-week or 24-week DEXA showing lean-mass-loss fraction modestly above the trial-program-pooled range (>30% for semaglutide backbone; >25% for tirzepatide backbone) AND/OR functional measure decline (grip strength relative decline; 5-STS prolongation) AND/OR continuing target weight-loss arc. Sequencing decision: adjunct stack initiated at the DEXA-triggered timepoint (i.e., reactive deployment) for the remaining active-weight-loss arc plus the pre-maintenance transition phase. Rationale: the DEXA signal documents the lean-mass-preservation need; the adjunct stack is deployed for the remaining catabolic-pressure window plus the transition to maintenance.

Branches A and B are anticipatory sequencing (adjunct stack deployed before lean-mass loss is documented, on baseline-phenotype-risk grounds); Branch C is reactive sequencing (adjunct stack deployed after lean-mass loss is documented, on body-composition-trajectory grounds). The three branches differ in the patient population they apply to, not in the adjunct stack protocol itself — the adjunct dosing, cycling, and monitoring discipline are identical across branches per [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] §4–§5.

1.6 Cross-reference to case construction

Worked clinical cases for this stack protocol are constructed against the §1.4 phenotype taxonomy plus the §1.5 three-branch sequencing framework. Cases anchor to a specific backbone selection (semaglutide / tirzepatide / retatrutide) and a specific phenotype branch (A / B / C) so the integration logic is operationally visible. A case that presents the stacked regimen without specifying backbone and branch is a Pattern R.2 design-step failure — the case generates the integration question rather than instantiating it against the three-backbone × three-branch framework.

1.7 Worked example — the canonical Branch C / Wegovy-backbone stacked-regimen patient

A 54-year-old post-menopausal female presents on Wegovy 2.4 mg weekly, Month 6 on target dose. She has lost 11 kg (~12% of starting weight; on STEP-1 trajectory). Her 12-week DEXA on Wegovy showed total weight loss with lean-mass-loss fraction approximately 33% of total weight loss — modestly above the Phase 3-pooled expected ~20–32% range for the semaglutide backbone, and the kind of signal that triggers stacked-regimen consideration in a post-menopausal female (highest sarcopenic-risk subpopulation per the 2025 multi-society advisory). Her grip strength has dropped from 28 kg at baseline to 24 kg at 24-week functional reassessment — within normal-range absolute values but a relative decline. She has been adherent to a Tier 1 foundation (1.4 g/kg protein, 3 resistance-training sessions/week with progressive overload, vitamin D >30 ng/mL on supplementation). She has no MTC / MEN-2 family history, no active malignancy, no diabetic retinopathy (no T2D), no acromegaly history, no pregnancy plans (post-menopausal).

This is the canonical stacked-regimen patient — Branch C / Wegovy-backbone. Post-menopausal female + documented lean-mass-loss fraction modestly above expected range for the semaglutide backbone + documented Tier 1 foundation adherence + no contraindications + lean-mass-preservation goal clinically meaningful given her sarcopenic-risk profile and the planned ongoing GLP-1 trajectory toward her target weight loss. The stacked-regimen counseling discussion (Pattern Z Anchor 5 framing; §10.6) is appropriate for this patient.

Pattern AA.marketing-claims precision in §1.7. Wegovy 2.4 mg semaglutide is FDA-approved for marketing claims for chronic weight management in adults with BMI ≥30 (or ≥27 with weight-related comorbidity) — Wegovy approval 2021. The adjunct stack compounds (CJC-1295 without DAC; Ipamorelin; MOTS-c) are NOT FDA-approved for marketing claims for any drug indication; they are research-state peptides available through 503A compounding pharmacies under the post-2023 FDA Category 2 listing variation. The combined regimen of “Wegovy + CJC-Ipamorelin + MOTS-c” combines an FDA-approved-for-marketing-claims molecule (Wegovy) with three research-state peptides; the regulatory framing is precise at the per-compound level and §10.6 counseling beat develops the stacked-regimen off-label framing.

Pattern V cross-check at §1.7. The lean-mass-loss-fraction expectation (~28–32% for semaglutide; ~20–25% for tirzepatide; retatrutide pending Phase 3 DEXA substudies) is the trial-program-anchored direction-of-effect per Look 2025 PMID 39996356 pooled DEXA analysis. This patient’s 33% on Wegovy is modestly above the semaglutide pooled range but not extreme. The lean-mass-preservation effect-size expectation from the integrated regimen is research-state-incomplete — no Phase 3 RCT specifically tests CJC-Ipamorelin + MOTS-c as adjunct to semaglutide for lean-mass preservation. Practitioner-observation data suggests the lean-mass-loss fraction can be reduced from the ~25–33% Wegovy-pooled range toward ~15–20% in the multi-peptide weight-management practice setting with foundation interventions in place. This is practitioner observation, not RCT evidence; §10.6 counseling beats frame the expectation at that resolution (Pattern Z Anchor 5 + Pattern Z.research-precision).

Pattern AB.1 inversion-risk check in §1.7. CJC-1295 without DAC is specified explicitly per the canonical adjunct-stack protocol. CJC-1295 with DAC is a different pharmacologic profile (sustained tonic GH elevation; ~8-day half-life via albumin conjugation; appropriate for sustained-elevation anti-aging contexts, not for the pulsatile lean-mass-preservation context of this protocol). Every reference to “CJC-1295” in this protocol means the without-DAC form unless explicitly qualified.

---

2. Selection criteria (inclusion / exclusion / contraindications)

2.1 Purpose

Define who the stacked regimen is for (the lean-mass-concern phenotype on or initiating an established or pre-FDA-approval GLP-1 RA backbone with Tier 1 foundation in place), who it is not for (the relative-exclusion phenotype where stacked-regimen benefit is uncertain or risk is elevated), and who it must not be given to (the hard-contraindication phenotype). The selection-criteria architecture mirrors the Module 5 Protocol Template §2 three-block structure with stacked-regimen-specific calibrations that integrate the backbone-protocol §2 and adjunct-stack-protocol §2 contraindication inventories.

Pattern R.1 enforcement: §2.2 inclusion → §2.3 relative exclusion → §2.4 contraindication ordering. Inclusion criteria lead — the patient phenotype the stacked regimen IS for.

Pattern AA.marketing-claims enforcement: every contraindication carries per-component source classification. The backbone-protocol contraindications (MTC, MEN-2 boxed warning class-wide for GLP-1 RAs; severe pancreatitis history precaution; pregnancy labeled contraindication for CWM indications) integrate with the adjunct-stack contraindications (the same MTC/MEN-2 boxed warning extends to the GH-secretagogue stack on mechanism-class grounds per the adjunct-stack canonical §2.4; active malignancy hard contraindication for the GH-axis adjunct; acromegaly mechanism-class contraindication for the GH-axis adjunct; concurrent somatostatin analog therapy mechanism-conflict contraindication for the adjunct). Where the backbone-protocol §2 and adjunct-stack §2 contraindications overlap (e.g., MTC / MEN-2 / pregnancy), the integrated regimen carries the union. Where they differ in source classification (e.g., labeled contraindication vs mechanism-class-grounded), the integrated regimen carries each per-component classification precisely.

2.2 Inclusion criteria — the integrated stacked-regimen phenotype

The patient must meet all of the following inclusion criteria to be a stacked-regimen candidate:

1. Inclusion for the GLP-1 RA backbone is met per the chosen backbone protocol §2.2. Semaglutide Wegovy CWM (BMI ≥30 or ≥27 with comorbidity; adult ≥18; STEP / SELECT enrollment scope per [[Semaglutide Protocol]] §2.2). Tirzepatide Zepbound CWM (BMI ≥30 or ≥27 with comorbidity; SURMOUNT / SURMOUNT-OSA enrollment scope per [[Tirzepatide Protocol]] §2.2). Retatrutide pre-FDA-approval CWM via active TRIUMPH program enrollment OR clinician-judgment off-label investigational-supply use per [[Retatrutide Protocol]] §2.2 anticipated indication scope. The backbone selection is phenotype-guided per §4 multi-dimensional comparator framework.

2. Inclusion for the adjunct stack is met per [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] §2.2. On established GLP-1 RA backbone at target dose and duration (typically Month 3+ on backbone target dose for sema/tirz; for retatrutide, established trial-protocol or research-protocol enrollment at target dose); Tier 1 foundation adherent (1.2–1.6 g/kg protein distributed across the day, 2–3 resistance-training sessions/week with progressive overload, vitamin D ≥30 ng/mL); a clinically meaningful lean-mass-concern trigger present per §1.2 / §1.5 phenotype branch; adult ≥18; baseline workup completed (§3); informed-consent discussion completed (§10).

3. The two inclusion sets are reconciled at the integrated regimen level. A patient who is inclusion-positive for the backbone but not yet meeting adjunct-stack inclusion criterion 1 (not yet at backbone target dose) is on the backbone-only pathway with anticipated stacked-regimen consideration at backbone target dose. A patient who is inclusion-positive for the adjunct stack but does not meet backbone inclusion (e.g., BMI <27 absent comorbidity) is not on the stacked-regimen pathway — the adjunct stack is not deployed in the absence of the catabolic-weight-loss pressure that the backbone creates.

4. Phenotype branch identified per §1.5. Branch A (sarcopenic baseline / older adult) or Branch B (athletic / high-baseline-lean-mass) anticipatory deployment timing OR Branch C (DEXA-triggered / mid-trajectory) reactive deployment timing. The branch identification informs §4 initiation timing and §9 sequencing.

5. Backbone-stack interaction screen. For Branch A and Branch B (anticipatory deployment at backbone target dose), the backbone-stack interaction screen verifies: backbone tolerability stable (no active escalation of backbone-protocol §6 AE class — no active pancreatitis-suspect symptom; no active cholecystitis-suspect symptom; no active NAION-suspect symptom for the semaglutide backbone; no active acute retinopathy-progression-suspect symptom for the tirzepatide backbone in DR-positive patients; no active diabetic ketoacidosis or severe glucose dysregulation). For Branch C (DEXA-triggered deployment), the same backbone-stability screen plus DEXA documentation of the lean-mass-concern trigger.

6. Informed-consent discussion completed (§10). The patient understands the integrated regimen carries (a) the FDA-approved-for-marketing-claims backbone with its labeled indications and labeled risks, OR the pre-FDA-approval-for-marketing-claims backbone (retatrutide) with its research-state regulatory framing; (b) the research-state adjunct stack with no FDA-approved-for-marketing-claims version of any of the three compounds; (c) the absence of Phase 3 RCT evidence for the combined regimen specifically; (d) the practitioner-observation pathway for the lean-mass-preservation effect-size expectation; (e) the integrated monitoring discipline including IGF-1 + glucose + body-composition + cancer-surveillance. Anchor 5 (off-label / extrapolation transparency) counseling beat completed for the integrated regimen; Anchor 1+2 (compounded counseling) beat completed for the adjunct stack; Anchor 3 (pregnancy) beat completed for reproductive-age patients; Anchor 4 (backbone comparator framing within the GLP-1 RA class) beat completed; patient has elected to proceed.

2.3 Relative exclusion criteria — clinician-judgment phenotype for the integrated regimen

Relative exclusion criteria identify phenotypes where the stacked regimen is not contraindicated on per-component mechanism grounds but where integrated-regimen benefit is uncertain, integrated-regimen risk is elevated, or integrated-regimen evidence is sparser than per-component evidence. Pattern V direction-of-effect: for under-represented or out-of-evidence-base phenotypes, expected integrated-regimen effect-size is research-state-incomplete and clinician judgment governs.

• Type 2 diabetes, particularly with established diabetic retinopathy. The GH-axis adjunct carries an IGF-1-elevation profile; IGF-1 elevation is associated with retinopathy progression in advanced background and proliferative diabetic retinopathy populations. Semaglutide backbone separately carries a rapid-HbA1c-improvement retinopathy-complication signal per SUSTAIN-6 sub-population; tirzepatide backbone separately carries a baseline-status-stratified retinopathy signal per Buckley 2025 Diabetologia PMID 40637847 (OR 2.15 for new-onset proliferative DR on tirzepatide in the overall multivariate analysis; “particularly evident” per authors in R1M1 or moderate-to-severe NPDR baseline; OR 0.73 protective in patients without retinopathy at baseline). The integrated-regimen retinopathy risk is the union of backbone-mediated rapid-HbA1c-improvement signal AND adjunct-mediated IGF-1-elevation signal. Relative exclusion in T2D with documented advanced background or proliferative DR; clinician-judgment posture with ophthalmology pre-screen, ophthalmology co-management, and on-protocol surveillance. For T2D-positive patients on the integrated regimen, the SUSTAIN-6 / Buckley 2025 retinopathy signal anchors backbone surveillance and the adjunct-stack IGF-1 monitoring (§6.10) anchors adjunct surveillance.

• Borderline glucose tolerance / pre-T2D. The GH-axis adjunct at supraphysiologic levels antagonizes insulin sensitivity; the physiologic-range dosing target (CJC-1295 100 mcg + Ipamorelin 200 mcg producing upper-quartile-of-reference IGF-1 Z 0 to +1) attenuates but does not eliminate the directional pressure. The MOTS-c component operates in the opposite direction (insulin sensitization via AMPK pathway), partially offsetting the GH-axis component effect. The GLP-1 backbone delivers substantial improving directional pressure on glucose tolerance. Net glucose-tolerance effect on the integrated regimen is typically maintained-or-improved against pre-stack on-GLP-1 baseline in practitioner-observation; reversal is uncommon but is a §5.4 + §6.7 + §6.10 dose-adjustment trigger.

• Personal history of malignancy beyond 5 years from treatment completion. The IGF-1-cancer-risk literature is the load-bearing safety consideration for the GH-axis adjunct (§6.10 three-pillar framework: Renehan 2004 observational signal + Child 2022 GH-replacement cohort + Boguszewski 2022 consensus statement). The 2026 cancer SR (Ko et al 2026 Annals Intern Med PMID 41359966; n=94,245 across 48 RCTs including tirzepatide) characterizes “GLP-1 RAs may have little or no effect on risk for obesity-related cancers” overall — backbone-side cancer-context evidence base is moderate-certainty null/protective at population level. The integrated-regimen cancer-surveillance posture in cancer survivors beyond 5 years from treatment completion is clinician-judgment with oncologist clearance, IGF-1 monitoring at the physiologic-range target (§6.10.1), PSA / mammography baseline plus annual on protocol (§3.4 + §5.5), and patient-specific risk-benefit weighing. Active malignancy or recent (within 5 years) cancer treatment is a hard contraindication (§2.4).

• Severe gastroparesis or gastroparesis-predisposing comorbidity. Backbone-side: all three GLP-1 backbones delay gastric emptying; tirzepatide product label includes severe gastroparesis as a functional contraindication. Adjunct-side: no direct mechanism on gastric emptying. The integrated-regimen posture is backbone-driven — severe gastroparesis is a functional contraindication to the backbone and therefore to the integrated regimen; mild-to-moderate gastroparesis is clinician-judgment with gastroenterology co-management.

• Active or recent (within 12 months) acute pancreatitis. Backbone-side: distinct from severe-prior-pancreatitis-history hard contraindication; recent acute pancreatitis is a backbone-protocol relative exclusion with clinician-judgment posture pending ≥12 months stable post-event. Wen 2025 SR (PMID 40988099; 62 RCTs n=66,232 including tirzepatide) — pooled RR 1.44 (95% CI 1.09–1.89, P=0.009) for acute pancreatitis across the GLP-1 RA + GLP-1/GIP coagonist class; modest signal, absolute event rates <1–2%/year. Adjunct-side: no direct pancreatitis association documented for CJC-1295, Ipamorelin, or MOTS-c. The integrated-regimen posture is backbone-driven — recent acute pancreatitis is a relative exclusion to the backbone and therefore to the integrated regimen.

• Severe renal impairment (eGFR <30) or severe hepatic impairment (Child-Pugh C). Backbone-side: SURPASS / SURMOUNT / STEP / ESSENCE typically enrolled eGFR ≥30; severe renal impairment is outside Phase 3 enrollment with Pattern V direction-of-effect flag. Adjunct-side: peptide pharmacokinetics in severe renal or hepatic impairment are not characterized for any of the three adjunct compounds. The integrated-regimen posture is union of per-component cautions — relative exclusion with clinician judgment, dose-reduction discipline, and nephrology / hepatology co-management as appropriate.

• Active sleep apnea, particularly untreated severe OSA. Backbone-side: tirzepatide has the SURMOUNT-OSA-anchored indication for moderate-severe OSA with obesity; semaglutide and retatrutide do not have OSA indications. Adjunct-side: GH-axis activation can exacerbate sleep apnea (GH-mediated soft-tissue / upper-airway effects). The integrated-regimen posture: untreated severe OSA is a relative exclusion to the adjunct (sleep-medicine pre-clearance required); for tirzepatide-backbone patients with moderate-severe OSA + obesity, the SURMOUNT-OSA indication aligns the backbone with the OSA-positive phenotype and the adjunct sleep-apnea-exacerbation surveillance overlays — clinician-judgment with sleep-medicine co-management; CPAP-adherent OSA patients are not excluded.

• Prior pituitary surgery or radiation, prior diagnosis of hypopituitarism. Adjunct-side: GH-secretagogue stimulation of a structurally compromised pituitary is research-state-incomplete in clinical context. Relative exclusion to the adjunct with endocrinology co-management; the backbone is not affected by this consideration.

• Active psychiatric condition affecting adherence or informed consent. The integrated regimen requires multi-compound adherence discipline (weekly GLP-1 injection + bedtime CJC-Ipa daily + AM MOTS-c on cycle days + reconstitution discipline + monitoring); patients unable to maintain adherence are relative exclusions.

• Pre-conception planning within 3–6 months for reproductive-age patients. Sequenced discontinuation washout per §8.4 — adjunct discontinuation 4 weeks pre-conception (pharmacodynamic IGF-1 return); backbone discontinuation 8 weeks pre-conception per label (semaglutide / tirzepatide t½ + 5 t½ + label margin). A patient planning conception within 1–2 months should not initiate the integrated regimen; a patient with 3–6 month planning horizon enters with §8 anticipatory discontinuation timeline.

• Prior tirzepatide intolerance at therapeutic dose (relevant for retatrutide-backbone selection per [[Retatrutide Protocol]] §2.5 Pattern V signal). The GIPR-agonism component of retatrutide overlaps with the dual-incretin mechanism that produced the tirzepatide intolerance; the GIPR-related tolerability question is a research-state-incomplete clinician-judgment consideration; this does not exclude retatrutide backbone but informs the §10.5 backbone-comparator counseling beat and the §4 anticipated titration approach.

2.4 Hard contraindications — integrated-regimen absolute contraindications

Hard contraindications apply per-component on integrated-regimen grounds: a contraindication applicable to the backbone OR the adjunct OR the combined regimen is absolute for the integrated regimen.

• Personal or family history of medullary thyroid carcinoma (MTC). FDA boxed warning class-wide for FDA-approved GLP-1 RAs (semaglutide, tirzepatide, liraglutide, dulaglutide), based on rodent C-cell tumorigenicity signal (Bjerre Knudsen 2010 Endocrinology PMID 20203154); the boxed-warning-mandated contraindication is absolute and applies to all GLP-1 RA backbone options. Class-level mechanism-grounded extension to the GH-axis adjunct on the conservative principle that GHRH-R and GHS-R1a C-cell expression is research-state-incomplete; the integrated-regimen contraindication is absolute. Retatrutide backbone (pre-FDA-approval) carries class-level MTC contraindication on mechanism grounds; specific TRIUMPH program calcitonin surveillance findings emerge from Phase 3 primary publications.

• Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Same boxed-warning source class-wide for GLP-1 RAs; extended to GH-axis adjunct on mechanism-class grounds; integrated-regimen absolute.

• Severe prior pancreatitis history (severe acute or chronic). Backbone-side: labeled relative contraindication / precaution per the GLP-1 RA class. Adjunct-side: no direct adjunct-specific contraindication. Integrated-regimen posture: severe prior pancreatitis is functionally hard-contraindication for the backbone and therefore for the integrated regimen.

• Known serious hypersensitivity to any backbone or any adjunct compound or formulation excipient. Labeled contraindication on the backbone side per the specific product labels (Wegovy / Ozempic / Zepbound / Mounjaro / Rybelsus); general-principle contraindication on the adjunct side for any peptide therapeutic. Integrated-regimen absolute.

• Pregnancy (for CWM indications) and lactation. Labeled contraindication for the FDA-approved-for-marketing-claims CWM indications on the backbone side (Wegovy, Zepbound) per the specific labels; class-level contraindication for retatrutide on the pre-FDA-approval side per anticipated label; no human safety data for CJC-1295, Ipamorelin, or MOTS-c during pregnancy or lactation on the adjunct side. Integrated-regimen absolute. Pregnancy is a §8 discontinuation trigger, not a §2 inclusion-screen-only criterion — a patient on the integrated regimen who becomes pregnant transitions out of the regimen immediately with §8.4 sequenced washout arithmetic applied retrospectively.

• Active malignancy on treatment or recent (within 5 years) cancer treatment. Adjunct-side hard contraindication on the IGF-1-elevation mechanism grounds (Renehan 2004 observational signal anchored). Backbone-side: Ko 2026 SR null/protective overall but trial programs typically excluded active cancer; clinician judgment with oncology co-management is the backbone-side relative-exclusion posture. Integrated-regimen posture: absolute for the integrated regimen given the adjunct-side hard contraindication.

• Acromegaly. Adjunct-side mechanism-class hard contraindication (endogenous GH excess; secretagogue stimulation is mechanism-conflict). Backbone-side: no contraindication on acromegaly grounds. Integrated-regimen posture: absolute for the integrated regimen given the adjunct-side hard contraindication.

• Active pituitary tumor. Adjunct-side mechanism-class hard contraindication (operational risk of tumor expansion under stimulation). Backbone-side: no contraindication on pituitary-tumor grounds. Integrated-regimen posture: absolute.

• Active proliferative diabetic retinopathy or severe non-proliferative DR with macular involvement. Adjunct-side mechanism-class hard contraindication on IGF-1-elevation grounds. Backbone-side: relative exclusion in advanced background DR or proliferative DR per the SUSTAIN-6 / Buckley 2025 retinopathy signals. Integrated-regimen posture: absolute for the integrated regimen given the adjunct-side hard contraindication; backbone alone may proceed with ophthalmology co-management per the backbone-protocol §2.3 posture.

• Concurrent somatostatin analog therapy (octreotide, lanreotide, pasireotide). Adjunct-side mechanism-conflict hard contraindication (somatostatin analogs block GH release; co-administration defeats the GH-axis adjunct mechanism). Backbone-side: no mechanism conflict. Integrated-regimen posture: hard contraindication for the integrated regimen on the adjunct-side grounds.

• Pediatric patients (<18 years). Adjunct-side hard contraindication (pediatric GH-axis manipulation is a separate clinical context outside this protocol). Backbone-side: semaglutide STEP-TEENS adolescent ≥12 CWM indication and tirzepatide SURPASS-PEDS adolescent T2D Phase 3 program exist for adolescent populations, but the integrated regimen with the adjunct stack is not deployed in pediatric populations.

• WADA-prohibited substance status for competitive athletes subject to WADA testing. CJC-1295, Ipamorelin, and MOTS-c are all WADA-prohibited substances. Competitive athletes subject to WADA testing are ineligible for the adjunct stack; the GLP-1 backbone is a separate WADA-status question (semaglutide / tirzepatide / retatrutide are not currently WADA-prohibited as of 2026-05-14, but specific event regulations vary; athletes verify current WADA status before integrated-regimen consideration). Integrated-regimen posture: hard contraindication for WADA-tested competitive athletes; non-competitive athletes and competitive athletes outside WADA-tested contexts are eligible.

2.5 Worked example — selection criteria applied to the §1.7 stacked-regimen patient

The 54-year-old post-menopausal female from §1.7 (on Wegovy 2.4 mg, Month 6, ~12% weight loss, lean-mass-loss fraction ~33% on 12-week DEXA, grip-strength relative decline, Tier 1 adherent, no contraindications).

§2.2 inclusion check. (1) Backbone inclusion: yes — Wegovy 2.4 mg for CWM (BMI ≥30 with weight-related comorbidity profile at baseline; STEP-1 enrollment scope; FDA-approved-for-marketing-claims for CWM 2021). (2) Adjunct stack inclusion: yes — on Wegovy at Month 6 on target dose; Tier 1 adherent (1.4 g/kg protein; 3 sessions/week resistance training; vitamin D >30); lean-mass-concern trigger (post-menopausal Branch A + documented elevated lean-mass-loss fraction ~33% on Branch C DEXA trigger); adult; baseline workup to be completed; informed-consent counseling to be completed. (3) Integrated inclusion: both sets reconciled — the patient is both backbone-inclusion-positive and adjunct-stack-inclusion-positive. (4) Phenotype branch: dual — Branch A baseline (post-menopausal sarcopenic-risk) AND Branch C reactive (documented lean-mass-loss fraction trigger); the dual-branch identification is favorable for stacked-regimen initiation. (5) Backbone-stack interaction screen: Wegovy tolerability stable at Month 6 on target dose (verify no active pancreatitis-suspect / cholecystitis-suspect / NAION-suspect symptoms at the §3 workup); DEXA documentation in hand. (6) Informed-consent counseling: per §10.

§2.3 relative exclusion check. No T2D; no DR concern (T2D-negative); no documented pre-T2D (verify with HbA1c at workup); not a cancer survivor; no severe renal or hepatic impairment; no OSA; no prior pituitary surgery; no psychiatric adherence concern; post-menopausal (pre-conception planning not applicable); no prior tirzepatide history (the patient is on Wegovy not Zepbound — relevant only if backbone reselection is considered per §7 non-response algorithm). Proceed.

§2.4 hard contraindication check. No personal / family MTC; no MEN-2; no severe pancreatitis history; no known peptide hypersensitivity (verify at history); post-menopausal (pregnancy / lactation not applicable); no active malignancy; no recent (5y) cancer treatment; no acromegaly; no active pituitary tumor; no active proliferative DR (T2D-negative); no concurrent somatostatin analog; adult; not a WADA-tested competitive athlete. Proceed to §3 workup and §10 counseling.

Selection-criteria conclusion: Patient passes integrated-regimen inclusion criteria, no relative exclusions trigger restriction, no hard contraindications. Proceed to §3 pre-treatment workup and §10 informed-consent counseling for the integrated regimen.

Pattern AA.marketing-claims precision in §2.5. Wegovy 2.4 mg is FDA-approved-for-marketing-claims for CWM in adults with BMI ≥30 or ≥27 with comorbidity per the 2021 Wegovy label; the adjunct stack compounds are NOT FDA-approved-for-marketing-claims for any drug indication; the integrated regimen combines an FDA-approved-for-marketing-claims backbone (Wegovy) with three research-state adjuncts. Per-component regulatory framing precise throughout.

Pattern V cross-check at §2.5. The integrated-regimen lean-mass-preservation effect-size expected in this patient is research-state-incomplete at the Phase 3 RCT evidence level for the combined regimen. The per-component evidence is strong (semaglutide backbone Phase 3 STEP-1 PMID 33567185 for the ~14.9% weight-loss anchor; semaglutide pooled DEXA lean-mass-loss-fraction ~28–32% per Look 2025 PMID 39996356 for the baseline lean-mass-loss expectation; CJC-Ipamorelin per-compound mechanism evidence at Tier 1/2 per [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] §11.2; MOTS-c mechanism at Tier 1 per Lee 2015 / Kim 2018 / Reynolds 2021 / Kong 2021). The integrated-regimen effect-size is practitioner-observation, not Phase 3 RCT; §10.6 counseling beat frames the expectation at that resolution.

Pattern AB.1 inversion-risk check at §2.5. Wegovy 2.4 mg (semaglutide) is distinguished from Ozempic (semaglutide for T2D) and Rybelsus (oral semaglutide for T2D); the CWM-indication Wegovy is the relevant FDA-approved-for-marketing-claims formulation for this CWM patient. Wegovy HD 7.2 mg (FDA-approved 2026-03-19 for CWM per STEP UP PMID 40961952) is a separate higher-dose Wegovy formulation; this patient is on the 2.4 mg formulation. CJC-1295 without DAC (Mod-GRF 1-29) is specified per the adjunct-stack protocol; the with-DAC form is not used in this lean-mass-preservation context.

---

3. Pre-treatment workup

3.1 Purpose

Define the pre-treatment laboratory, imaging, and clinical-assessment workup that must be completed and reviewed before integrated-regimen initiation. Section 3 operationalizes the §2 selection criteria into the workup that anchors §4 initiation, §5 maintenance monitoring, and §6 AE management triggers. The integrated-regimen workup is the union of the backbone-protocol §3 workup and the adjunct-stack-protocol §3 workup, with redundancies consolidated (a baseline lab needed for both backbone and adjunct is drawn once) and additions documented (panels specific to the stacked-regimen integration — particularly the IGF-1 + glucose-tolerance + cancer-surveillance + body-composition baseline triad that anchors §6.10 surveillance and the stacked-regimen body-composition endpoint).

The integrated workup is structured into the same seven panels as the Module 5 Protocol Template §3 architecture, plus a stacked-regimen-specific eighth panel for the integrated-regimen-specific additions:

1. Standard metabolic panel (§3.2)
2. Diabetes-specific panel (T2D indication or T2D comorbidity) (§3.3)
3. MASH-specific panel (MASH indication or MASH risk profile) (§3.4)
4. Kidney-specific panel (CKD context or borderline baseline) (§3.5)
5. CV-risk-specific panel (CVOT context or HFpEF + obesity context) (§3.6)
6. Organ-baseline panels (thyroid, pancreas, ophthalmology — class-wide for GLP-1 RAs + GH-axis adjunct-specific calibrations) (§3.7)
7. Body-composition baseline (§3.8 — load-bearing for the stacked-regimen endpoint)
8. Stacked-regimen-specific additions (§3.9 — IGF-1 + cancer-surveillance + glucose-tolerance + GH-axis baseline) (§3.9)

Pattern W cross-section consistency: every lab in §3.2–§3.9 is reconciled with §5 maintenance monitoring intervals and §6 AE management triggers. The integrated-regimen workup does not duplicate per-component workup — it integrates and adds. A patient who has already completed the backbone-protocol §3 workup as part of their existing backbone protocol does not repeat those panels at integrated-regimen initiation; instead, the stacked-regimen workup adds the §3.9 stacked-regimen-specific additions to the existing backbone baseline.

3.2 Standard metabolic panel

Applies to every integrated-regimen initiation. Anchored to the constituent backbone-protocol §3.2 across [[Semaglutide Protocol]] §3.2 / [[Tirzepatide Protocol]] §3.2 / [[Retatrutide Protocol]] §3.2 plus [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] §3.2.

• Comprehensive metabolic panel (CMP). Establishes hepatic and renal baseline. Reconciles with §2.3 relative-exclusion thresholds for severe renal or hepatic impairment. Backbone-side hepatic monitoring particularly relevant for retatrutide backbone given the GCGR-component hepatic-biology framework (canonical §6.13).
• Fasting lipid panel. Establishes CV-risk baseline; informs §6 monitoring.
• Fasting glucose and HbA1c. Establishes glycemic baseline regardless of indication; the integrated-regimen monitoring tracks the dual directional pressure (GLP-1 backbone insulin-sensitization + MOTS-c insulin-sensitization vs GH-axis adjunct insulin-antagonism at supraphysiologic levels; net effect typically maintained-or-improved per §6.10.2 surveillance discipline).
• Fasting insulin and HOMA-IR. Quantifies insulin sensitivity at baseline; informs phenotype-targeting (§1.4) and §5 monitoring trajectory.
• Body weight, height, BMI, waist circumference. Anthropometric baseline; waist circumference anchors visceral-adiposity-distribution context.
• Blood pressure (seated, two readings, standardized). Baseline for CV-risk context and for monitoring.

3.3 Diabetes-specific panel (T2D indication or T2D comorbidity)

Applies when the integrated regimen is being deployed in a T2D-positive patient (T2D-indication backbone selection — Ozempic for T2D glycemic control; tirzepatide Mounjaro for T2D; retatrutide T2D-indication via TRANSCEND-T2D pathway) or when T2D is a comorbidity within a CWM-indication integrated regimen.

• HbA1c (above; standard panel).
• Fasting C-peptide. Establishes endogenous insulin reserve.
• GAD-65 and IA-2 antibodies if LADA suspected.
• Diabetes complication screen (if not within the last 12 months): dilated retinal exam (class-wide pre-treatment per §3.7), UACR for diabetic nephropathy, monofilament / vibratory testing for diabetic neuropathy.
• CGM data review if available. Particularly informative on the integrated regimen given the dual directional pressure on glucose tolerance; CGM trajectory baseline informs §5 monitoring sensitivity.

3.4 MASH-specific panel (MASH indication or MASH risk profile)

Applies when the integrated regimen is being deployed in a MASH-positive or MASH-at-risk patient. The semaglutide backbone has the FDA-approved-for-marketing-claims MASH indication for F2–F3 fibrosis per ESSENCE Phase 3 (Sanyal, Newsome 2025 NEJM PMID 40305708; FDA approval 2025-08-15). The tirzepatide backbone has the SYNERGY-NASH Phase 2 evidence base (Loomba, Sanyal 2024 NEJM PMID 38856224) with Phase 3 in development. The retatrutide backbone has the Phase 2a MASLD substudy ~82% MRI-PDFF reduction at 12 mg (Sanyal 2024 PMID 38858523) plus the SYNERGY-Outcomes Phase 3 multi-agent master protocol (NCT07165028; RECRUITING).

• AST, ALT, GGT, alkaline phosphatase, total and direct bilirubin. Hepatic-function baseline.
• Platelet count. Component of FIB-4 calculation.
• FIB-4 score. Calculated non-invasive fibrosis score. Low <1.3, indeterminate 1.3–2.67, high >2.67.
• Vibration-controlled transient elastography (VCTE / FibroScan) if FIB-4 indeterminate or high.
• MRI-PDFF if research-protocol pathway exists or clinical pathway available (particularly relevant for retatrutide-backbone Phase 2a-anchored use).
• Hepatitis B surface antigen and Hepatitis C antibody, iron studies, autoimmune liver-disease screen if clinically indicated.

3.5 Kidney-specific panel (CKD context or borderline baseline kidney function)

Applies when the integrated regimen is being deployed in a CKD-positive or CKD-at-risk patient. Semaglutide backbone has the FDA-approved-for-marketing-claims CKD-in-T2D indication (Ozempic 2025-08 per FLOW Phase 3 PMID 38785209). Tirzepatide backbone CKD outcomes are in development (SURMOUNT-MMO secondary endpoints). Retatrutide backbone CKD-in-T2D pathway via TRANSCEND-T2D-3 enrollment plus NCT05936151 renal-outcomes Phase 2 trial.

• Serum creatinine, eGFR. Standard renal-function baseline (also in §3.2 CMP).
• Cystatin C-based eGFR if creatinine-eGFR is discordant with clinical picture.
• Urine albumin-to-creatinine ratio (UACR). Quantifies albuminuria — the FLOW enrollment criterion was UACR 100–5000.
• Urinalysis with microscopy.
• Renin-angiotensin system (RAS) blockade documentation. Standard background therapy for CKD-in-T2D context.
• Serum bicarbonate, phosphorus, calcium, PTH if eGFR <60. CKD-MBD workup.

3.6 CV-risk-specific panel (CVOT context or HFpEF + obesity context)

Applies when the integrated regimen is being deployed in an ASCVD-positive or HFpEF-suspect patient. Semaglutide backbone has FDA-approved-for-marketing-claims CV-risk-reduction indications (Ozempic 2020 in T2D + CVD; Wegovy 2024 in BMI ≥27 + CVD without diabetes per SELECT PMID 37952131). Tirzepatide SUMMIT Phase 3 HFpEF + obesity primary result HR 0.62 (Packer 2025 PMID 39555826) supports the SUMMIT-anchored investigational extension; SURMOUNT-MMO CV outcomes pending 2027-10 readout. Retatrutide TRIUMPH-3 / TRIUMPH-Outcomes Phase 3 CV outcomes pending readout.

• ECG (12-lead). Baseline rhythm and conduction status; relevant for retatrutide-backbone-specific cardiac glucagon-receptor expression / inotropic-effects research-state context per PMID 40613938 (preclinical work in isolated human atrial preparations; canonical §6.6 + §6.13).
• High-sensitivity troponin if symptomatic baseline.
• NT-proBNP or BNP if HFpEF-suspect (obesity + dyspnea on exertion + age ≥60).
• Echocardiogram if HFpEF-suspect.
• Carotid intima-media thickness or CAC score if part of practice CV-risk workflow.

3.7 Organ-baseline panels — thyroid, pancreas, ophthalmology

Class-wide pre-treatment workup applicable to every integrated-regimen initiation regardless of indication. Anchors to §2.4 contraindications and §6 AE-management algorithms. The integrated regimen carries the union of backbone-protocol §3.7 and adjunct-stack-protocol §3.5 organ-baseline panels, with the GH-axis-adjunct-specific calibrations from the adjunct-stack canonical §3.3 + §3.4.

• Thyroid baseline. TSH at minimum (extended to free T4 per adjunct-stack-canonical §3.3 — the GH-axis adjunct can unmask central hypothyroidism); neck examination for thyroid nodules; personal / family history MTC / MEN-2 screening (§2.4 hard contraindication). Routine calcitonin screening is clinician-judgment, not protocol-mandated; the boxed-warning rationale is rodent C-cell signal with debated human MTC signal. Retatrutide-backbone-specific: triagonist-class C-cell expression for GIPR + GCGR is research-state-incomplete; TRIUMPH program calcitonin surveillance per Giblin 2026 design paper PMID 41090431.

• Pancreas baseline. Serum lipase, serum amylase. Triglycerides (hypertriglyceridemic pancreatitis context). Pancreatitis-history documentation per §2.4 + §2.3.

• Ophthalmology — dilated retinal examination. Class-wide on the backbone side, particularly for T2D patients per the §3.3 diabetes-complication-screen overlap. Backbone-specific signal context: semaglutide carries the SUSTAIN-6 rapid-HbA1c-improvement retinopathy signal in pre-existing DR sub-population; semaglutide additionally carries the post-marketing NAION signal per Hathaway 2024 JAMA Ophthalmology PMID 38958939 (signal under evaluation; not labeled warning as of 2026-05-14). Tirzepatide carries the Buckley 2025 Diabetologia PMID 40637847 RWE retinopathy stratified finding (OR 2.15 overall multivariate; “particularly evident” per authors in R1M1 / moderate-severe NPDR baseline; OR 0.73 protective in no-retinopathy-baseline subgroup); tirzepatide NAION signal absent per Lawrenson 2025 Am J Ophthalmol PMID 40383360 multicenter pharmacovigilance — class-differentiation within the GLP-1 RA family. Retatrutide-specific NAION characterization research-state-pending TRIUMPH Phase 3 ophthalmologic safety reporting.

  Adjunct-side: the GH-axis adjunct’s IGF-1 elevation profile carries theoretical retinopathy-progression risk in advanced background or proliferative DR populations; baseline retinal exam is good clinical practice for any integrated-regimen patient regardless of T2D status.

  Integrated-regimen posture: baseline dilated retinal exam for every integrated-regimen patient; ophthalmology pre-screen + co-management for T2D-positive patients with known DR or HbA1c ≥9.0; ophthalmology co-management for any patient with disc-at-risk anatomy, prior NAION, or unexplained visual symptoms (the NAION signal is semaglutide-specific in current evidence but the cross-class direction-of-effect is research-state-incomplete; Pattern V discipline).

3.8 Body-composition baseline — load-bearing for the stacked-regimen endpoint

Applies to every integrated-regimen initiation. The body-composition baseline is the load-bearing baseline for the stacked-regimen primary clinical endpoint — lean-mass preservation. Without an accurate baseline, the on-protocol body-composition trajectory cannot be evaluated and the stacked-regimen clinical benefit cannot be assessed.

• Dual-energy X-ray absorptiometry (DEXA) — preferred. Quantifies total body composition: lean body mass, fat mass, visceral adipose tissue (where DEXA software supports VAT estimation), regional distribution. DEXA at baseline establishes the reference for the §5 monitoring cadence; the integrated-regimen monitoring schedule is DEXA at integrated-regimen initiation + 12 weeks + 24 weeks; biannual thereafter through the active-weight-loss arc. Bone mineral density (BMD) measurement on the same DEXA scan is informative — Beavers 2025 meta-analysis (PMID-pending; PMCID PMC11774015) documented small DEXA BMD reductions across the GLP-1 RA Phase 3 program; BMD monitoring is warranted in high-risk populations (post-menopausal women, elderly, patients with low baseline BMD).
• Bioelectrical impedance analysis (BIA) — alternative where DEXA is not accessible.
• Functional measures. Grip strength (hand dynamometry, both hands, three trials each, record maximum; standardize against age- and sex-specific NHANES or EWGSOP2 / AWGS cutoffs); 5-time sit-to-stand (5-STS) chair-stand test (seconds; ≥15 seconds raises sarcopenia probability per EWGSOP2 — Cruz-Jentoft 2019 Age Ageing PMID 30312372); Short Physical Performance Battery (SPPB) optional. These complement DEXA mass measurement and capture the strength / performance dimension required for contemporary sarcopenia operational definitions.
• Resting energy expenditure (REE) if indirect-calorimetry-equipped. Particularly relevant for retatrutide-backbone integrated regimens given the GCGR-mediated thermogenesis-via-futile-substrate-cycling mechanism (Retatrutide canonical §2.3).

3.9 Stacked-regimen-specific additions — IGF-1 + cancer-surveillance + GH-axis baseline

Applies to every integrated-regimen initiation. The stacked-regimen-specific additions extend the standard backbone-protocol workup with the adjunct-stack-specific baselines that anchor §6.10 IGF-1 + glucose + cancer-surveillance discipline.

• IGF-1 (serum) with age/sex Z-score. Load-bearing baseline. The therapeutic target on the integrated regimen is upper-quartile-of-reference-range (Z-score 0 to +1 for age and sex); supraphysiologic elevation is a §6.10 dose-reduction trigger. Baseline IGF-1 establishes the starting point for the on-protocol trajectory. Reference-range and Z-score interpretation are age- and sex-specific; report IGF-1 with the age/sex Z-score.
• IGFBP-3. Optional but informative — IGFBP-3 carries IGF-1 in circulation; the IGF-1 / IGFBP-3 ratio informs free-IGF-1 estimation in borderline-baseline-IGF-1 patients.
• Random GH (serum). Documented for completeness; not load-bearing as baseline (GH is pulsatile and a single timepoint has limited interpretive value).
• 8 AM serum cortisol. Class-level adrenal-baseline screen for the GH-axis adjunct; Ipamorelin’s selectivity profile (no cortisol elevation at therapeutic doses; Raun 1998 Eur J Endocrinol PMID 9849822) is the differentiator from earlier GHRPs.
• Prolactin. Class-level pituitary-axis screen; Ipamorelin’s selectivity profile (no prolactin elevation at therapeutic doses) is the differentiator from hexarelin and GHRP-2 at higher doses.
• PSA (prostate-specific antigen) — men ≥40. Baseline for prostate-cancer surveillance per the §6.10.3 three-pillar framework (Renehan 2004 Lancet PMID 15110491 observational association of elevated IGF-1 with prostate cancer OR 1.49). PSA at baseline + annual on the integrated regimen.
• Mammography status — women ≥40. Verify within-recommended-interval mammography (typically annual or biennial age 40–74). Renehan 2004 association of elevated IGF-1 with premenopausal breast cancer OR 1.65. Mammography at baseline + per standard screening intervals on the integrated regimen.
• Personal and family cancer history. Documented at baseline. First-degree family history of MEN-2 / MTC is §2.4 hard contraindication; broader first-degree family history of hormone-sensitive cancers (breast, prostate, endometrial) is §2.3 relative-exclusion factor requiring patient-specific risk-benefit weighing in §10.6 counseling beat.
• Active or recent (within 5 years) malignancy. §2.4 hard contraindication — confirmed absent at this baseline panel.
• STOP-BANG sleep-apnea screening. Applies to every integrated-regimen patient regardless of backbone; sleep-apnea exacerbation is an adjunct-side §6.9 AE-class concern (GH-axis activation can exacerbate sleep apnea via soft-tissue / upper-airway effects). For high-risk patients (BMI ≥35, neck circumference ≥17 inches men / 16 inches women, observed apnea, daytime sleepiness), sleep study or HSAT referral pre-initiation; CPAP-adherent OSA patients are not excluded but should be on stable CPAP therapy before integrated-regimen initiation.

3.10 Workup-to-monitoring reconciliation (Pattern W)

Every panel in §3.2–§3.9 is reconciled with §5 monitoring intervals:

Workup panel	Baseline (§3)	On-regimen monitoring (§5)	AE-trigger basis (§6)
CMP, lipid panel, fasting glucose, HbA1c	Yes	Quarterly Y1 / biannual thereafter	§6.7 glucose-tolerance worsening; §6.11 backbone-side LFT trigger for retatrutide-backbone hepatic surveillance
Fasting insulin, HOMA-IR	Yes	Optional intermediate	§6.7 glucose-tolerance metric
IGF-1 with Z-score	Yes	Week 8–12 of each stack cycle	§6.10.1 supraphysiologic-IGF-1 dose-reduction trigger
TSH / free T4	Yes	Annual	§6 thyroid-axis surveillance
8 AM cortisol, prolactin	Yes	Not routine; symptom-prompted	§6 pituitary-axis surveillance
PSA (men ≥40)	Yes	Annual	§6.10.3 cancer-surveillance trigger
Mammography (women ≥40)	Yes	Per standard screening intervals	§6.10.3 cancer-surveillance trigger
Dilated retinal exam	Yes	Annual for T2D-positive or DR-history patients	§6.5 backbone-side NAION trigger (sema); §6.5 backbone-side baseline-status-stratified DR trigger (tirz)
DEXA / BIA	Yes	12 wk + 24 wk of each stack cycle; biannual thereafter	§5.4 body-composition trajectory dose-adjustment trigger
Functional measures (grip, 5-STS)	Yes	12 wk of each stack cycle	§5.4 functional-trajectory adjunct
ECG	Yes (CV-risk indication or age ≥50)	Symptom-prompted	§6 cardiac surveillance (retatrutide-specific HR + inotropic context)
STOP-BANG	Yes	Annual + symptom-prompted	§6.9 sleep-apnea exacerbation

Pattern W standing scan confirms every monitoring lab in §5 is established as a baseline lab in §3; every AE-trigger lab in §6 is established as a baseline lab in §3. No monitoring lab is recommended that is not established as baseline.

3.11 Worked example — integrated-regimen pre-treatment workup for the §1.7 / §2.5 patient

The 54-year-old post-menopausal female from §1.7 (on Wegovy 2.4 mg Month 6, ~12% weight loss, lean-mass-loss fraction ~33% on 12-week DEXA, Tier 1 adherent, no contraindications).

Workup consolidation context. This patient is already on Wegovy Month 6 — her backbone-protocol §3 workup was completed at Wegovy initiation. The integrated-regimen workup at this stacked-regimen initiation timepoint adds the §3.9 stacked-regimen-specific additions to her existing backbone baseline; it does not duplicate the backbone-protocol baseline labs unless those labs are dated (>12 months old) and warrant refresh.

§3.2 standard metabolic panel (refresh / verify). CMP, lipid panel, fasting glucose, HbA1c, fasting insulin and HOMA-IR. Wegovy Month 6 routine monitoring labs likely fresh; verify dates and refresh if older than 3 months. Anthropometrics and BP documented at stacked-regimen initiation visit.

§3.3 diabetes-specific panel. Not applicable (T2D-negative); HbA1c documented at §3.2 confirms.

§3.4 MASH-specific panel. Risk-stratified — calculate FIB-4 from §3.2 CMP plus platelet count. If FIB-4 <1.3, no further MASH workup; if indeterminate / high, advance to FibroScan.

§3.5 kidney-specific panel. Not applicable (no CKD; verify eGFR from §3.2).

§3.6 CV-risk-specific panel. ECG given age ≥50 baseline good practice; no symptomatic baseline so no troponin / echo unless HFpEF-suspect.

§3.7 organ-baseline panels. TSH + free T4 per §3.9 GH-axis baseline (consolidated); 8 AM cortisol and prolactin per §3.9 (consolidated); pancreas baseline lipase / amylase (refresh from Wegovy monitoring if older than 12 months); ophthalmology dilated retinal exam if not within last 12 months — particularly given she is initiating the integrated regimen with its IGF-1 elevation profile (good practice rather than protocol-mandated in this T2D-negative patient).

§3.8 body-composition baseline. Her recent 12-week-on-Wegovy DEXA at lean-mass-loss fraction ~33% serves as the pre-integrated-regimen baseline if within 4–6 weeks of planned stacked-regimen initiation. Functional measures: baseline grip strength (28 kg → 24 kg already documented as her trend); baseline 5-STS at integrated-regimen initiation visit. SPPB optional. REE optional.

§3.9 stacked-regimen-specific additions. Serum IGF-1 with age/sex Z-score (load-bearing baseline; the on-protocol target is upper-quartile-of-reference Z 0 to +1; for this 54-year-old post-menopausal female, the age-specific reference range is the relevant anchor); TSH + free T4 (consolidated with §3.7); 8 AM cortisol; prolactin; mammography status confirmed within-interval; personal cancer history (none) and family history documented for §10 counseling; STOP-BANG sleep-apnea screen (low-risk profile typical for post-menopausal Month 6-on-Wegovy patient given the 12% weight loss already achieved).

Workup conclusion for this patient. Operationally simple — most of the backbone-protocol §3 work is already in progress on her Wegovy protocol; the integrated-regimen workup additions are IGF-1 + Z-score, TSH/free T4, cortisol, prolactin, mammography confirmation, baseline grip strength and 5-STS documentation at integrated-regimen initiation visit, and the pre-stack DEXA reference. Workup completion ~1–2 weeks coordinated with her Wegovy monitoring schedule eliminates redundancy.

Pattern W cross-check at §3.11. Every lab and measurement reconciles with §5 monitoring intervals: IGF-1 at Week 8–12 of stack cycle per §5.3; HbA1c and glucose at Week 8–12 per §5.3; DEXA at Week 12 and 24 of stack cycle per §5.4; functional measures at Week 12 per §5.4; PSA / mammography per standard intervals per §6.10.3. No monitoring lab in §5 is introduced that is not established as baseline in §3.

---

4. Initiation protocol — backbone selection + adjunct stack sequencing

4.1 Purpose

Define the operational sequence for initiating the integrated regimen, covering (a) backbone selection per the §4.2 multi-dimensional comparator framework (semaglutide / tirzepatide / retatrutide), (b) backbone titration / initiation if backbone-naive OR backbone target-dose verification if backbone-established, (c) adjunct-stack initiation timing per the §1.5 / §4.4 three-branch phenotype framework, (d) the integrated-regimen tolerability and adherence verification cadence, and (e) the early-monitoring discipline that bridges initiation to maintenance (§5).

The integrated-regimen initiation is NOT a simultaneous-backbone-and-adjunct deployment. Per the adjunct-stack canonical §9.2 core sequencing rule, the adjunct stack is initiated ON an established GLP-1 RA backbone, not before, not concurrently with GLP-1 initiation, not as a substitute. The integrated-regimen initiation therefore covers two distinct operational phases:

• Phase A — backbone initiation (or backbone target-dose verification). If the patient is backbone-naive, this is the standard backbone-protocol §4 titration (semaglutide Wegovy 0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks per [[Semaglutide Protocol]] §4.3; OR tirzepatide Zepbound 2.5 mg → 5 → 7.5 → 10 → 12.5 → 15 mg over 20 weeks per [[Tirzepatide Protocol]] §4.3; OR retatrutide investigational supply per [[Retatrutide Protocol]] §4.3 Phase 2/Phase 3 titration framework). If the patient is backbone-established (already on backbone target dose for ≥3 months), Phase A is a verification step (backbone tolerability stable; backbone monitoring labs current; backbone selection appropriate for the planned integrated-regimen indication).

• Phase B — adjunct-stack initiation. Per [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] §4.3 standard dosing protocol: CJC-1295 (without DAC; Mod-GRF 1-29) 100 mcg + Ipamorelin 200 mcg SubQ combined-injection bedtime fasted-state, 5 days on / 2 days off, 12–16 week cycle; MOTS-c 5–10 mg (10 mg typical) SubQ AM, 3x/week (standard) or 10 mg weekly pulse (alternative), 4 weeks on / 4 weeks off cycling within the broader 12–16 week stack cycle. Initiation timing depends on the §1.5 phenotype branch (Branch A or B anticipatory at backbone target dose; Branch C reactive at DEXA-triggered timepoint).

Pattern AA.marketing-claims discipline at this section: the backbone titration / target doses are FDA-label-recommended (or trial-protocol-recommended for retatrutide pre-approval); the adjunct dosing is practitioner-consensus per the adjunct-stack canonical, NOT FDA-label-recommended (no FDA label exists for any of the three adjunct compounds). §10.6 counseling beat carries this distinction.

4.2 Backbone selection — Pattern Z Anchor 4 multi-dimensional comparator

Backbone selection is phenotype-guided per the Pattern Z Anchor 4 multi-dimensional comparator framework. The selection is NOT a one-dimensional weight-magnitude comparison; the conversation presents 8+ comparator dimensions for shared decision-making.

The three backbone options.

• Semaglutide (Wegovy 2.4 mg OR Wegovy HD 7.2 mg) — FDA-approved-for-marketing-claims for chronic weight management (Wegovy 2021; Wegovy HD 2026-03-19). Single GLP-1R agonist; ~7-day half-life; once-weekly subcutaneous injection (Wegovy / Ozempic) or once-daily oral (Rybelsus 25 mg for T2D approved 2025). Effect-size anchors: STEP-1 (PMID 33567185) ~−14.9% at Wegovy 2.4 mg / 68 weeks in non-diabetic obesity; STEP UP (Wharton 2025 PMID 40961952) ~−18.7% at Wegovy HD 7.2 mg / 72 weeks. Indication portfolio: T2D (Ozempic 2017; Rybelsus 2019); CWM (Wegovy 2021; Wegovy HD 2026-03); adolescent CWM ≥12 (STEP-TEENS PMID 36322838); CV-risk-reduction in T2D + CVD (SUSTAIN-6 PMID 27633186); CV-risk-reduction in non-diabetic obesity + CVD (SELECT PMID 37952131; FDA label expansion 2024); MASH F2/F3 (ESSENCE PMID 40305708; FDA approval 2025-08-15); CKD-in-T2D (FLOW PMID 38785209; FDA approval 2024). Investigational extensions: HFpEF + obesity (STEP-HFpEF PMID 37622681 KCCQ-CSS between-group treatment difference +7.8 points; per-arm +16.6 semaglutide vs +8.7 placebo). NAION signal documented per Hathaway 2024 PMID 38958939 (post-marketing pharmacovigilance; signal under evaluation; not labeled warning as of 2026-05-14).

• Tirzepatide (Zepbound 15 mg) — FDA-approved-for-marketing-claims for chronic weight management (Zepbound 2023) and moderate-to-severe OSA with obesity (Zepbound 2024-12). Dual GLP-1R / GIPR agonist; ~5-day half-life; once-weekly subcutaneous injection. Effect-size anchors: SURMOUNT-1 (PMID 35658024) ~−20.9% treatment-regimen / ~−22.5% efficacy estimand at 15 mg / 72 weeks in non-diabetic obesity; SURMOUNT-5 head-to-head (Aronne 2025 PMID 40353578) tirzepatide −20.2% vs semaglutide −13.7% at week 72 max-tolerated-dose comparison; SURPASS-2 head-to-head in T2D (PMID 34170647) tirzepatide HbA1c reductions −2.01% / −2.24% / −2.30% (5 / 10 / 15 mg) vs semaglutide 1 mg −1.86% at 40 weeks. Indication portfolio: T2D (Mounjaro 2022); CWM (Zepbound 2023); moderate-to-severe OSA with obesity (Zepbound 2024-12 per SURMOUNT-OSA PMID 38912654 — first FDA-approved pharmacological agent for OSA with obesity). Investigational extensions: HFpEF + obesity (SUMMIT PMID 39555826; HR 0.62); MASH F2/F3 (SYNERGY-NASH Phase 2 PMID 38856224; Phase 3 in development); CV outcomes (SURMOUNT-MMO active; readout 2027-10); pediatric T2D (SURPASS-PEDS Phase 3 PMID 40975112). NAION signal absent per Lawrenson 2025 PMID 40383360 (class-differentiation within GLP-1 RA family); DR signal stratified per Buckley 2025 PMID 40637847 (OR 2.15 in overall multivariate; OR 0.73 in no-baseline-DR subgroup).

• Retatrutide (12 mg per TRIUMPH-4 sponsor topline) — pre-FDA-approval-for-marketing-claims. Triple GLP-1R / GIPR / GCGR agonist; ~6-day half-life; once-weekly subcutaneous injection. Effect-size anchors: Phase 2 obesity (Jastreboff 2023 NEJM PMID 37366315) up to ~−24.2% at 12 mg / 48 weeks (treatment-policy estimand); TRIUMPH-4 obesity + knee OA (NCT05931367; sponsor topline December 2025) ~−28.7% at 12 mg / 68 weeks vs placebo (peer-reviewed primary publication PMID assignment pending as of 2026-05-14). Phase 2a MASLD substudy (Sanyal 2024 PMID 38858523) ~−82% MRI-PDFF reduction at 12 mg / 48 weeks. TRIUMPH Phase 3 program: TRIUMPH-1 obesity (NCT05929066; primary completion 2026-04; ACTIVE_NOT_RECRUITING); TRIUMPH-3 severe obesity + CVD; TRIUMPH-4 obesity + knee OA; TRIUMPH-Outcomes BMI ≥27 + ASCVD/CKD MACE/MAKE composite (n=10,000; primary completion 2029-02); TRANSCEND-T2D-1/-2/-3; SYNERGY-Outcomes Phase 3 MASLD multi-agent master protocol (NCT07165028; RECRUITING). Pattern AA.marketing-claims precision throughout: retatrutide is pre-FDA-approval-for-marketing-claims; access is via active TRIUMPH program enrollment OR clinician-judgment off-label investigational-supply use where research-protocol acquisition pathways exist; the anticipated post-approval indication scope is multi-indication (CWM, T2D, CV, MASLD, knee OA, CKD-in-T2D) but the specific FDA-approved indications and labels emerge at FDA approval. Cardiac glucagon-receptor expression / inotropic-effects research-state context per PMID 40613938 (preclinical work in isolated human atrial preparations); class-level heart-rate elevation (typically 2–4 bpm at therapeutic doses) characterized per PMID 41582189.

The 8+ comparator dimensions for the backbone-selection conversation (Pattern Z Anchor 4):

1. Weight-loss magnitude (Pattern V trial-anchored, Pattern V.metric-axis disclosed). Sema 2.4 mg ~−14.9% (STEP-1 PMID 33567185 treatment-policy estimand) / sema HD 7.2 mg ~−18.7% (STEP UP PMID 40961952); tirz 15 mg ~−20.9% treatment-regimen / ~−22.5% efficacy estimand (SURMOUNT-1 PMID 35658024); reta 12 mg ~−24.2% Phase 2 treatment-policy (Jastreboff 2023 PMID 37366315) / ~−28.7% Phase 3 sponsor topline (TRIUMPH-4 December 2025 disclosure; peer-reviewed publication pending). Head-to-head: SURMOUNT-5 tirzepatide −20.2% vs semaglutide −13.7% at week 72 (PMID 40353578). No head-to-head Wegovy HD 7.2 mg vs Zepbound 15 mg trial exists as of 2026-05-14. No head-to-head retatrutide vs tirzepatide trial completed as of 2026-05-14; TRIUMPH-5 head-to-head retatrutide vs tirzepatide (NCT06662383; primary completion 2026-12; ACTIVE_NOT_RECRUITING) is the forthcoming direct comparison.

2. T2D glycemic effect. Sema 1 mg HbA1c reduction ~−1.8 percentage points (SUSTAIN-7); sema 2 mg ~+0.2 pp incremental (SUSTAIN FORTE); tirz 15 mg HbA1c reduction ~−2.30 pp head-to-head vs sema 1 mg ~−1.86 pp (SURPASS-2 PMID 34170647); reta Phase 2 T2D HbA1c reductions across dose-response framework (Rosenstock 2023 PMID 37385280).

3. Cardiovascular outcomes evidence base. Sema: SELECT (PMID 37952131; HR ~0.80 for 3-point MACE in BMI ≥27 + established CVD without T2D); SUSTAIN-6 (PMID 27633186; HR ~0.74 in T2D + established CVD). Tirz: SUMMIT HFpEF + obesity HR 0.62 (PMID 39555826); SURMOUNT-MMO CV outcomes pending 2027-10. Reta: TRIUMPH-3 + TRIUMPH-Outcomes pending Phase 3 readouts.

4. MASH evidence base. Sema: ESSENCE Phase 3 (PMID 40305708; FDA-approved 2025-08-15 for F2/F3 MASH; ~62.9% MASH resolution without worsening fibrosis vs 34.3% placebo; ~36.8% fibrosis improvement vs 22.4% placebo at 72 weeks). Tirz: SYNERGY-NASH Phase 2 (PMID 38856224; MASH resolution 44% / 56% / 62% at 5 / 10 / 15 mg vs 10% placebo); Phase 3 in development. Reta: Phase 2a MASLD substudy ~−82% MRI-PDFF reduction (Sanyal 2024 PMID 38858523); SYNERGY-Outcomes Phase 3 MASLD pending.

5. Kidney outcomes evidence base. Sema: FLOW (PMID 38785209; HR ~0.76 in T2D + CKD). Tirz: SURMOUNT-MMO secondary endpoints. Reta: NCT05936151 renal-outcomes Phase 2 completed; TRIUMPH-Outcomes MAKE composite pending.

6. OSA evidence base. Tirz: SURMOUNT-OSA dual-trial AHI reduction ~−25.3 / −29.3 events/hour (PMID 38912654; first FDA-approved pharmacological agent for OSA with obesity). Sema: not directly studied. Reta: not directly studied.

7. Ophthalmologic class-differentiation (NAION + DR). Sema: NAION signal documented per Hathaway 2024 (PMID 38958939; post-marketing pharmacovigilance; signal under evaluation; not labeled warning as of 2026-05-14). Tirz: NAION signal absent per Lawrenson 2025 (PMID 40383360); DR signal baseline-status-stratified per Buckley 2025 (PMID 40637847; OR 2.15 overall multivariate; OR 0.73 protective in no-baseline-DR subgroup). Reta: retatrutide-specific NAION characterization research-state-pending TRIUMPH Phase 3 ophthalmologic safety reporting. Pattern V discipline: signal-direction is not generalized beyond what is established per backbone.

8. GI tolerability profile. All three backbones have GI-dominant AE profile; cross-trial-program comparison places tirzepatide GI AE incidence similar-to-modestly-higher than semaglutide at equivalent body-weight-reduction magnitudes; retatrutide GI AE profile in Phase 2 was dose-dependent with peak frequencies at the 8 mg and 12 mg arms.

9. Route / platform availability. Sema: SubQ (Wegovy / Ozempic) + oral (Rybelsus 25 mg approved 2025 for T2D). Tirz: SubQ (Zepbound / Mounjaro) only as of 2026-05-14. Reta: SubQ (TRIUMPH trial supply or research-protocol acquisition; no FDA-approved formulation as of 2026-05-14).

10. Cost and access. Patient-specific; insurance coverage variable by indication and jurisdiction. Compounded vs branded compounded-pharmacy considerations apply for semaglutide and tirzepatide (Wegovy + Zepbound — see Anchor 1+2 framing in §10.3); retatrutide compounded-vs-trial-supply considerations apply per [[Retatrutide Protocol]] §10.3.

11. Backbone-specific contraindication context. All three carry the class-wide MTC / MEN-2 boxed warning. Severe gastroparesis: tirzepatide product label includes severe gastroparesis as functional contraindication. Severe prior pancreatitis: class-level precaution / cautionary use across all three.

12. Backbone-adjunct interaction context. All three backbones are compatible with the adjunct stack on mechanism grounds — no contraindicated combinations across backbone × adjunct (verify §9 contraindicated combinations). The integrated regimen sequencing rules in §9 apply uniformly across the three backbone selections.

Phenotype-guided backbone selection per integrated-regimen indication. The backbone selection is patient-anchored within the §4.2 multi-dimensional comparator framework. Typical patterns (not exhaustive):

• Polycondition phenotype (T2D + ASCVD + CKD ± MASH). Semaglutide is the polycondition-anchored choice given the FDA-approved-for-marketing-claims indication portfolio across T2D (Ozempic) + CV risk (SUSTAIN-6, SELECT) + MASH (ESSENCE) + CKD-in-T2D (FLOW) — a single backbone covering most polycondition indications. Tirzepatide alternative supported by SURPASS-2 head-to-head in T2D and SURMOUNT-OSA for OSA comorbidity; SUMMIT for HFpEF + obesity (investigational). Retatrutide alternative supported by anticipated multi-indication coverage post-FDA-approval.
• OSA + obesity phenotype. Tirzepatide is the OSA-indication-anchored choice (Zepbound 2024-12 OSA approval per SURMOUNT-OSA). Sema and reta do not have OSA indications.
• High-target-weight-loss phenotype (>20%). Tirzepatide 15 mg (~−22.5% efficacy estimand per SURMOUNT-1) or retatrutide 12 mg (~−24.2% Phase 2 / ~−28.7% Phase 3 sponsor topline) are the high-magnitude options. Wegovy HD 7.2 mg (~−18.7% per STEP UP) closes the gap modestly. The high-target-weight-loss phenotype intersects most directly with the stacked-regimen lean-mass-preservation indication — high absolute lean-mass-loss across the larger weight-loss range.
• Pre-FDA-approval willingness phenotype. Retatrutide via active TRIUMPH trial enrollment OR clinician-judgment off-label investigational-supply use under explicit informed consent. The §10.6 stacked off-label counseling beat addresses the double off-label / off-pathway combination (pre-FDA-approval primary agent + research-state adjunct stack).
• Compounded-vs-branded preference. All three backbones have compounded-pharmacy access pathways; the §10.3 Anchor 1+2 counseling beat addresses the compounded-vs-branded conversation per [[Semaglutide Protocol]] §10.3 + [[Tirzepatide Protocol]] §10.3 + [[Retatrutide Protocol]] §10.3.
• Prior backbone intolerance. Prior semaglutide intolerance at therapeutic dose with non-GI-AE pattern (e.g., persistent eructation; injection-site reaction) → tirzepatide or retatrutide consideration per § comparator. Prior tirzepatide intolerance at therapeutic dose (the §1.5 / §2.3 retatrutide Pattern V signal) → semaglutide alternative or retatrutide with informed consent about dual-incretin-class overlap.

4.3 Phase A — backbone initiation or backbone target-dose verification

Phase A.1 — backbone-naive patient. Standard backbone-protocol §4 titration per the chosen backbone:

• Semaglutide Wegovy (CWM): 0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks (or slow-titration variant doubling each interval per [[Semaglutide Protocol]] §4.3). Wegovy HD 7.2 mg adds 3.2 mg → 4.5 → 6.0 → 7.2 mg titration steps post-2.4 mg attainment per STEP UP protocol. For T2D-indication semaglutide Ozempic: 0.25 mg → 0.5 → 1.0 → 2.0 mg target per SUSTAIN protocols.

• Tirzepatide Zepbound (CWM): 2.5 mg → 5 → 7.5 → 10 → 12.5 → 15 mg over 20 weeks per [[Tirzepatide Protocol]] §4.3 (4-week interval at each step).

• Retatrutide: 2 mg → 4 → 6-8 → 9-12 mg over ~12 weeks per Phase 2 protocol (Jastreboff 2023 PMID 37366315) OR 2 mg → 4 → 8 → 12 mg over ~12-16 weeks per anticipated Phase 3 / post-approval framework (Giblin 2026 PMID 41090431 design paper).

The backbone initiation discipline is anchored to the constituent backbone-protocol §4 — the integrated-regimen protocol does not re-state the full titration framework but references each backbone’s canonical titration. GI tolerability management at each titration step per the backbone-protocol §4.4.

Phase A.2 — backbone-established patient. Verify: backbone target dose attained for ≥3 months; backbone tolerability stable (no active escalation of backbone-protocol §6 AE class); backbone monitoring labs current; weight-loss trajectory documented (typically ≥5% of starting body weight by Month 3 of backbone target dose to confirm GLP-1-driven catabolic-pressure-positive state; if weight loss is below this threshold, evaluate per §7 non-response algorithm before considering integrated-regimen initiation — the lean-mass-preservation indication is contingent on the catabolic weight-loss pressure being created by the backbone). Backbone-established patients are the typical integrated-regimen initiation phenotype, particularly for Branch C (DEXA-triggered / mid-trajectory) sequencing.

4.4 Phase B — adjunct-stack initiation per the three-branch phenotype framework

Branch A — sarcopenic baseline / older adult phenotype (anticipatory). Adjunct stack initiated at backbone target dose attainment (Month 3+ on backbone target). The patient has documented baseline sarcopenic risk (age ≥65, post-menopausal with low baseline lean mass, prior sarcopenia signal on grip strength, or documented baseline DEXA lean-mass below age/sex-specific population median). Anticipatory deployment rationale: baseline risk high enough that anticipatory adjunct deployment is mechanism-class-favorable; waiting for documented lean-mass loss exposes the patient to preventable lean-mass reduction during the first months of the catabolic arc.

Branch B — athletic / high-baseline-lean-mass phenotype (anticipatory). Adjunct stack initiated at backbone target dose attainment (Month 3+ on backbone target). The patient has documented baseline athletic / high-baseline-lean-mass profile (well-developed skeletal muscle; baseline grip strength and 5-STS in favorable percentiles; athletic / strength-training history). Anticipatory deployment rationale: absolute lean-mass at risk is large; relative lean-mass loss is more visible to the patient; absolute lean-mass-loss magnitude across planned target weight-loss range (typically >15%) is operationally meaningful. WADA caveat reiterated: competitive athletes subject to WADA testing are ineligible for the adjunct stack regardless of phenotype-targeting.

Branch C — post-50lb / DEXA-triggered / mid-trajectory phenotype (reactive). Adjunct stack initiated at the DEXA-triggered timepoint (typically Month 6–12 on backbone). The patient has documented mid-trajectory weight loss (8–20% already achieved) AND a 12-week or 24-week DEXA showing lean-mass-loss fraction modestly above the trial-program-pooled range (>30% for semaglutide backbone; >25% for tirzepatide backbone; retatrutide-backbone threshold pending Phase 3 DEXA substudies) AND/OR functional measure decline (grip strength relative decline; 5-STS prolongation) AND/OR continuing target weight-loss arc with substantial remaining weight loss planned. Reactive deployment rationale: DEXA signal documents lean-mass-preservation need; adjunct stack is deployed for the remaining catabolic-pressure window plus the transition to maintenance.

Branch-agnostic adjunct stack dosing. Per [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] §4.3:

• CJC-1295 (Mod-GRF 1-29; without DAC): 100 mcg SubQ bedtime (≥2 hours post-meal; fasted state — load-bearing for the GH-pulse response), 5 days on / 2 days off (or daily x 7 per clinician discretion), 12–16 week cycle.
• Ipamorelin: 200 mcg SubQ bedtime combined with CJC-1295 in same syringe.
• MOTS-c: 5–10 mg (10 mg typical) SubQ AM (typically before breakfast or fasting morning), 3x/week (standard) or 10 mg weekly pulse (alternative), 4 weeks on / 4 weeks off cycling within the 12–16 week stack cycle.
• Combined injection logistics. CJC-1295 + Ipamorelin combined in same syringe at point of administration (pre-combined blends available from many 503A compounding pharmacies); MOTS-c always separate injection (different timing AM vs bedtime; different reconstitution / stability profile; do NOT shake MOTS-c reconstituted product — gentle swirling preserves alpha-helical structure; use within 2–7 days of reconstitution).
• Cycle duration. 12–16 weeks on; 4–8 weeks off; typically 2–3 total cycles per active-weight-loss arc; maximum operational duration ~6–12 months total stack exposure aligned with backbone active-weight-loss phase.

Fasted-state requirement is load-bearing for the GH-axis component. Bedtime CJC-Ipa in fasted state (≥2 hours post-meal) aligns with the natural slow-wave-sleep endogenous GH pulse; fed-state administration substantially blunts the GH response and defeats the mechanism. This is not optional; §10.2 initiation counseling reinforces.

Backbone injection timing vs adjunct injection timing — no conflict. Weekly backbone (semaglutide / tirzepatide / retatrutide) injection is patient-selected weekday; bedtime CJC-Ipa daily and AM MOTS-c are independent of backbone injection timing. The integrated regimen’s injection schedule is: backbone once weekly (any day); CJC-Ipa bedtime daily 5-on/2-off; MOTS-c AM 3x/week or weekly pulse. No two injections are administered simultaneously; CJC-Ipa and MOTS-c use 30G insulin syringes (the same gauge / technique as the patient’s existing backbone self-injection — Pattern Z.injection-framing: routine clinical skill equivalent to existing GLP-1 RA self-injection).

4.5 Backbone-stack interaction considerations at initiation

No pharmacokinetic interactions documented. GLP-1 RA backbones are receptor-mediated (incretin receptors on pancreatic β-cells, hypothalamus, etc.); GH-axis adjunct compounds engage pituitary GHRH-R + GHS-R1a; MOTS-c engages mitochondrial / AMPK pathway. Direct pharmacokinetic interactions are not documented across the integrated regimen.

Pharmacodynamic considerations — directional pressures.

• Appetite axis. Backbone-side: appetite suppression is a primary backbone mechanism. Adjunct-side: Ipamorelin engages GHS-R1a (the ghrelin receptor) but at the selective-binding profile and the 200 mcg dose does not produce appetite-stimulating effect; MOTS-c does not engage appetite mechanism. Net integrated-regimen appetite effect: backbone-dominated (suppression).
• Glucose-tolerance axis. Backbone-side: improving directional pressure (all three GLP-1 RAs). MOTS-c: improving directional pressure (insulin-sensitization via AMPK). GH-axis adjunct (CJC-Ipamorelin): at supraphysiologic levels, insulin-antagonist directional pressure; at physiologic-range dosing target (IGF-1 Z 0 to +1), the directional pressure is typically not clinically meaningful. Net integrated-regimen glucose-tolerance effect: typically maintained-or-improved against pre-stack on-backbone baseline; reversal is uncommon but is a §6.7 + §6.10 monitoring trigger.
• GI motility axis. Backbone-side: delayed gastric emptying (all three backbones). Adjunct-side: no direct GI motility effect. Net: backbone-dominated.
• Cardiovascular axis. Backbone-side: heart rate elevation (modest; class-level 2–4 bpm at therapeutic doses per PMID 41582189); BP reduction (modest; class-level 3–5 mmHg SBP); CV-event-reduction in established CVD or BMI ≥27 + CVD per backbone-specific CVOT (SUSTAIN-6, SELECT for sema; SURMOUNT-MMO pending for tirz; TRIUMPH-3 / TRIUMPH-Outcomes pending for reta). Adjunct-side: no documented arrhythmogenic profile in practitioner-observation literature for the GH-axis stack; mild transient fluid retention (peripheral edema) per adjunct-stack canonical §6.4. Net integrated-regimen CV directional pressure: backbone-dominated (improving CV-risk in established-CVD populations); §6 surveillance overlays adjunct fluid-retention monitoring.

The retatrutide-backbone-specific cardiac glucagon-receptor research-state. Cardiac glucagon-receptor expression and inotropic-effects characterization per PMID 40613938 (preclinical work in isolated human atrial preparations) is research-state-active research direction for retatrutide; the integrated regimen with retatrutide backbone + adjunct stack carries this research-state-pending overlay. Heart rate is monitored at clinic visits per the class-level heart-rate elevation framework; the TRIUMPH-3 (severe obesity + CVD) and TRIUMPH-Outcomes (event-driven MACE/MAKE composite) Phase 3 trial cardiac safety primary endpoints will populate the human-trial-population cardiac safety evidence base for retatrutide.

4.6 Early monitoring cadence — integrated-regimen initiation period

The integrated-regimen early-monitoring cadence consolidates the backbone-protocol §4.5 and adjunct-stack §4.6 cadences:

• Backbone Week 2 / 5–6 / 9–12 / 17–20 contact per the chosen backbone protocol (semaglutide § 4.6 / tirzepatide § 4.5 / retatrutide § 4.5). For backbone-established patients (Phase A.2), this cadence is already in place at maintenance frequency.
• Adjunct stack Week 1 contact (telehealth or phone post-first-adjunct-dose tolerability check). Verify reconstitution discipline (especially MOTS-c reconstitution and storage; do NOT shake); verify injection technique and site rotation; verify dosing-timing adherence (fasted-state bedtime CJC-Ipa; AM MOTS-c); verify Tier 1 foundation maintenance.
• Adjunct stack Week 2–4 contact (telehealth or in-person mid-cycle tolerability check). Verify adherence; document any tolerability concerns; verify no new symptoms suggestive of glucose-tolerance worsening, sleep-apnea exacerbation, or unexpected AE.
• Integrated-regimen Week 8 in-person visit. Mid-stack-cycle comprehensive reassessment. IGF-1, fasting glucose, HbA1c, fasting insulin (§5.3 monitoring labs); body-composition reassessment (DEXA or BIA; functional measures); review per-compound adherence and operational considerations; reconcile with the backbone monitoring visit cadence to optimize patient visit burden. For Branch A and Branch B (anticipatory deployment at backbone target dose), the Week 8 visit is the first integrated-regimen body-composition check. For Branch C (DEXA-triggered deployment), the Week 8 visit is the first post-stack-initiation IGF-1 check; the body-composition trajectory was already documented at DEXA-trigger timepoint and the next DEXA is at Week 12 of stack cycle.
• Integrated-regimen Week 12 in-person visit. End-of-stack-cycle comprehensive reassessment. IGF-1 / glucose / HbA1c / fasting insulin / DEXA / functional measures. Compare lean-mass trajectory to pre-stack baseline and to expected unsupplemented trajectory. Make Cycle 2 decision per §5.5 inter-cycle reassessment.

Contact modality (in-person vs telehealth vs message) is practice-specific. Escalation triggers: any contact identifying severe AE, suspected pancreatitis, suspected gallbladder event, suspected NAION (semaglutide-backbone), suspected DR progression (tirzepatide-backbone in DR-positive patients), suspected severe glucose worsening, sleep-apnea exacerbation, vision change, severe injection-site reaction, suspected hypersensitivity → in-person evaluation within 48 hours.

4.7 Worked example — integrated-regimen initiation for the §1.7 / §2.5 / §3.11 patient

The 54-year-old post-menopausal female from §1.7 (on Wegovy 2.4 mg Month 6, ~12% weight loss, lean-mass-loss fraction ~33% on 12-week DEXA, Tier 1 adherent, no contraindications). Phenotype branch: dual Branch A baseline (post-menopausal sarcopenic-risk) + Branch C reactive (documented elevated lean-mass-loss fraction). Backbone selection: Wegovy 2.4 mg (already established).

Phase A — backbone target-dose verification. Wegovy 2.4 mg, Month 6 on target dose; backbone tolerability stable (no active escalation of §6 backbone AE class); backbone monitoring labs current; weight-loss trajectory documented (~12% from baseline, on STEP-1 trajectory). Phase A verification: complete; proceed to Phase B.

Phase B — adjunct stack initiation, Day 0 initiation visit. Confirm informed-consent counseling complete per §10 (Anchor 5 off-label + Anchor 1+2 compounded + Anchor 3 pregnancy [n/a post-menopausal] + Anchor 4 backbone comparator [for context — Wegovy already chosen] + Tier 1 foundation framing). Provide reconstitution training: CJC-Ipamorelin compounded vials (typically lyophilized 2 mg or 5 mg vials of each compound, or pre-combined blend) with bacteriostatic water for reconstitution per pharmacy directions; draw 100 mcg CJC + 200 mcg Ipa into single 30G insulin syringe. MOTS-c separate reconstitution (10 mg lyophilized vial; reconstitute with 1.0–2.0 mL bacteriostatic water; do NOT shake; gentle swirling; store at 2–8°C; use within 2–7 days). Demonstrate subcutaneous injection technique (abdominal SC, rotate sites; equivalent to existing Wegovy injection technique — Pattern Z.injection-framing: routine clinical skill).

Week 1 contact. Telehealth tolerability check. Patient reports mild injection-site erythema with first MOTS-c dose (resolving within 24 hours); no other concerns. Reinforce site rotation; verify reconstitution and storage discipline.

Weeks 2–4. Continue protocol per §4.4. Mid-cycle tolerability remains within expected range.

Week 8 in-person visit. First mid-stack-cycle IGF-1 + glucose + DEXA reassessment. Verify IGF-1 trajectory (typically rising from mid-reference baseline toward upper-quartile target; for this 54-year-old post-menopausal female, age-specific upper reference ~280 ng/mL); verify fasting glucose and HbA1c remain on the Wegovy-driven improving trajectory or stable; verify body-composition trajectory (early signal; typically not definitive at 8 weeks; 12-week timepoint is the operational read).

Week 12 in-person visit (end of Cycle 1 on phase). Comprehensive reassessment. IGF-1, glucose / HbA1c, fasting insulin, DEXA, functional measures. Compare lean-mass trajectory to pre-stack baseline (her 12-week-on-Wegovy DEXA at ~33%) and to expected unsupplemented trajectory. The clinically meaningful read: whether the lean-mass-loss fraction is trending toward the practitioner-observation expectation of ~15–20% (reduced from her pre-stack ~33%). Continue to Week 16 of Cycle 1; transition to washout per §5.5.

Pattern V applied to §4.7. The lean-mass-loss-fraction effect-size expectation (~33% pre-stack → ~15–20% expected on integrated regimen with Tier 1 foundation) is practitioner-observation, not Phase 3 RCT-anchored for the combined regimen. The per-component evidence is strong (semaglutide STEP-1 PMID 33567185 for the ~14.9% weight anchor; Look 2025 PMID 39996356 for the baseline lean-mass-loss-fraction expectation; CJC-Ipamorelin per-compound mechanism evidence at Tier 1/2 per the adjunct-stack canonical §11.2; MOTS-c mechanism at Tier 1). The integrated-regimen effect-size is practitioner observation; §10.6 counseling beat frames the expectation at that resolution.

Pattern AA.marketing-claims applied to §4.7. The backbone (Wegovy 2.4 mg semaglutide) is FDA-approved-for-marketing-claims for CWM in adults with BMI ≥30 or ≥27 with comorbidity per Wegovy 2021 label; the adjunct compounds (CJC-1295 without DAC; Ipamorelin; MOTS-c) are NOT FDA-approved-for-marketing-claims for any drug indication; the integrated regimen combines an FDA-approved-for-marketing-claims backbone with three research-state adjuncts. Per-component regulatory framing precise throughout.

Pattern Z.injection-framing applied to §4.7. The additional injections (bedtime combined CJC-Ipa + AM MOTS-c) are subcutaneous with 30G insulin syringe — routine clinical skill, taught in the integrated-regimen initiation visit, equivalent in technique to the patient’s existing Wegovy self-injection. No “scary” / “daunting” / “intimidating” framing applied; self-injection presented factually.

---

5. Maintenance protocol — stacked-regimen monitoring

5.1 Purpose

Define the post-initiation, on-cycle operating state of the integrated regimen: target doses across backbone + adjunct, monitoring intervals, dose-adjustment triggers, the cycle structure for the adjunct, and the transition between maintenance, plateau-or-non-response (§7), and discontinuation (§8). For the integrated regimen, the maintenance phase has two distinct rhythms: the backbone is open-ended at target dose for the duration of clinical benefit (or until the GLP-1 RA transitions to maintenance-at-target-weight per the backbone-protocol §8); the adjunct stack is cyclical (12–16 weeks on / 4–8 weeks off; up to 2–3 total cycles per active-weight-loss arc; planned discontinuation at lean-mass-preservation goal achievement or GLP-1 transition-to-maintenance per §8.2).

Section 5 is the longest operational phase of the integrated regimen — for a patient who tolerates target doses and continues both the backbone and the adjunct stack, the backbone maintenance is open-ended and the adjunct stack runs its cyclical structure across the active-weight-loss arc plus the pre-maintenance transition phase.

5.2 Target doses — backbone + adjunct

Backbone target doses per backbone selection:

• Semaglutide Wegovy: 2.4 mg SubQ once weekly (CWM target dose). For sema HD: 7.2 mg SubQ once weekly per STEP UP. For sema Ozempic in T2D-indication integrated regimens: 1.0 mg or 2.0 mg weekly; FLOW-anchored CKD-in-T2D typically 1.0 mg with 2.0 mg titration permitted if HbA1c target not met and tolerability permits.
• Tirzepatide Zepbound: 5 / 10 / 15 mg SubQ once weekly per individualized titration to maximum-tolerated dose. The 15 mg dose is the SURMOUNT-1 efficacy-estimand anchor and the standard target for max-effect-magnitude CWM patients; 10 mg or 5 mg target for tolerability-priority patients. SURMOUNT-OSA Trial 1 + Trial 2 enrollment used max-tolerated-dose framework (typically 10 or 15 mg).
• Retatrutide: 12 mg SubQ once weekly per the Phase 2 obesity / Phase 2a MASLD / TRIUMPH-4 framework; 8 mg as tolerability-preferred alternative. Pattern AA precision: anticipated post-approval target-dose framework; label-recommended target dose emerges at FDA approval.

Adjunct target doses (uniform across backbone selection):

• CJC-1295 (Mod-GRF 1-29; without DAC): 100 mcg SubQ bedtime fasted-state, 5-on/2-off, 12–16 wk cycle.
• Ipamorelin: 200 mcg SubQ bedtime combined with CJC-1295.
• MOTS-c: 5–10 mg (10 mg typical) SubQ AM, 3x/week or 10 mg weekly pulse, 4-on/4-off within stack cycle.

5.3 Monitoring intervals — integrated regimen

The integrated-regimen monitoring schedule consolidates the backbone-protocol §5.3 + adjunct-stack §5.3 cadences, reconciled to minimize patient visit burden:

Routine quarterly visits during the first year on integrated regimen. Months 4, 7, 10, 13 from integrated-regimen initiation (or quarterly from adjunct-stack-cycle-1 initiation if backbone is established at integrated-regimen initiation). At each visit: weight, BP, brief AE-and-adherence interview, body-composition reassessment per §3.8 cadence (DEXA at Weeks 12 and 24 of each stack cycle; biannual thereafter), indication-specific labs (HbA1c for T2D-indication backbones; lipid panel; UACR and eGFR for CKD-context; ALT/AST for MASH-context or retatrutide-backbone hepatic surveillance per [[Retatrutide Protocol]] §5.3; functional measures for the stacked-regimen body-composition endpoint).

Stacked-regimen-specific monitoring at Week 8–12 of each adjunct stack cycle. IGF-1 with age/sex Z-score (the load-bearing on-protocol monitoring lab); fasting glucose, HbA1c, fasting insulin (the glucose-tolerance surveillance for the dual directional pressure on glucose metabolism). The Week 8–12 timepoint of each stack cycle is the operational read for adjunct-stack dose-adjustment per §5.4 + §6.10.

Body-composition reassessment at Week 12 and Week 24 of each adjunct stack cycle. DEXA (or BIA) plus functional measures (grip strength, 5-STS). Body-composition reassessment is the load-bearing stacked-regimen endpoint — the lean-mass trajectory is the clinical question the integrated regimen is deployed to address (beyond the backbone-driven weight-loss trajectory).

Annual cancer-surveillance. PSA in men ≥40; mammography in women ≥40 per standard screening intervals. Cancer-surveillance baseline from §3.4 carries forward as on-protocol surveillance.

Biannual maintenance-stable patients. Once the patient is stable on the integrated regimen (typically Year 2+ with no AE escalation or dose adjustment), the visit cadence transitions to biannual; IGF-1 and DEXA continue at the cycle-aligned cadence during active stack cycles; PSA / mammography continue annually / per standard intervals.

Symptom-prompted labs and imaging. Lipase if abdominal pain (pancreatitis-suspect — backbone-side); LFTs if hepatic-symptom or retatrutide-backbone scheduled surveillance per [[Retatrutide Protocol]] §5.3; ECG if cardiac symptom; ophthalmology if vision change (NAION-suspect for sema-backbone; DR-progression-suspect for tirz-backbone in DR-positive patients); sleep study if new daytime sleepiness or apnea symptoms.

5.4 Dose-adjustment triggers — integrated regimen

Dose adjustment in the maintenance phase of the integrated regimen is driven by three trigger categories at each component level (backbone or adjunct):

Backbone dose-adjustment triggers (per the backbone-protocol §5.4):

• Target-not-met. For CWM-backbone: <5% weight loss at Month 6 on backbone target dose with documented adherence → §7 non-response algorithm or backbone transition. For T2D-backbone: HbA1c above individualized target at Month 6 → escalate dose (sema 1.0 → 2.0 mg; tirz 10 → 15 mg) or transition.
• Target-overshoot. Unintended weight loss below patient’s pre-specified target floor; hypoglycemia risk in T2D-context with concurrent insulin / sulfonylurea.
• AE-emergent. Persistent moderate-severity GI AE; backbone-side AE-class triggers per backbone-protocol §6.

Adjunct stack dose-adjustment triggers (per adjunct-stack canonical §5.4):

• IGF-1 above reference range. Primary adjunct dose-reduction trigger. If on-protocol IGF-1 exceeds age/sex-specific reference upper bound, reduce CJC-1295 to 75 mcg or 50 mcg per injection; or reduce frequency (4-on/3-off instead of 5-on/2-off). Re-check IGF-1 in 4–8 weeks. Persistent above-reference IGF-1 despite dose-reduction → discontinue GH-axis component pending endocrinology consultation.
• Glucose-tolerance trajectory reversal. If HbA1c rises >0.3 percentage points from pre-stack on-backbone baseline, or fasting glucose rises into pre-T2D range, reduce CJC-1295 or temporarily hold the GH-axis component while continuing MOTS-c and backbone.
• Body-composition trajectory. If 12-week DEXA shows lean-mass trajectory consistent with practitioner-observation expectation (~15–20% lean-mass-loss fraction; reduced from pre-stack baseline), continue current adjunct dose. If trajectory is flat (no improvement vs pre-stack lean-mass-loss fraction) and adherence is confirmed, → §7 plateau / non-response algorithm.
• AE-emergent triggers per adjunct-stack canonical §6.
• Patient preference. Patient-anchored adjunct dose adjustment is legitimate; the protocol’s role is to inform, not override.

Integrated-regimen-specific dose-adjustment considerations.

• Backbone-adjunct directional-pressure conflict on glucose tolerance. If glucose-tolerance worsening emerges on the integrated regimen, the differential diagnosis includes: (a) backbone tolerability-driven dose reduction → less GLP-1 driven insulin-sensitization; (b) adjunct GH-axis at supraphysiologic levels → insulin-antagonism. The MOTS-c component is insulin-sensitizing and is unlikely to be the driver. Per the §6.7 + §6.10 surveillance discipline, the typical first-line response is reduce CJC-1295 (rather than reduce backbone) given the backbone is the dominant weight-loss driver and the catabolic-pressure-positive state is the indication for the stacked regimen.
• Backbone weight-loss-overshoot with stable body composition. If the patient achieves target weight before completing the planned adjunct-stack cycle (e.g., Cycle 1 patient reaching target weight at Week 8 of stack cycle), the operational decision is: continue current adjunct cycle through Week 12–16 completion (the cycle-end timepoint is the natural washout transition); transition backbone to maintenance dose (per backbone-protocol §8 maintenance-phase transition); plan adjunct discontinuation at end of current cycle per §8.2 goal-achieved trigger.
• Backbone-side AE requires dose-reduction or discontinuation while adjunct stack continues. Per backbone-protocol §6 AE-class management, backbone-side dose-reduction or discontinuation does not automatically require adjunct-stack discontinuation. The adjunct stack’s lean-mass-preservation mechanism is independent of the backbone mechanism (within the integrated-regimen mechanism rationale). However, if backbone is fully discontinued and the catabolic-pressure indication ends, the adjunct stack’s clinical indication also ends — discontinue per §8.2 indication-resolution trigger.

5.5 Cycle structure and inter-cycle reassessment

The adjunct stack operates on a cyclical structure within the open-ended backbone maintenance:

Cycle 1: 12–16 weeks on; 4–8 weeks off. First cycle is the operational learning cycle — establishing reconstitution discipline, adherence, monitoring data, tolerability profile, body-composition trajectory.

Inter-cycle reassessment at end of Cycle 1 washout. Review: was the lean-mass-preservation goal achieved (did the lean-mass-loss fraction trend toward the practitioner-observation expectation)? Is the backbone still in the active-weight-loss phase (patient still losing weight at clinically meaningful rate) or transitioning toward maintenance (weight stable at target)? Is the patient still meeting §1.2 lean-mass-concern triggers, or has the body-composition trajectory normalized? The inter-cycle decision: (a) initiate Cycle 2 (continued active weight-loss phase with lean-mass concern); (b) discontinue stack (lean-mass goal achieved; backbone transitioning to maintenance; patient preference); (c) modify dose or schedule (response trajectory suggests dose adjustment).

Cycle 2 and beyond. If continuing, Cycle 2 typically mirrors Cycle 1. Most patients run 1–3 cycles aligned with their backbone active-weight-loss arc; protracted multi-year adjunct stack use beyond 6–12 months total exposure is uncommon in current practitioner practice. Backbone continues per its own maintenance-phase trajectory.

5.6 Worked example — integrated-regimen maintenance for the §4.7 patient

The 54-year-old post-menopausal female on Wegovy backbone + adjunct stack Cycle 1.

Week 12 monitoring read: IGF-1 has risen from pre-stack 145 ng/mL (age-specific Z-score ~0) to 198 ng/mL (Z-score ~+0.8) — on target, upper-quartile-of-reference, not supraphysiologic. Fasting glucose unchanged from pre-stack on-Wegovy improving trajectory (continued improvement, no reversal). HbA1c stable. DEXA at Week 12 shows continued weight loss over the cycle window with lean-mass-loss fraction ~22% — improved from her pre-stack ~33%, trending toward the practitioner-observation expectation. Grip strength stable at 24 kg (no further relative decline; consistent with the stabilization expectation of lean-mass preservation on the stack). 5-STS stable. Wegovy backbone monitoring: weight continues to trend down (~14% total from baseline now); BP stable; no backbone-side AE escalation.

Cycle 1 continuation decision. Continue Cycle 1 at current doses through Week 16. At Week 16, transition to 4–8 week washout. Re-assess body composition at Month 6 (end of washout) and decide on Cycle 2 based on (a) ongoing weight-loss trajectory on Wegovy; (b) sustained lean-mass-preservation effect; (c) patient preference. Wegovy backbone continues unchanged at 2.4 mg weekly throughout the adjunct washout.

Inter-cycle decision at end of Cycle 1 washout (Month ~6 of integrated regimen / Month ~12 of Wegovy). Body-composition reassessment: DEXA shows continued favorable body-composition trajectory (lean-mass status preserved during washout; the catabolic pressure on Wegovy continues but at slower rate as patient approaches her target weight). Weight: ~16% total from Wegovy baseline. Decision: initiate Cycle 2 to support the final 3–6 months of active-weight-loss arc through Wegovy target-weight attainment; plan adjunct-stack discontinuation at end of Cycle 2 when backbone transitions to maintenance dose.

Pattern W cross-check at §5.6. The Week 12 monitoring read uses the labs and body-composition measures established at §3 baseline (IGF-1, glucose, HbA1c, DEXA, grip strength, 5-STS); no monitoring metric is introduced without baseline-anchor. The §6 AE-trigger labs (lipase if abdominal symptom; ECG if cardiac symptom; ophthalmology if vision change) are not triggered in this patient at this read. Backbone monitoring (Wegovy weight + BP) reconciles with adjunct monitoring at the same visit timepoint — no duplication.

Pattern V cross-check at §5.6. The improvement in lean-mass-loss fraction (~33% → ~22%) is consistent with practitioner-observation expectation for the integrated regimen; it is not anchored to a Phase 3 RCT effect-size because no such trial exists for the combined regimen. The patient’s individual trajectory is one data point within the practitioner-observation distribution; the inter-cycle counseling beat (§5.5) frames the trajectory at that resolution. The continued Wegovy-driven weight-loss trajectory at ~14% by Month 12 is consistent with STEP-1 trajectory (~14.9% at 68 weeks); the patient is on backbone-anchored direction-of-effect per Pattern V discipline.

---

6. Side-effect management — combined-regimen AE classes

6.1 Purpose

Define the anticipatory framing and clinician response algorithms for AE categories that apply to the integrated regimen. The integrated regimen carries the union of backbone-protocol §6 AE classes (GI, gallbladder, pancreatitis, NAION for sema-backbone, DR for tirz-backbone, injection-site, hypoglycemia in T2D-context-with-concurrent-insulin, dysesthesia for Wegovy HD specifically, immunogenicity, drug-drug interactions) AND adjunct-stack-canonical §6 AE classes (injection-site, transient flu-like / cytokine-pattern predominantly MOTS-c, fluid retention and head-rush predominantly CJC-Ipamorelin, carpal-tunnel-like symptoms, joint stiffness, glucose-tolerance worsening, sleep disturbance, sleep-apnea exacerbation, IGF-1 + glucose + cancer-surveillance) with stacked-regimen-specific considerations where the two AE inventories interact.

Pattern R applies at this section: each AE-class sub-block opens with anticipatory framing — what the AE is, why it occurs, how common it is in the per-component evidence base — before management algorithms. Opening with discontinuation triggers would steer toward fear-framed AE response rather than expectation-anchored response.

Pattern V applies at this section: post-marketing-style signals (NAION for sema-backbone; baseline-status-stratified DR for tirz-backbone; IGF-1 cancer-risk for adjunct GH-axis; class-level heart-rate elevation) are framed with primary-source effect-size and population qualification; signal direction is not generalized beyond what is established.

§6.10 (IGF-1 surveillance + glucose-metabolism surveillance + cancer-surveillance — the load-bearing 3-pillar framework for the integrated regimen) is the most weight-bearing AE-class section. The cancer-surveillance and glucose-tolerance dimensions are the safety concerns that distinguish the integrated regimen from the backbone-alone regimen in terms of monitoring discipline.

6.2 GI AE class — backbone-dominated

Anticipatory framing. All three GLP-1 RA backbones produce a characteristic GI AE profile: nausea, vomiting, diarrhea, constipation, eructation (semaglutide-specific “sulfur burps”), abdominal pain. The AE profile peaks at each dose-escalation step and typically attenuates within 2–4 weeks at stable dose. Trial-program prevalence per backbone:

• Sema 2.4 mg STEP-1: nausea ~44% (vs ~18% placebo); vomiting ~24% (vs ~6%); diarrhea ~32% (vs ~16%); constipation ~24% (vs ~11%). Discontinuation due to GI AE in STEP-1 was ~4.5% of the semaglutide arm.
• Tirz 15 mg SURMOUNT-1: GI AE profile similar-to-modestly-higher than sema at equivalent body-weight-reduction magnitude per cross-trial comparison. SURMOUNT-OSA reported comparable GI AE profile in the OSA + obesity population.
• Reta Phase 2 obesity: dose-dependent GI AE profile with peak frequencies at 8 mg and 12 mg arms; consistent with GLP-1 RA class dose-dependent GI AE pattern.

Adjunct-side: no significant GI AE contribution. CJC-Ipamorelin and MOTS-c do not produce GI motility or nausea / vomiting effects at protocol doses. The integrated-regimen GI AE profile is backbone-dominated; adjunct addition does not exacerbate the backbone-side GI AE.

Identification. Patient-reported during early-monitoring contacts (§4.6) and maintenance visits (§5). Standardized severity grading via CTCAE. Most protocol-relevant GI AEs are Grade 1–2.

First-line management. Non-pharmacologic: meal-size reduction, slow eating pace, low-fat / non-greasy meal composition, hydration emphasis. Pharmacologic: ondansetron 4 mg PRN for nausea; loperamide PRN for diarrhea; osmotic laxative for constipation; reassurance and meal-pairing adjustments for eructation.

Escalation triggers. Grade 3 severity at any step; persistent Grade 2 severity beyond 4 weeks at stable dose; vomiting with severe abdominal pain (assess for pancreatitis — §6.4); significant unintended weight loss exceeding the protocol’s target trajectory.

Discontinuation triggers. Grade 3 GI AE that does not resolve with backbone dose-down; patient preference. The integrated-regimen GI AE discontinuation decision is backbone-side; adjunct stack continuation may proceed if backbone is dose-reduced (rather than discontinued) and the catabolic-pressure indication remains.

6.3 Gallbladder AE class — backbone-dominated

Anticipatory framing. GLP-1 RA association with cholelithiasis and cholecystitis is documented across the trial program; mechanism attributed to weight-loss-rate-related bile supersaturation plus direct effects on gallbladder motility. Trial-program prevalence: cholelithiasis ~1.6% sema vs 0.7% placebo in STEP-1; pooled across STEP program gallbladder-disease AE ~2.6% vs 1.2%. Adjunct-side: no significant gallbladder AE contribution.

Identification. Symptom-prompted — RUQ pain, post-prandial colicky pain, fever-and-pain combination. Ultrasound first-line imaging; HIDA if functional cholecystitis suspected without stones.

First-line management. Symptomatic gallstones with confirmed cholelithiasis: surgical consultation; laparoscopic cholecystectomy typical trajectory. Backbone temporary hold during peri-operative window; resume at maintenance dose post-cholecystectomy if no other contraindication has emerged. Adjunct stack continuation per clinician judgment within the peri-operative window (typically held during the immediate peri-operative period; resumed post-recovery).

Escalation / Discontinuation triggers. Per backbone-protocol §6.

6.4 Pancreatitis AE class — backbone-side; adjunct-side null

Anticipatory framing. Acute pancreatitis signal in GLP-1 RA pharmacovigilance has been debated since the exenatide era. Wen 2025 SR (PMID 40988099; 62 RCTs n=66,232 including tirzepatide) — pooled RR 1.44 (95% CI 1.09–1.89, P=0.009) for acute pancreatitis across the GLP-1 RA + GLP-1/GIP coagonist class. Modest signal; absolute event rates <1–2%/year. Authors frame as “slightly increased risk, likely minimal.” Pivotal-trial data for individual backbones (STEP, SUSTAIN, SELECT, FLOW, ESSENCE for sema; SURPASS, SURMOUNT for tirz) did not demonstrate statistically significant pancreatitis-incidence signals in trial populations with the explicit acknowledgment that severe-prior-pancreatitis-history patients were excluded from trial enrollment (§2.4 hard contraindication).

Adjunct-side: no documented pancreatitis association for CJC-1295, Ipamorelin, or MOTS-c.

Identification. Symptom-prompted — persistent severe upper abdominal pain radiating to back, often with vomiting, often worse with food. Differential: GI AE class (§6.2) typically does not produce severe persistent localized pain; the protocol differentiates “GI AE expected at titration” from “pancreatitis-suspect abdominal pain” via persistence, severity, localization, and lipase.

First-line management. Acute persistent severe abdominal pain with vomiting → immediate evaluation, lipase + amylase + CMP + CBC + lipid panel (rule out hypertriglyceridemic pancreatitis), abdominal imaging (CT or MRCP). Discontinue backbone pending evaluation; adjunct stack hold during evaluation but the pancreatitis attribution is backbone-side (mechanism-class GLP-1 RA signal).

Escalation triggers. Confirmed acute pancreatitis (clinical + lab + imaging) → hospitalization, supportive management per standard of care.

Discontinuation triggers. Confirmed acute pancreatitis attributable to the backbone (alternative etiologies — gallstones, hypertriglyceridemia, alcohol — ruled out) → permanent backbone discontinuation; transition to non-GLP-1 alternative if Module 5 indication continues; adjunct stack discontinuation aligned with backbone-discontinuation indication-resolution per §8.2.

6.5 Ophthalmologic AE class — backbone-specific class-differentiation + adjunct-side IGF-1 overlay

Anticipatory framing — semaglutide-backbone NAION signal. Non-arteritic anterior ischemic optic neuropathy (NAION) signal in semaglutide pharmacovigilance was described in Hathaway 2024 JAMA Ophthalmology PMID 38958939 (retrospective-cohort observed-to-expected analysis from Mass Eye and Ear cohort). The signal is post-marketing and under active evaluation — not a labeled contraindication or labeled warning as of 2026-05-14. Pattern AA precision: counseling beats (§10) frame as “signal under evaluation; absolute risk in the population studied was small; clinician judgment in patients with disc-at-risk anatomy or prior NAION applies.” Class-differentiation: NAION signal absent for tirzepatide per Lawrenson 2025 PMID 40383360 multicenter pharmacovigilance.

Anticipatory framing — tirzepatide-backbone baseline-status-stratified DR signal. Buckley 2025 Diabetologia PMID 40637847 (retrospective matched cohort, n=6,869): in the overall multivariate analysis, OR 2.15 (95% CI 1.24–3.74) for new-onset proliferative DR on tirzepatide adjusted for established risk factors; signal “particularly evident” per authors in R1M1 (mild non-proliferative DR + maculopathy) or moderate-to-severe NPDR baseline; in patients without retinopathy at baseline, OR 0.73 (95% CI 0.62–0.86) — protective. Pattern V direction-of-effect: this is a baseline-status-stratified finding; the protocol does NOT summarize as one-directional. Class-differentiation: within the SURPASS controlled-trial population (Rosenstock 2023 underlying pooled DR data), no increased risk of DR progression was observed; the controlled-trial population excluded patients with unstable or severe baseline retinopathy.

Anticipatory framing — retatrutide-backbone ophthalmologic safety. Research-state-pending TRIUMPH Phase 3 ophthalmologic safety reporting; class-level rapid-HbA1c-improvement retinopathy-progression consideration applies per the broader GLP-1 RA class framework.

Anticipatory framing — adjunct-side IGF-1 elevation retinopathy overlay. The GH-axis adjunct’s IGF-1 elevation profile carries theoretical retinopathy-progression risk in advanced background or proliferative DR populations. In T2D-negative integrated-regimen patients with no DR history, the adjunct-side IGF-1 effect on retinopathy is not clinically meaningful at physiologic-range dosing. In T2D-positive patients with DR history, the adjunct-side IGF-1 elevation adds to the backbone-side rapid-HbA1c-improvement signal (sema-backbone SUSTAIN-6 context) or the backbone-side baseline-status-stratified signal (tirz-backbone Buckley 2025 context) — relative exclusion in active proliferative DR or advanced background DR is the §2.4 + §2.3 disposition.

Identification.

• NAION: acute monocular vision loss, typically painless, often altitudinal visual field defect; optic disc edema on exam in acute phase. Differential: GCA (arteritic AION — separate entity), retinal vascular occlusion, optic neuritis.
• DR progression: routine ophthalmology surveillance for T2D-positive patients per §3.7 + §5.5 schedule; symptom-prompted (vision change, floaters, scotoma).

First-line management — NAION (sema-backbone). Urgent ophthalmology evaluation; discontinue backbone pending evaluation; cross-reference ESR/CRP to rule out arteritic etiology. Adjunct stack hold during evaluation. Confirmed NAION → permanent semaglutide-backbone discontinuation; cross-class direction-of-effect (tirzepatide alternative) is research-state-incomplete but Lawrenson 2025 PMID 40383360 documents class-differentiation (NAION signal absent for tirzepatide at the same analytic threshold). Adjunct stack discontinuation decision per the indication-resolution context — if backbone discontinuation ends the catabolic-pressure indication, adjunct stack also discontinues.

First-line management — DR progression (tirz-backbone or T2D-context). Ophthalmology evaluation; assess severity and intervention (panretinal photocoagulation, anti-VEGF, vitreoretinal surgery as indicated). Backbone management per ophthalmology + endocrinology co-management; integrated-regimen reassessment if the IGF-1-elevation overlay is contributing.

Discontinuation triggers. Confirmed NAION (sema-backbone) → permanent semaglutide-backbone discontinuation. Confirmed proliferative DR progression with adjunct-side IGF-1 contribution → adjunct stack discontinuation; backbone management per ophthalmology + endocrinology co-management.

6.6 Injection-site AE class

Anticipatory framing. Injection-site reactions (erythema, induration, pruritus, nodule) occur in ~5% of patients on weekly subcutaneous GLP-1 RA injections (all three backbones); usually mild and self-resolving. Adjunct-side: CJC-Ipamorelin combined-injection and MOTS-c separate-injection produce injection-site reactions in a minority of administrations — typically mild erythema, local pruritus, mild induration, transient flushing; self-resolving within hours to ~48 hours. The integrated regimen has multiple injection sites (weekly backbone + daily CJC-Ipa during 5-on/2-off + 3x/week MOTS-c); site-rotation discipline is operationally important.

Identification. Patient-reported or visit-observed. Photo documentation if reaction is moderate or atypical.

First-line management. Site-rotation reinforcement across all injection sites — abdomen, thigh, upper arm; alternate per injection day; do not co-locate backbone, CJC-Ipa, and MOTS-c injection sites within a 1-week window. Topical hydrocortisone for pruritus. Cool compress for transient erythema. Discontinuation is rarely indicated for injection-site AE alone.

Escalation triggers. Systemic hypersensitivity-pattern reaction (generalized urticaria, angioedema, anaphylaxis) → emergency evaluation. Persistent moderate-severity local reaction with documented per-compound-specific recurrence → consider compound-substitution (e.g., switching compounding pharmacy / formulation; rare hypersensitivity to excipients) for the specific compound implicated.

Discontinuation triggers. Severe systemic hypersensitivity reaction to any component is a §2.4 hard contraindication for that component and triggers permanent discontinuation of the implicated component. Cross-compound hypersensitivity is not documented for the integrated regimen but theoretical risk applies (peptide-class hypersensitivity considerations).

6.7 Glucose-tolerance worsening AE class — integrated-regimen-specific surveillance

Anticipatory framing. GH at supraphysiologic levels antagonizes insulin sensitivity; the adjunct physiologic-range dosing target (CJC-1295 100 mcg + Ipamorelin 200 mcg producing upper-quartile-of-reference IGF-1 Z 0 to +1) attenuates but does not eliminate the directional pressure. MOTS-c operates in the opposite direction (insulin sensitization via AMPK). The GLP-1 RA backbone delivers substantial improving directional pressure on glucose tolerance. Net glucose-tolerance effect on the integrated regimen is typically maintained-or-improved against pre-stack on-backbone baseline in practitioner-observation; reversal is uncommon but is the §5.4 + §6.10 surveillance trigger.

Identification. Per §5.3 monitoring labs at Week 8–12 of each adjunct stack cycle: fasting glucose, HbA1c, fasting insulin. Also patient-reported new-onset polyuria / polydipsia / unexplained fatigue.

First-line management. If HbA1c rises >0.3 percentage points from pre-stack baseline on-backbone trajectory, or if fasting glucose rises into pre-T2D range, dose-reduce or temporarily hold CJC-1295. Re-check glucose / HbA1c at 4–8 weeks post-adjustment.

Escalation triggers. New-onset T2D diagnosis on integrated regimen → discontinue GH-axis component permanently; continue MOTS-c at clinician judgment (MOTS-c is mechanism-favorable in T2D context); continue backbone (T2D is typically a backbone-indication-expansion rather than discontinuation trigger).

Discontinuation triggers. Persistent glucose worsening despite GH-axis dose reduction → discontinue GH-axis component (CJC-Ipamorelin); continue MOTS-c + backbone.

6.8 Sleep-disturbance and sleep-apnea exacerbation AE classes

Anticipatory framing — sleep disturbance (adjunct-side). Bedtime CJC-Ipamorelin dosing can produce vivid dreams, restless sleep, or sleep-disruption pattern in a minority of patients — most commonly during the first 2 weeks of a cycle, attenuating with continued dosing. Mechanism: GH-pulse-mediated effect on sleep architecture (GH amplifies slow-wave sleep at physiologic doses but can produce arousal at higher pulse amplitudes).

Anticipatory framing — sleep-apnea exacerbation (adjunct-side). GH-axis activation can theoretically exacerbate sleep apnea (GH-mediated soft-tissue / upper-airway effects). The §2.3 relative-exclusion screens severe untreated OSA at baseline; CPAP-adherent OSA patients are not excluded but require surveillance. Backbone-side: tirzepatide-backbone has the SURMOUNT-OSA indication for moderate-severe OSA + obesity (Zepbound 2024-12 approval); the AHI reduction on tirzepatide backbone (~−25 to −29 events/hour) typically dominates the net OSA-trajectory in the integrated regimen on tirz-backbone, but the adjunct-side IGF-1 / soft-tissue overlay requires ongoing surveillance.

Identification. Patient-reported (vivid dreams, restless sleep, daytime sleepiness, sleep-partner-observed apneas, new-onset CPAP-adherence difficulty).

First-line management — sleep disturbance. Dose-timing adjustment — move CJC-Ipa injection earlier (e.g., 2 hours before sleep instead of immediately pre-sleep). Adjunct dose-reduction if persistent.

First-line management — sleep-apnea exacerbation. Sleep-medicine consultation; CPAP titration if patient is on CPAP; sleep study if new symptoms. Consider GH-axis dose reduction or hold pending evaluation.

Discontinuation triggers. Severe / persistent sleep disruption despite adjustment → discontinue GH-axis component. Documented sleep-apnea exacerbation attributable to GH-axis stack → discontinue GH-axis component; backbone continues per its own indication framework.

6.9 Adjunct-side AE classes — transient flu-like, fluid retention, carpal-tunnel, joint stiffness

These are adjunct-side AE classes documented in [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] §6.3–§6.6 with stacked-regimen integration considerations:

• Transient flu-like / cytokine-pattern (predominantly MOTS-c) — §6.3 of adjunct-stack canonical. MOTS-c initiation in some patients produces transient flu-like symptoms (mild myalgia, fatigue, low-grade temperature, malaise) typically resolving within first week of starting. Reassurance + symptomatic care; the pattern is self-resolving. Differential at integrated regimen: distinguish MOTS-c-pattern transient flu-like from backbone-side AE (uncommon backbone-side flu-like pattern) — temporal association with MOTS-c initiation is the diagnostic anchor.
• Fluid retention and head-rush (predominantly CJC-Ipamorelin) — §6.4 of adjunct-stack canonical. Mild transient peripheral edema, ring tightness, transient weight-stability against the underlying weight-loss trend (a 1–2 lb upward shift over a few days, distinct from the underlying weight-loss trajectory). Mechanism: GH-mediated sodium-and-water retention plus acute vasodilatory effect. Self-resolving over 2–4 weeks; dose-frequency reduction if persistent / disruptive. Differential at integrated regimen: distinguish CJC-Ipa-pattern fluid retention from backbone-side weight stabilization (backbone-side weight-loss plateau typically lacks the peripheral edema component).
• Carpal-tunnel-like symptoms — §6.5 of adjunct-stack canonical. Nocturnal hand numbness, paresthesias, mild grip weakness — particularly at higher GH-secretagogue doses or in patients with pre-existing carpal-tunnel risk factors. Mechanism: fluid retention in carpal-tunnel anatomy + IGF-1-mediated soft-tissue effects. Wrist splinting at night; CJC-1295 dose reduction; reassessment at 4 weeks on reduced dose.
• Joint stiffness and arthralgia — §6.6 of adjunct-stack canonical. Mild joint stiffness, particularly at hand and shoulder joints. Mechanism: IGF-1-mediated soft-tissue / cartilage effects. Reassurance; activity modification; CJC-1295 dose reduction if persistent.

For the retatrutide-backbone integrated regimen specifically, the TRIUMPH-4 obesity + knee OA indication (NCT05931367; sponsor topline December 2025) suggests the retatrutide-backbone may have favorable knee-OA outcome data — the integrated-regimen arthralgia / joint-stiffness directional pressure is therefore mixed: backbone-side may be improving for knee OA; adjunct-side may be modestly worsening for hand / shoulder joint stiffness. Net is patient-specific; §6.6 monitoring discipline applies.

6.10 IGF-1 surveillance + glucose-metabolism surveillance + cancer-surveillance — 3-PILLAR FRAMEWORK FOR THE INTEGRATED REGIMEN

The load-bearing safety section for the integrated regimen. The integrated-regimen-specific safety overlay arises from the GH-axis adjunct (CJC-1295 + Ipamorelin) IGF-1 elevation. The backbone does not elevate IGF-1; the adjunct GH-axis does, as its intended pharmacologic effect. The 3-pillar surveillance framework addresses (a) IGF-1 elevation magnitudes — physiologic-range vs supraphysiologic targeting; (b) glucose-metabolism surveillance — the dual directional pressure on glucose tolerance from GH-axis insulin-antagonism vs backbone + MOTS-c insulin-sensitization; (c) cancer-surveillance — the IGF-1-cancer-risk literature with two opposing signal pillars adapted for the stacked context.

6.10.1 IGF-1 elevation magnitudes — per-arm and treatment-effect framing (Pattern V).

Baseline IGF-1 typically rises on the integrated regimen from mid-reference-range (Z-score ~0) toward upper-quartile-of-reference (Z-score 0 to +1) at the practitioner-consensus dose of CJC-1295 100 mcg + Ipamorelin 200 mcg bedtime with 5-on/2-off cycling. The magnitude of elevation depends on:

• Baseline IGF-1 level. Patients with higher baseline IGF-1 reach upper-quartile target at lower exogenous stimulation; patients with lower baseline IGF-1 may not reach upper-quartile target even at protocol doses.
• Dose. 100 mcg CJC vs higher / lower doses scales the GH-pulse amplitude.
• Cycle length. Within-cycle IGF-1 typically rises over the first 4–6 weeks and stabilizes for the remainder of the cycle.
• Co-administration with Ipamorelin. 7–10× supra-additive GH pulse with both compounds vs single-compound dosing produces larger IGF-1 elevation than either alone (Teichman 2006 PMID 16352683; Ionescu & Bhatt 2006 PMID 17018654).

Per-arm framing (Pattern V.metric-axis disclosed). In the per-compound human PK/PD literature (Teichman 2006 PMID 16352683; Ionescu & Bhatt 2006 PMID 17018654): single-dose CJC-1295 in healthy adults produced 2–10-fold GH increases and 1.5–3-fold IGF-1 increases that persisted for 6–11 days at the supraphysiologic acute-trial doses tested (notably, these acute single-dose trials used dose ranges higher than the practitioner-consensus 100 mcg / day chronic dosing protocol). The protocol target — upper-quartile-of-reference Z-score 0 to +1 — is an order-of-magnitude smaller IGF-1 elevation than the acute single-dose PK/PD trial range, and is the practitioner-consensus physiologic-range target for the integrated regimen.

Treatment-effect framing. No Phase 3 RCT of the CJC-Ipa protocol-dosing schedule (100 mcg + 200 mcg bedtime, 5-on/2-off, 12–16 week cycles) anchored to IGF-1 trajectory exists. No Phase 3 RCT of the combined regimen (CJC-Ipa + MOTS-c stack on GLP-1 RA backbone) anchored to IGF-1 trajectory or to lean-mass-preservation outcome exists. Practitioner-observation data and individual-patient on-protocol IGF-1 monitoring are the operational reference. The clinical-practice direction-of-effect: protocol-dose IGF-1 elevation is intended to bring IGF-1 toward upper-quartile-of-reference and not above. Supraphysiologic elevation (above reference range) is a dose-reduction trigger per §5.4 + §6.10 integrated-regimen monitoring discipline.

6.10.2 Glucose-metabolism surveillance.

GH-axis activation at supraphysiologic levels antagonizes insulin sensitivity. At protocol doses targeting upper-quartile-of-reference IGF-1, the insulin-antagonist effect is typically not clinically meaningful, and the MOTS-c component’s insulin-sensitization plus the GLP-1 RA backbone’s substantial glucose-improvement directional pressure dominate net glucose-tolerance trajectory.

The integrated-regimen monitoring discipline: HbA1c and fasting glucose at Week 8–12 of each adjunct stack cycle (§5.3). If HbA1c rises >0.3 percentage points from pre-stack on-backbone baseline → §6.7 management.

Pattern V framing. The glucose-metabolism direction-of-effect on the integrated regimen is typically maintained-or-improved against the pre-stack on-backbone trajectory in practitioner-observation; reversal is uncommon but is a monitored trigger. The direction-of-effect is not “integrated regimen worsens glucose tolerance” or “integrated regimen improves glucose tolerance” — it is dose-, dose-titration-, backbone-selection-, and patient-phenotype-dependent. Specifically:

• Sema-backbone integrated regimens: sema delivers ~1.8 percentage-point HbA1c reduction in T2D; the integrated regimen typically maintains this trajectory.
• Tirz-backbone integrated regimens: tirz delivers ~2.3 percentage-point HbA1c reduction at 15 mg in T2D (SURPASS-2); the integrated regimen typically maintains this trajectory.
• Reta-backbone integrated regimens: reta Phase 2 T2D HbA1c reductions across dose-response framework; the integrated regimen typically maintains the Phase 2-anchored trajectory.

The MOTS-c additive insulin-sensitization may incrementally improve glucose-tolerance trajectory beyond the backbone-alone baseline in some patients; the GH-axis insulin-antagonism may incrementally worsen trajectory in patients with baseline borderline glucose tolerance — net effect is patient-specific.

6.10.3 Cancer-surveillance — three-pillar framework adapted for the stacked regimen.

The IGF-1-cancer-risk literature is the load-bearing safety consideration for the GH-axis adjunct component. The literature has three pillars that frame the operational surveillance posture:

• Pillar 1 — The Renehan 2004 Lancet meta-analysis (PMID 15110491). Observational association of elevated IGF-1 with prostate cancer (OR 1.49) and premenopausal breast cancer (OR 1.65). The observational association does not establish causation — it does not distinguish whether elevated IGF-1 is a risk factor for cancer development vs a biomarker of underlying cancer biology vs a co-variable confounded with another risk factor. But it is the load-bearing observational signal in the cancer-surveillance framing.

• Pillar 2 — The 2022 large GH-replacement cohort (Child 2022 PMID 35368070; n=15,809; HypoCCS observational study). Cancer incidence in this large GH-replacement cohort was comparable to the general population (SIR 0.92). The clinical interpretation: in the GH-replacement clinical context, the IGF-1 elevation profile did not associate with elevated cancer incidence at population level — counter-signal to the Renehan 2004 observational association in a much larger cohort with clinical-care context.

• Pillar 3 — The 2022 expert-consensus statement on GH replacement in cancer survivors (Boguszewski 2022 PMID 35319491). “No association with cancer recurrence” in the post-cancer-treatment setting, while still recommending oncologist clearance and IGF-1 monitoring as standard practice.

Integrated-regimen-specific cancer-surveillance overlay — the backbone-side cancer-context evidence. The 2026 cancer SR (Ko et al 2026 Annals Intern Med PMID 41359966; n=94,245 across 48 RCTs including tirzepatide) characterizes “GLP-1 RAs may have little or no effect on risk for obesity-related cancers” overall — moderate-certainty null/protective at population level. The backbone-side cancer-context evidence is reassuring (no signal of increased cancer risk from the GLP-1 RA backbone class); the adjunct-side cancer-surveillance is the load-bearing surveillance overlay for the integrated regimen.

Surveillance discipline on the integrated regimen:

• Target IGF-1 in upper-quartile-of-reference (Z-score 0 to +1), NOT supraphysiologic. Supraphysiologic IGF-1 elevation is the dose-reduction trigger (§6.10.1 + §5.4).
• PSA monitoring in men ≥40. Baseline (§3.9) + annual on integrated regimen. Rise above age-specific reference range or rapid PSA velocity warrants urologic evaluation.
• Mammography in women ≥40 per standard screening intervals. Up-to-date mammography required at baseline and maintained on schedule.
• Family-history cancer-context counseling. First-degree family history of hormone-sensitive cancers (breast, prostate, endometrial) warrants patient-specific risk-benefit weighing in §10.6 counseling beat. The decision is patient-specific clinician judgment; protocol does not establish a hard rule.
• Active or recent (5y) malignancy: §2.4 hard contraindication. Cancer survivors beyond 5 years from treatment completion: §2.3 relative exclusion with oncologist clearance per the Boguszewski 2022 consensus statement.

Pattern V cross-check at §6.10.3. The Renehan observational association is real; the 2022 cohort reassurance is real; the consensus practice is monitor-and-stay-in-physiologic-range. The signal-direction is not generalized beyond the population studied; the clinical-practice posture is conservative monitoring with patient-specific risk-benefit weighing. The Ko 2026 backbone-side null/protective signal contextualizes the integrated-regimen cancer-context as backbone-favorable + adjunct-monitoring-overlay.

6.11 Worked example — AE management at maintenance dose on the integrated regimen

Scenario A — IGF-1 above reference range at Week 12 on tirz-backbone integrated regimen. A 58-year-old male on Zepbound 15 mg + adjunct stack Cycle 1. IGF-1 baseline 175 ng/mL (Z-score ~+0.3 mid-reference); Week 12 on-integrated-regimen IGF-1 295 ng/mL — above age-specific reference range upper bound (reference upper ~280 ng/mL for his age). Per §6.10.1 protocol: above-reference IGF-1 is a dose-reduction trigger. Reduce CJC-1295 from 100 mcg to 75 mcg per injection (Ipamorelin unchanged at 200 mcg). Re-check IGF-1 in 4 weeks. If IGF-1 returns to upper-quartile-of-reference (Z-score 0 to +1), continue at reduced dose. If IGF-1 remains above reference at 4 weeks → further reduce to 50 mcg CJC-1295 or hold CJC-1295 for 1–2 weeks then resume at 50 mcg. PSA monitored per §6.10.3 baseline + annual. Tirzepatide backbone continues unchanged at 15 mg weekly; backbone is not the IGF-1-elevation driver.

Scenario B — HbA1c rises 0.4 percentage points at Week 12 on sema-backbone integrated regimen in a pre-T2D patient. A 62-year-old female on Wegovy 2.4 mg + adjunct stack Cycle 1, pre-stack HbA1c 5.8 on improving trajectory (was 6.1 pre-Wegovy). Week 12 on-integrated-regimen HbA1c 6.2 — reversal of pre-stack trajectory. Per §6.7 + §5.4 protocol: glucose-tolerance worsening is a dose-adjustment trigger. Reduce CJC-1295 to 50 mcg or hold the GH-axis component for 1 cycle while continuing MOTS-c (which is insulin-sensitizing) and Wegovy. Re-check HbA1c at 8 weeks. If HbA1c returns to pre-stack improving trajectory, reassess whether to re-introduce GH-axis at lower dose or to discontinue GH-axis component while continuing MOTS-c. Counseling beat: glucose-tolerance worsening reflects the GH-axis component’s directional pressure on the integrated regimen; the integrated-regimen’s lean-mass-preservation goal can be partially maintained through MOTS-c monotherapy + Tier 1 foundation if GH-axis component must be discontinued.

Scenario C — Confirmed acute pancreatitis on sema-backbone integrated regimen. A 56-year-old male on Wegovy 2.4 mg + adjunct stack Cycle 2 Week 8 presents with acute severe upper abdominal pain radiating to back, vomiting; lipase 5× upper limit normal; abdominal CT mild peripancreatic fat stranding without necrosis; triglycerides 220 mg/dL; no gallstones; no alcohol. Confirmed semaglutide-attributable acute pancreatitis (alternative etiologies ruled out). Discontinue Wegovy permanently. Adjunct stack discontinuation aligned: confirmed acute pancreatitis is not adjunct-attributable (no pancreatitis association documented for the adjunct compounds) but the indication-resolution context (backbone discontinuation ends the catabolic-pressure indication) discontinues the adjunct stack. Transition to non-GLP-1 alternative weight-management approach (or tirzepatide alternative with informed consent about cross-class GLP-1 RA pancreatitis signal per Wen 2025 PMID 40988099; clinician judgment for backbone-class transition vs out-of-class transition).

Scenario D — Confirmed NAION on sema-backbone integrated regimen. A 49-year-old female on Wegovy 2.4 mg + adjunct stack Cycle 1 Week 6 develops acute painless monocular vision loss; ophthalmology urgent evaluation confirms left optic disc edema with altitudinal visual field defect; ESR / CRP normal. Diagnosis: NAION, left eye. Discontinue Wegovy permanently. Adjunct stack hold during evaluation; subsequent decision: the NAION signal is sema-specific in current evidence; cross-class direction-of-effect is research-state-incomplete; tirzepatide alternative is supported on the Lawrenson 2025 class-differentiation finding (NAION signal absent for tirzepatide at the same analytic threshold). If the patient and clinician decide to transition to tirzepatide backbone for continued weight management, the adjunct stack can resume on the new backbone after the backbone transition is stable (typically Month 3+ on tirzepatide target dose); the lean-mass-preservation indication continues if the catabolic-pressure profile continues. If the patient elects to transition out of GLP-1 RA therapy entirely, the adjunct stack discontinues per indication-resolution.

Scenario E — Carpal-tunnel symptoms at Week 6 on the integrated regimen. A 56-year-old patient on integrated regimen (Wegovy backbone + adjunct stack Cycle 1, Week 6). Reports nocturnal hand numbness in the dominant hand, mild paresthesias. Phalen test positive. Per §6.9 / adjunct-stack canonical §6.5 protocol: GH-axis-related carpal-tunnel-like symptoms. Wrist splinting at night; reduce CJC-1295 to 50 mcg per injection. Re-check at 4 weeks. If symptoms persist despite dose reduction → discontinue GH-axis component (CJC-Ipamorelin); orthopedic referral if symptoms persist post-discontinuation. The MOTS-c component may continue alone if the patient elects to maintain the AMPK-pathway adjunct. Backbone (Wegovy) continues unchanged.

Pattern AA precision in §6.11. The dose adjustments above are practitioner-consensus within the un-labeled stacked-regimen protocol (adjunct side) plus FDA-label-aligned for the backbone (semaglutide / tirzepatide AE-management algorithms per their respective product labels). The framing is per-component-precise — backbone-side adjustments are FDA-label-aligned clinician-judgment-within-label; adjunct-side adjustments are practitioner-consensus within the research-state stacked-regimen protocol.

Pattern V cross-check at §6.11. Each scenario above invokes specific monitoring triggers (IGF-1; HbA1c; symptom pattern) and specific dose-adjustment responses. The trigger-to-response chain is anchored to the §5 monitoring panel and the §6 AE-class management algorithms; no scenario invokes a trigger or response not established in §3 / §5 / §6.

---

7. Plateau and non-response algorithm — stacked-regimen endpoints

7.1 Purpose

Define the structured clinical-decision approach when the integrated regimen’s effect has stalled below clinical-benefit threshold (plateau) or has not met its target from the start (non-response). The integrated regimen has two distinct clinical endpoints — backbone-side weight-loss trajectory AND adjunct-side lean-mass-preservation trajectory — and the plateau / non-response algorithm differentiates which endpoint is the relevant decision point.

For the backbone-side weight-loss endpoint, the algorithm anchors to the backbone-protocol §7 (semaglutide §7 / tirzepatide §7 / retatrutide §7). For the adjunct-side lean-mass-preservation endpoint, the algorithm anchors to the adjunct-stack-canonical §7. The integrated regimen plateau / non-response algorithm in this section integrates both per-endpoint algorithms with stacked-regimen-specific considerations where the two endpoints interact.

7.2 Diagnostic distinctions for the two endpoints

Backbone-side endpoint: weight-loss trajectory.

• Pseudo-plateau (weight). Apparent stall in weight that is within normal week-to-week or month-to-month variation, or reflects body-composition change (lean-mass preservation with fat-mass continued loss — particularly relevant on the integrated regimen where the adjunct stack is specifically deployed to attenuate lean-mass loss; the patient may experience perceived weight stall that is in fact favorable body-composition trajectory), or occurs in the predictable trial-trajectory deceleration pattern (Month 6–9 deceleration common across the STEP / SURMOUNT / TRIUMPH programs).
• True plateau (weight). Legitimate weight stall — patient was responding to backbone, then response flattens or reverses. Recognized by trajectory inflection plus adequate observation window (typically 2–3 months at stable backbone dose).
• Non-response (weight). Insufficient initial backbone effect from the start. Recognized at Month 3–6 on backbone target dose with effect substantially below the trial-program-typical effect for the patient’s phenotype.

Adjunct-side endpoint: lean-mass-preservation trajectory.

• Pseudo-plateau (lean-mass). Apparent stall in lean-mass-loss-fraction improvement that is within DEXA between-scan variability (~±1–2% absolute precision for lean-mass-loss-fraction measurement), or reflects continued favorable trajectory at a slowed but ongoing rate, or reflects a different aspect of body-composition shift (favorable visceral-fat reduction while lean mass stable).
• True plateau (lean-mass). Legitimate response stall — lean-mass-loss-fraction was improving from pre-stack baseline, then trajectory flattens or reverses. Recognized by trajectory inflection plus ≥1 full stack cycle observation (12–16 weeks).
• Non-response (lean-mass). Insufficient initial adjunct effect from the start. Recognized at 12-week DEXA on stack with lean-mass-loss-fraction not improved (or only marginally improved) from pre-stack baseline despite documented Tier 1 adherence and adjunct adherence.

7.3 Set-point reset framing — backbone-side and adjunct-context

Weight-regulation physiology operates on a defended set-point that the body actively resists changes from. Weight loss into a new set-point window typically requires sustained pharmacologic and behavioral intervention; loss beyond the body’s defended range tends to recruit counter-regulatory responses (increased hunger signals, decreased energy expenditure — adaptive thermogenesis). True plateau on the backbone-side in CWM context is often the body’s defense at a new set-point — not therapeutic failure but biological-equilibrium attainment. The protocol framing in §10 counseling does not pathologize plateau but reframes it as biological equilibrium and as the decision point for continuation, backbone-class intensification, transition between backbones, or maintenance-at-new-set-point.

The adjunct-context overlay: the lean-mass-preservation overlay on the integrated regimen does not change set-point physiology directly; it attenuates the lean-mass fraction of the weight loss that occurs at the backbone-driven set-point change. A backbone-side plateau at a new set-point does not automatically end the adjunct-stack indication — if the patient continues backbone at the new set-point (typically transitioning to maintenance dose) and the lean-mass-loss fraction was preserved during the active-loss arc, the adjunct stack typically discontinues per §8.2 goal-achieved trigger.

7.4 Decision tree for plateau / non-response on the integrated regimen

Step 1 — Confirm adherence (both components). Missed doses, injection-technique issues, fed-state CJC-Ipa administration (fed-state blunts GH response — load-bearing for the adjunct mechanism), incorrect MOTS-c reconstitution / storage, oral-formulation absorption issues (PIONEER program PPI counseling for Rybelsus backbone), backbone missed weekly doses, Tier 1 foundation adherence (most common pseudo-non-response cause on the adjunct side). Confirm via patient interview and via prescription-refill audit.

Step 2 — Confirm trajectory-context (both endpoints).

• Weight: plot the patient’s curve against trial-program-typical curve for their phenotype and backbone (STEP-1 for sema-CWM; SURMOUNT-1 for tirz-CWM; reta Phase 2/3 trajectory framework). If on-trajectory, pseudo-plateau on weight — continue.
• Lean-mass: plot the patient’s DEXA trajectory against pre-stack baseline AND against practitioner-observation expectation (~15–20% lean-mass-loss fraction on integrated regimen vs ~25–32% Phase 3-pooled-DEXA unsupplemented baseline). If the lean-mass-loss fraction trended favorably (e.g., pre-stack 33% → on-stack 22% per §5.6 example), continue.

Step 3 — Confirm dose attainment (both components).

• Backbone: at maximum-tolerated dose? Sema 2.4 mg or Wegovy HD 7.2 mg; tirz 15 mg; reta 12 mg.
• Adjunct: at protocol-target doses? CJC-1295 100 mcg + Ipamorelin 200 mcg; MOTS-c 10 mg. Verify no dose-reduction from §6 AE triggers has compromised the protocol-target dosing.

Step 4 — Reassess phenotype (both endpoints). Does the patient’s clinical picture support the phenotype the trial program enrolled (backbone)? Does the patient’s clinical picture support the phenotype the stacked-regimen practitioner-observation framework was developed in (adjunct)? Pattern V direction-of-effect — for under-represented or out-of-trial phenotypes, expected effect-size may be smaller; recalibrate target. For adjunct-side specifically: untreated subclinical hypothyroidism, glucocorticoid co-administration, somatostatin analog use, or other GH-axis-attenuating context blunts adjunct response (per adjunct-stack canonical §7.3 Step 4).

Step 5 — Backbone-side decision branches if non-response confirmed.

• CWM context: consider transition to higher-effect backbone — sema → tirz (SURMOUNT-5 head-to-head supports higher-effect alternative), sema → reta (Phase 2 PMID 37366315 / TRIUMPH-4 sponsor topline supports higher-effect alternative, pre-FDA-approval); intensification of behavioral / nutritional / activity program (STEP-3 + IBT effect-additive PMID 33567185 framework).
• T2D context: transition to higher-effect backbone — sema → tirz (SURPASS-2 head-to-head supports higher-effect alternative); add SGLT2 inhibitor; add insulin per ADA/EASD progression algorithm.
• MASH context: ESSENCE-anchored semaglutide is the FDA-approved-for-marketing-claims first-line for MASH F2/F3 (FDA approval 2025-08-15); non-response transition options are limited — clinician judgment for adjunct (vitamin E, pioglitazone in non-diabetic MASH; resmetirom Rezdiffra), hepatology co-management, retatrutide via SYNERGY-Outcomes trial enrollment if eligible.
• CKD context (FLOW-anchored): non-response framing usually not applicable at individual-patient level over short observation windows — primary endpoint is composite event reduction, not surrogate-marker improvement.
• CV-risk context: similar — CVOT indication is event-reduction, not surrogate; individual-patient “non-response” framing is less applicable.

When backbone-side transition is planned (e.g., sema → tirz), the adjunct stack typically continues across the backbone transition if the catabolic-pressure indication continues — the adjunct stack is mechanism-independent of the backbone selection. The backbone transition follows backbone-protocol §8 (discontinuation of original backbone) + §4 (initiation of new backbone) with adjunct-stack continuation through the transition; backbone-naive titration of the new backbone may temporarily attenuate the catabolic-pressure during the titration period, but the adjunct-stack cycling continues.

Step 6 — Adjunct-side decision branches if non-response confirmed.

• Option A — Dose intensification within practitioner-consensus range. Increase CJC-1295 from 100 mcg to 150 mcg per injection (verify IGF-1 not above reference range first); move to daily x 7 administration; or add a daytime CJC-Ipa pulse. Each option requires re-evaluating IGF-1 and glucose monitoring at 4–8 weeks post-adjustment. The intensification shifts the GH-axis stimulation outside the typical practitioner-consensus range and the risk-benefit shifts toward higher IGF-1 elevation; patient-specific clinician judgment.
• Option B — Switch CJC-1295 form. Move from CJC-1295 without DAC to CJC-1295 with DAC for one cycle. With-DAC produces sustained elevated GH/IGF-1 (vs pulsatile without-DAC); some practitioners use with-DAC for non-responders to the pulsatile protocol. Pattern V framing: lean-mass-preservation effect-size of with-DAC vs without-DAC in the integrated-regimen context is not anchored to comparative RCT data. Glucose-tolerance directional pressure of sustained GH elevation is more concerning; monitor glucose closely.
• Option C — Add tesamorelin (Egrifta). Tesamorelin is FDA-approved-for-marketing-claims for HIV-associated lipodystrophy (Egrifta 2010); off-label for non-HIV lean-mass / visceral-fat-targeting. Substitute tesamorelin 2 mg SubQ evening for CJC-1295; retain Ipamorelin and MOTS-c. Tesamorelin is a different GHRH analog (GRF(1-44) vs CJC-1295’s modified GRF(1-29)); different PK profile; may produce different individual-patient response. Monitor IGF-1 closely (tesamorelin produces robust IGF-1 elevation; supraphysiologic levels at standard doses documented in tesamorelin trial data).
• Option D — Continue Tier 1 foundation alone; discontinue adjunct stack adjuncts. If foundation reinforcement and adherence verification have not produced response, the patient may continue Tier 1 + backbone without the adjunct stack. Legitimate clinical decision; the stack’s research-state framing supports the discontinuation pathway as much as the continuation pathway.
• Option E — Reassess backbone strategy. If lean-mass-loss-fraction is high and continued weight-loss trajectory on the current backbone is creating an unacceptable lean-mass risk profile, the conversation may move to: transition from sema to tirz (which has modestly more favorable fat-to-lean ratio at equivalent weight loss per Look 2025 PMID 39996356); consider pause at current weight (let patient stabilize at new set-point before further weight loss); discuss with patient whether the current weight-loss trajectory aligns with their actual clinical goal.

7.5 Worked example — non-responder algorithm on the integrated regimen

A 57-year-old female on sema-backbone integrated regimen (Wegovy 2.4 mg + adjunct stack Cycle 1). Pre-stack 12-week DEXA showed lean-mass-loss fraction ~30%; post-stack 12-week DEXA shows lean-mass-loss fraction ~28% — minimal improvement vs the practitioner-observation expectation of ~15–20%. Backbone weight-loss trajectory: on track (~11% at Month 8, on-trajectory STEP-1).

Algorithm walkthrough.

Step 1 — adherence: review food log: protein intake ~0.9 g/kg/day — below the 1.2–1.6 g/kg target. Resistance training adherence ~1 session/week — below the 2–3 session target. Foundation adherence is inadequate.

Conclusion. Pseudo-non-response on the adjunct-side is foundation-driven, not adjunct-stack-driven. Backbone-side weight-loss trajectory is on-track and no backbone-side intervention is indicated. Path forward: reinforce Tier 1 foundation (nutritional consultation; resistance-training-program engagement; consider dietician referral). Continue adjunct stack at current dose; reassess at Cycle 2 end with foundation adherence reinforced. Do not modify adjunct dose or backbone selection until foundation is established.

A different 49-year-old male on tirz-backbone integrated regimen (Zepbound 15 mg + adjunct stack Cycle 1), with documented Tier 1 adherence, shows pre-stack ~26% lean-mass-loss fraction and post-stack 12-week ~22% — modest improvement consistent with practitioner-observation expectation for tirz-backbone integrated regimen (the baseline lean-mass-loss fraction is lower on tirz than on sema per Look 2025 pooled DEXA; the integrated-regimen improvement margin is therefore smaller in absolute terms). Backbone weight-loss trajectory: on track (~18% at Month 9, on-trajectory SURMOUNT-1). No adjunct intervention indicated — the lean-mass-loss-fraction trajectory is on the practitioner-observation expectation for the tirz-backbone integrated regimen.

A third 60-year-old female on sema-backbone integrated regimen, with documented Tier 1 adherence and confirmed stack adherence, shows pre-stack ~30% lean-mass-loss fraction and post-stack 12-week ~26% — modest improvement but below practitioner-observation expectation. Step 4 — phenotype reassessment: patient has untreated subclinical hypothyroidism (TSH 4.2 at baseline workup — borderline elevated, not flagged at initial review). The thyroid-axis attenuation of GH-axis response is the most likely contributor.

Conclusion. Subclinical hypothyroidism treatment is the path forward — endocrinology referral for evaluation and possible levothyroxine initiation. Continue adjunct stack at current dose during the workup. Reassess body composition at Cycle 2 end after thyroid status is addressed. Backbone weight-loss trajectory unchanged (no backbone intervention indicated).

Pattern AA precision in §7.5. Each option above is framed at the appropriate regulatory-precision: Tier 1 foundation interventions are evidence-based recommendations without regulatory-claim implications; backbone-side transitions (sema → tirz / sema → reta) carry per-backbone regulatory framing (tirz is FDA-approved-for-marketing-claims for CWM; reta is pre-FDA-approval-for-marketing-claims); adjunct dose intensification within practitioner-consensus is clinician judgment within un-labeled-protocol; CJC-1295 with-DAC switch is form-substitution within the same NOT-FDA-approved class; tesamorelin add is FDA-approved-for-marketing-claims for HIV-lipodystrophy, off-label for lean-mass-preservation context.

Pattern V cross-check at §7.5. The lean-mass-loss-fraction effect-size attribution to each algorithm option is practitioner-observation-based; no Phase 3 RCT establishes the comparative-effect-size of these options on the integrated regimen. The backbone-side transition direction-of-effect (sema → tirz higher weight-loss magnitude per SURMOUNT-5 PMID 40353578) is Phase 3-RCT-anchored at the backbone-alone level; the cross-class behavior of the adjunct-stack overlay on the tirz-backbone is practitioner-observation. §10.6 counseling beats frame at that resolution.

---

8. Discontinuation and tapering — sequenced discontinuation

8.1 Purpose

Define when to stop the integrated regimen, how to taper / sequence component discontinuation, and how to frame post-discontinuation expectations. The integrated regimen carries two component-level discontinuation tracks — backbone discontinuation and adjunct discontinuation — that may discontinue together (typical at goal achievement) or independently (typical for AE-driven discontinuation of one component while the other continues, or for pre-conception planning where sequenced washout differs).

For the typical goal-achieved or GLP-1-transition-to-maintenance discontinuation, the adjunct discontinues at end of current cycle washout (the cycle structure builds in the natural washout); the backbone transitions to maintenance dose per backbone-protocol §8 framework — open-ended continuation at maintenance, not pharmacologic discontinuation.

For pre-conception planning, the sequenced washout arithmetic differs between adjunct (~4 weeks pharmacodynamic IGF-1 return) and backbone (~8 weeks per label for sema / tirz; reta arithmetic anticipated post-approval).

8.2 Discontinuation triggers for the integrated regimen

Discontinuation triggers are organized by component-level vs regimen-level scope:

Adjunct-side-only discontinuation triggers (backbone continues):

• Lean-mass-preservation goal achieved. Body-composition trajectory favorable; lean-mass-loss fraction has been preserved at target range; functional measures stable. The adjunct has served its purpose. Backbone continues per its own indication-driven trajectory.
• GLP-1 backbone transition to maintenance. When the backbone transitions from active-weight-loss to maintenance phase (patient at target weight, on stable maintenance dose, weight trajectory flat), the catabolic-pressure indication for the adjunct ends; planned adjunct discontinuation at next cycle washout is the standard pathway. Backbone continues at maintenance.
• Persistent supraphysiologic IGF-1 despite adjunct dose reduction (§6.10.1) → discontinue GH-axis component; continue MOTS-c at clinician judgment; backbone unchanged.
• Persistent glucose-tolerance worsening on adjunct despite dose reduction (§6.7) → discontinue GH-axis component; backbone unchanged.
• Adjunct-side AE-class severe AE (per §6 per-adjunct-class severe-AE discontinuation triggers).
• Cost / access barriers for adjunct. Practice-level reality for compounded peptide protocols.
• Patient preference (adjunct only). Patient-anchored decision is legitimate; protocol’s role is to inform, not override.

Backbone-side-only discontinuation triggers (adjunct continues for remainder of current cycle then discontinues per indication-resolution):

• Confirmed contraindication discovery on protocol (new MTC diagnosis, new MEN-2 family-history identification, new pregnancy in CWM-backbone-indication) → immediate backbone discontinuation; adjunct stack discontinuation aligned per indication-resolution (the lean-mass-preservation indication is contingent on the catabolic-pressure backbone).
• Confirmed severe AE attributable to backbone (acute pancreatitis, NAION for sema-backbone, severe hypersensitivity reaction) → backbone permanent discontinuation; adjunct decision per indication-resolution context.
• Indication remission or resolution (backbone-side). T2D HbA1c sustained below target with weight stable; MASH histologic resolution sustained. Rare in Module 5.
• Backbone-side cost / access barriers. Practice-level reality; particularly for non-T2D Wegovy / Zepbound indication where insurance coverage is more variable.

Regimen-level discontinuation triggers (both components stop together):

• Pre-conception planning for reproductive-age patients on integrated regimen. Sequenced washout arithmetic per §8.4 — adjunct discontinuation 4 weeks pre-conception; backbone discontinuation 8 weeks pre-conception per label (sema / tirz). Reta pre-conception arithmetic anticipated post-approval.
• Patient preference (entire regimen). Patient elects to discontinue both backbone and adjunct.
• Goal achievement with planned regimen exit. Less common in CWM context (chronic-relapsing-condition framing per backbone-protocol §10.7 — backbone continuation at maintenance dose is the standard pathway, not regimen exit), more common in time-bounded contexts (e.g., pre-cosmetic-surgery body-composition optimization with planned post-procedure discontinuation; pre-conception planning).

8.3 How to taper / sequence — integrated-regimen-specific considerations

Adjunct stack tapering — cycle-end natural washout. The adjunct stack does not require pharmacokinetic tapering on the model of GLP-1 RA gradual taper. The cycle structure (12–16 weeks on / 4–8 weeks off) builds in scheduled washout; the final cycle is the de facto taper — at end of final cycle, planned washout serves as the discontinuation pathway. For most discontinuation scenarios (goal achieved; backbone transition to maintenance; patient preference), the cycle-end washout is sufficient. For AE-driven or contraindication-driven discontinuation mid-cycle, abrupt discontinuation is acceptable given short-acting pharmacokinetics:

• CJC-1295 without DAC (Mod-GRF 1-29) — half-life ~30 minutes; PK clearance complete within hours.
• Ipamorelin — half-life ~2 hours; PK clearance within ~10 hours.
• MOTS-c — half-life not well characterized but short; PK clearance rapid.
• IGF-1 elevation pharmacodynamic effect attenuates over ~2–4 weeks post-discontinuation as GH-pulse stimulation ceases and IGF-1 returns to baseline.

Backbone tapering — clinician-judgment within label. For GLP-1 RAs in CWM indication: pharmacokinetic tapering is not pharmacologically required (half-life-driven PK washout occurs at fixed kinetics regardless of taper schedule). However, gradual dose reduction is the protocol-recommended pattern for weight-regain-trajectory smoothing and AE-class symmetry. Typical taper patterns:

• Semaglutide Wegovy CWM: 2.4 mg → 1.7 mg × 4 weeks → 1.0 mg × 4 weeks → 0.5 mg × 4 weeks → off. Total taper ~12 weeks. Clinician-judgment within label; FDA label permits abrupt discontinuation.
• Tirzepatide Zepbound CWM: similar gradual reduction pattern; clinician-judgment within label.
• Retatrutide: anticipated similar gradual pattern; specific label recommendation emerges at FDA approval.

Integrated-regimen sequenced discontinuation. When both backbone and adjunct are being discontinued together (e.g., pre-conception planning, regimen exit), the operational sequence:

1. Complete current adjunct stack cycle through end-of-cycle washout (~12–16 weeks on + 4–8 weeks off; total ~16–24 weeks).
2. Initiate backbone gradual taper at start of adjunct cycle-end washout (so adjunct washout and backbone taper proceed in parallel).
3. End-of-backbone-taper is the regimen end-of-treatment milestone.

For pre-conception planning where the timing windows are more constrained:

1. Time-budget the discontinuation window: 8 weeks backbone-discontinuation pre-conception (label-recommended) + 4 weeks adjunct-discontinuation pre-conception (pharmacodynamic).
2. Sequence: discontinue adjunct stack 4 weeks pre-conception (typical pattern — at end of current cycle if timing aligns; abrupt mid-cycle discontinuation acceptable given short-acting PK).
3. Discontinue backbone 8 weeks pre-conception (label-recommended; gradual taper or abrupt per clinician judgment within label).
4. Conception planning proceeds at ~8 weeks post-final-backbone-dose.

8.4 Pre-conception washout arithmetic — integrated regimen

The integrated regimen pre-conception washout requires per-component arithmetic that the §10.4 Anchor 3 counseling beat presents to the patient:

Adjunct stack arithmetic.

• CJC-1295 without DAC: t½ ~30 min; ~5 t½ = ~2.5 hours; PK clearance essentially complete within hours.
• Ipamorelin: t½ ~2 h; ~5 t½ = ~10 hours; PK clearance within ~10 hours.
• MOTS-c: t½ rapid; PK clearance within days.
• Pharmacodynamic IGF-1 trajectory returns to baseline within ~2–4 weeks post-discontinuation.
• Recommended pre-conception adjunct washout: ~4 weeks (covers PD IGF-1 return).

Backbone arithmetic.

• Semaglutide: t½ ~1 week (160–168 hours); ~5 t½ = ~35 days for >95% PK clearance; FDA label for Wegovy and Ozempic specifies discontinuation at least 8 weeks before planned pregnancy. The 8-week label recommendation is the conservative clinical recommendation accounting for PK + PD clearance plus margin.
• Tirzepatide: t½ ~5 days; ~5 t½ = ~25 days for substantial clearance; ~35 days for complete clearance; label recommendation discontinue at least 2 months before planned conception.
• Retatrutide: t½ ~6 days; ~5 t½ ≈ 30 days for substantial clearance; anticipated similar 8-week pre-conception label recommendation; specific label arithmetic emerges at FDA approval.
• Recommended pre-conception backbone washout: 8 weeks per label (sema / tirz; reta anticipated).

Operational pre-conception sequence (sema or tirz backbone):

1. Conception planning timeline: anticipated conception at month X.
2. Backbone discontinuation: month X minus 8 weeks (~2 months pre-conception).
3. Adjunct discontinuation: month X minus 4 weeks (~1 month pre-conception). Typically aligned with current cycle end if cycle timing permits; abrupt acceptable given short-acting PK.
4. Pre-conception counseling: present both arithmetics together (Anchor 3 — §10.4); decision is patient-anchored within her reproductive-planning context.

8.5 Post-discontinuation framing

Post-adjunct-discontinuation lean-mass trajectory. Practitioner-observation suggests:

• If the backbone continues at maintenance dose with stable weight, the lean-mass status preserved during the stack is generally maintained — the catabolic pressure of active weight loss has eased; maintenance phase is not associated with continued lean-mass loss.
• If the backbone continues at active-weight-loss-phase dose with continued weight loss, the lean-mass-loss fraction may return toward the unsupplemented expectation (~20–32% per Phase 3-pooled DEXA); the adjunct stack’s lean-mass-preservation effect is on-protocol, not durable post-discontinuation.
• The Tier 1 foundation (resistance training, protein) is the durable lean-mass-preservation intervention; the adjunct stack is the time-bounded amplifier of the foundation’s effect.

Post-backbone-discontinuation weight-regain trajectory. Trial-program data per backbone:

• Semaglutide: STEP-4 / STEP-1 extension (Rubino 2021 PMID 33755728; Wilding 2022 PMID 35441470) — approximately two-thirds of lost weight typically regained by 12 months post-discontinuation.
• Tirzepatide: SURMOUNT-4 (Aronne 2024 PMID 38078870) — randomized-withdrawal design demonstrated +14% regain on placebo-switch through Week 88 (two-thirds of run-in weight loss regained).
• Retatrutide: post-discontinuation trajectory pending Phase 3 readouts; class-level pattern anticipated to be similar.

Mechanism — set-point physiology. Without pharmacologic support, the body’s counter-regulatory responses re-establish a higher equilibrium. The §10.7 counseling beat does not pathologize weight regain post-discontinuation; it frames the regain trajectory as the expected biological response, the same way pre-treatment counseling framed the appetite-suppression mechanism as the biological intervention. Patients considering discontinuation are counseled on the expected regain trajectory and the re-initiation pathway if regain occurs and warrants re-treatment.

8.6 Re-initiation pathway

A patient who discontinued the integrated regimen and is considering re-initiation:

Backbone re-initiation: typically re-titration from the starting dose is the protocol-recommended pattern — the tolerability re-priming is equivalent to initial titration; abrupt re-initiation at the prior target dose is not recommended due to GI AE recurrence risk. Backbone-protocol §4 titration applies. Indication confirmation per §1, selection-criteria re-screening per §2, and pre-treatment workup refresh per §3 if the discontinuation period exceeded ~12 months or if new comorbidity has emerged.

Adjunct re-initiation: operationally similar to initial initiation (§4) — no protracted re-titration needed; per-compound tolerability profile is mild and reproducible. Verify §3 baseline workup is current (within ~6–12 months); update IGF-1, glucose, cancer-surveillance baselines if dated. Re-initiate at protocol target doses; re-initiate cycle structure.

Re-initiation sequencing. Re-initiation of the integrated regimen follows the standard sequencing rule — backbone first (or backbone-established at the time of re-initiation), adjunct stack second. Concurrent re-initiation of both is not standard; the backbone titration / target-dose verification window provides the early-tolerability screen before adjunct addition.

8.7 Worked example — discontinuation scenarios for the integrated regimen

Scenario A — Goal achieved at end of Cycle 2 of integrated regimen. The 54-year-old female (the §1.7 patient) at end of Cycle 2 washout, Month 18 on Wegovy. Has lost 18 kg total (~19% of starting weight); DEXA shows lean-mass-loss fraction ~18% (improved from pre-stack ~33%; in the practitioner-observation target range); functional measures stable. Wegovy transitioning to maintenance dose. Plan: discontinue adjunct stack permanently for this active-weight-loss arc; continue Wegovy at 2.4 mg maintenance dose; continue Tier 1 foundation. Post-discontinuation monitoring at Month 21, 24, 30 with weight and BP; body-composition at Month 24 and annually thereafter. Re-initiation of adjunct considered if weight regain or lean-mass loss re-emerges.

Scenario B — Pre-conception planning at Month 14 of integrated regimen. A 34-year-old female on Wegovy + adjunct stack Cycle 1, planning conception in ~5 months. Counseling beat (Anchor 3): discontinue adjunct stack 4 weeks pre-conception (pharmacodynamic IGF-1 return); discontinue Wegovy 8 weeks pre-conception per label. Sequenced plan: adjunct stack discontinuation at end of current cycle (Week 14 of Cycle 1; cycle washout begins; conception timeline aligns); Wegovy gradual taper initiated at start of adjunct washout (2.4 → 1.7 mg × 4 weeks → 1.0 mg × 4 weeks → 0.5 mg × 4 weeks → off, completing the taper ~12 weeks); 4-week post-taper PK clearance window; conception planning ~8 weeks post-final-Wegovy-dose. Adjunct PD IGF-1 return ~2–4 weeks post-adjunct-discontinuation, well within the longer backbone window.

Scenario C — Confirmed acute pancreatitis on sema-backbone integrated regimen (per §6.11 Scenario C). Backbone permanent discontinuation (abrupt; no taper given AE-attributable etiology). Adjunct discontinuation aligned per indication-resolution. Transition to non-GLP-1 alternative weight-management approach OR tirzepatide alternative backbone with informed consent about cross-class GLP-1 RA pancreatitis signal per Wen 2025 PMID 40988099; if tirzepatide alternative is selected, the integrated regimen can resume with new backbone after Month 3+ tirz target-dose stabilization (per §4 Phase A.1 backbone-naive titration + Phase B adjunct initiation).

Scenario D — Patient-preference adjunct discontinuation at Cycle 2 Week 8 for cost reasons. A 45-year-old patient on integrated regimen elects to discontinue adjunct adjuncts; will continue backbone + Tier 1 foundation. Counseling: adjunct discontinuation mid-cycle is fine — abrupt discontinuation acceptable given short-acting PK; the lean-mass-preservation goal may be only partially achieved at this point vs the practitioner-observation expectation at full cycle completion; Tier 1 foundation continues as the durable intervention. Backbone continues unchanged. Re-initiation pathway available if cost / circumstance changes.

Scenario E — New pregnancy on integrated regimen. A 29-year-old female on Wegovy + adjunct stack Cycle 1, discovers pregnancy at ~6 weeks gestation. Wegovy is a labeled contraindication in pregnancy for CWM indication; adjunct stack is class-level contraindicated in pregnancy. Immediate discontinuation of both components. Obstetrics co-management; PK clearance windows documented for the obstetrics record (adjunct ~hours to days for PK + ~2–4 weeks for PD IGF-1 return; backbone ~35 days for PK + label-recommended-8-week margin; first-trimester exposure has already occurred). Post-pregnancy and post-lactation, re-initiation decision per §8.6 + §1 + §2 reapplication.

Pattern Z calibration anchor 3 precision in §8.7. Pre-conception planning counseling (Scenario B) presents both PK arithmetics (adjunct + backbone) and the post-discontinuation weight-regain trajectory — facts the patient uses to make her reproductive-and-treatment-planning decision. The protocol does not steer the patient toward continued pharmacotherapy by emphasizing weight-regain risk, nor toward discontinuation by emphasizing pregnancy-exposure risk. Both facts are presented per-component; the patient decides within her reproductive-planning context.

---

9. Combination rules (stack-combination operational core)

9.1 Purpose — §9 IS this protocol

§9 is the load-bearing operational section of this protocol — this protocol IS the combination. Section 9 codifies how the integrated regimen operates as one clinical entity across the four substantive sub-sections: (a) sequencing relative to the GLP-1 RA backbone (§9.2); (b) timing within the weight-loss arc (§9.3 — active-loss vs maintenance vs pre-maintenance transition vs pre-discontinuation set-point preservation); (c) duration discipline (§9.4 — stacking is time-bounded; the adjunct stack cycles align with the backbone active-weight-loss arc); (d) discontinuation pathway after the lean-mass-preservation goal is achieved (§9.5); plus the cross-Module / cross-peptide combination rules (§9.6 — interactions with tesamorelin, AOD-9604, GHK-Cu, BPC-157, MK-677, creatine, protein), the contraindicated combinations (§9.7), and worked combination scenarios (§9.8).

Pattern W cross-section consistency: every combination rule in §9 is reconciled with §2 (no contraindicated agent enters the combination), §6 (combinations cannot mask or exacerbate AE-class concerns), §8 (combination discontinuation aligns with §8 trigger framework), and §10 (counseling beats for combinations are Pattern Z calibration-anchor-compliant).

9.2 Core sequencing rule — adjunct stack on established GLP-1 backbone

The core sequencing rule. The adjunct stack is initiated on top of an established GLP-1 RA backbone, not before, not concurrently with backbone initiation, not as a substitute. The patient must be:

• On an FDA-approved-for-marketing-claims GLP-1 RA at established target dose (semaglutide Wegovy 2.4 mg at Month 3+ on target; semaglutide Wegovy HD 7.2 mg at Month 3+ on target; tirzepatide Zepbound 5–15 mg at Month 3+ on target; semaglutide Ozempic for T2D-indication integrated regimens; OR
• On a pre-FDA-approval-for-marketing-claims primary weight-management agent at established target dose under explicit informed consent (retatrutide 8–12 mg via active TRIUMPH trial enrollment OR clinician-judgment off-label investigational-supply use where research-protocol acquisition pathway exists). Pattern AA.marketing-claims precision: pre-FDA-approval primary agent + research-state adjunct stack = double off-label / off-pathway combination; §10.6 counseling beat addresses explicitly.
• Demonstrating backbone-driven weight-loss response. Patient has lost ≥5% of starting body weight by Month 3 of backbone target dose — the adjunct stack is not deployed for non-responders to the backbone (the lean-mass-preservation indication is contingent on the catabolic weight-loss pressure created by the backbone).
• On the Tier 1 foundation (resistance training + 1.2–1.6 g/kg protein + vitamin D + monitoring). The foundation is the substrate; the integrated regimen is the foundation + backbone + adjunct overlay.

What this sequencing rules out.

• Adjunct stack initiation in patients not yet on a GLP-1 RA backbone (the lean-mass-preservation indication does not apply without the catabolic weight-loss pressure of the primary agent).
• Adjunct stack initiation concurrent with backbone initiation (the backbone’s own initiation / titration tolerability work should not be confounded with adjunct tolerability; the adjunct stack is added once backbone target dose is stable).
• Adjunct stack initiation as a weight-loss strategy in lieu of an FDA-approved-for-marketing-claims primary weight-management agent (the adjunct stack is not a primary weight-loss therapy).
• Adjunct stack initiation in backbone-non-responders (the catabolic-pressure indication is not present).

9.3 Timing within the weight-loss arc

Active-weight-loss phase: integrated-regimen indication-on. Patient is actively losing weight on the GLP-1 RA backbone; the catabolic pressure is driving the lean-mass-loss-fraction concern; the adjunct stack’s lean-mass-preservation mechanism is operationally needed. This is the indication-positive phase. Phenotype branches per §1.5: Branch A (sarcopenic baseline / older adult — anticipatory at backbone target dose); Branch B (athletic / high-baseline-lean-mass — anticipatory at backbone target dose); Branch C (post-50lb / DEXA-triggered / mid-trajectory — reactive at DEXA-trigger).

Maintenance phase: integrated-regimen indication-off (in most cases). Patient is at target weight on backbone at stable maintenance dose; weight is stable; catabolic pressure has eased. In most patients at maintenance, the lean-mass-loss concern has resolved (lean mass stabilizes when weight loss stabilizes); the adjunct stack’s lean-mass-preservation indication is no longer active. Plan adjunct discontinuation at next cycle washout (§8.2 + §5.5 inter-cycle decision); backbone continues at maintenance dose.

Exception: maintenance phase with residual sarcopenic concern. Some patients at backbone maintenance have residual sarcopenic risk (post-menopausal, ≥65 age, functional measure decline, athletic-population baseline) and may benefit from intermittent adjunct stack cycling at maintenance phase. Clinician-judgment within the protocol; practitioner-observation evidence base for maintenance-phase adjunct use is thinner than for active-phase use.

Pre-maintenance transition phase: integrated-regimen indication-on with discontinuation-planning. Patient is approaching target weight (within ~5% of target); catabolic pressure is easing but has not yet fully resolved. Continue adjunct through the transition phase to support lean-mass preservation during the final weight-loss arc; plan adjunct discontinuation at maintenance attainment. Most common integrated-regimen use-case timing.

Pre-discontinuation set-point preservation phase. For patients planning backbone discontinuation (rare; typically cost / access barriers; pre-conception planning; patient preference): consider running an adjunct cycle in the 3–6 months pre-backbone-discontinuation to support set-point preservation and post-discontinuation weight-regain-trajectory smoothing (mechanism rationale; not RCT-anchored). Pattern V framing: effect-size of pre-discontinuation adjunct on post-discontinuation weight-regain trajectory is research-state-incomplete; the practitioner-observation framing is the explicit honesty.

9.4 Duration discipline — stacking is time-bounded

Cycle structure (from §5.5). 12–16 weeks on; 4–8 weeks off; up to 2–3 total cycles per active-weight-loss arc.

Maximum operational duration on adjunct stack. Typical practitioner-observation use: 6–12 months of total adjunct exposure (2–3 cycles of 12–16 weeks each plus washouts), aligned with the backbone active-weight-loss phase. Protracted multi-year adjunct use beyond 12 months total is uncommon; long-term safety profile (particularly cancer-surveillance over multi-year IGF-1 elevation) is research-state-thin beyond the typical use horizon.

Why time-bounding matters — three reasons.

1. Receptor-level tachyphylaxis risk. GHRH-R and GHS-R1a downregulation under sustained stimulation; practitioner-consensus cycling discipline mitigates.
2. IGF-1 cancer-surveillance considerations. Multi-year sustained IGF-1 upper-quartile elevation is operationally similar to GH-replacement-cohort exposure profile; the Renehan vs 2022-cohort tension is reassuring but counsels conservative time-bounding.
3. Indication alignment with backbone active-weight-loss phase. The lean-mass-preservation indication is contingent on catabolic pressure; when weight loss stabilizes at backbone maintenance, the indication ends.

Backbone duration is open-ended. GLP-1 RA backbones in CWM indication are typically continued at maintenance dose for the duration of clinical benefit (chronic-relapsing-condition framing per backbone-protocol §10.7); the time-bounding is on the adjunct side, not the backbone side.

9.5 Discontinuation pathway after lean-mass-preservation goal is achieved

Discontinuation timing. When the patient achieves their target weight on the backbone, with body-composition trajectory favorable (lean-mass status preserved per stack endpoint at §5.4), planned adjunct discontinuation at the next cycle washout is the standard pathway. Backbone continues at maintenance dose.

Operational sequence.

1. Complete current adjunct stack cycle through on-phase (Weeks 12–16).
2. Cycle washout (4–8 weeks) serves as natural taper-equivalent; no pharmacologic adjunct taper required.
3. End of washout: adjunct discontinue permanently for this active-weight-loss arc.
4. Backbone transitions to maintenance dose per backbone-protocol §5 / §8 framework — open-ended continuation, not pharmacologic discontinuation.

Post-discontinuation monitoring. Body-composition reassessment at Month 3, 6, 12 post-adjunct-discontinuation (DEXA / BIA + functional measures). IGF-1 returns to baseline within ~2–4 weeks post-adjunct-discontinuation; no on-going IGF-1 monitoring required post-adjunct unless cancer-surveillance baseline rationale extends (§6.10.3). Tier 1 foundation continues as the durable intervention. Backbone monitoring continues per backbone-protocol §5 cadence.

Re-initiation pathway (§8.6). Available if backbone re-enters active-weight-loss phase (e.g., backbone dose intensification to address weight-regain; new backbone initiation if prior discontinuation), or if a new lean-mass-concern phenotype emerges (e.g., new sarcopenia signal on continued backbone maintenance), or if patient elects re-initiation per clinical-education-supported discussion.

Alternative discussion: with-DAC form for sustained-elevation context. This protocol specifies CJC-1295 without DAC (Mod-GRF 1-29) for the pulsatile lean-mass-preservation context. The CJC-1295 with DAC form (~8-day half-life via albumin conjugation; sustained tonic GH elevation) is a different pharmacologic profile used in different clinical contexts (sustained GH/IGF-1 anti-aging protocols). For lean-mass preservation on the integrated regimen, this protocol uses without-DAC. Some practitioners use with-DAC in non-response contexts (§7.4 Option B); this is clinician-judgment within informed consent; the glucose-tolerance directional pressure of sustained GH elevation is more concerning than pulsatile and requires closer glucose monitoring.

9.6 Cross-Module / cross-peptide combination rules for the integrated regimen

Integrated regimen + tesamorelin (M5.5 visceral-fat-targeting). Tesamorelin is FDA-approved-for-marketing-claims for HIV-associated lipodystrophy (Egrifta 2010); off-label use in non-HIV settings for visceral-fat-targeting is clinician judgment. Combining tesamorelin with the integrated regimen’s GH-axis adjunct (CJC-1295) produces additive GHRH-pathway stimulation (both are GHRH analogs operating on the same GHRH receptor). The additive effect requires careful IGF-1 monitoring (above-reference IGF-1 risk is higher with two GHRH analogs co-administered); typically used as an alternative-substitute for CJC-1295 rather than additive (i.e., switch CJC-1295 for tesamorelin per §7.5 Option C). Pattern AA precision: tesamorelin is FDA-approved-for-marketing-claims for HIV-lipodystrophy; off-label for lean-mass-preservation context.

Integrated regimen + AOD-9604 (M5.5 visceral-fat-targeting). AOD-9604 is a 16-amino-acid fragment of the C-terminus of human GH (residues 177–191), characterized as a fat-loss-targeted GH-fragment without growth-promoting / IGF-1-elevating effects. AOD-9604 is NOT FDA-approved-for-marketing-claims for any drug indication. Combination with the integrated regimen is mechanism-class-complementary (the adjunct GH-axis engages full-length signaling; AOD-9604 engages a fat-loss-fragment pathway); practitioner-observation use exists. Pattern V framing: additive effect-size of AOD-9604 on the integrated regimen is research-state-incomplete.

Integrated regimen + GHK-Cu (M5.7 skin-rejuvenation). GHK-Cu (copper tripeptide) used in M5.7 for post-weight-loss skin laxity. Mechanism is not GH-axis-related; no mechanism-conflict with the integrated regimen; co-administration is operationally compatible. Pattern Z framing in patient counseling presents the multi-peptide protocol structure honestly without overstating combined effect-size.

Integrated regimen + BPC-157 (recovery / connective-tissue). BPC-157 is a pentadecapeptide used in recovery-protocol contexts. No mechanism-conflict with the integrated regimen; co-administration is compatible. Pattern AA: BPC-157 is NOT FDA-approved-for-marketing-claims for any drug indication.

Integrated regimen + MK-677 / ibutamoren (oral ghrelin mimetic). MK-677 is an oral ghrelin mimetic (GHS-R1a agonist). Combining MK-677 with Ipamorelin produces additive GHS-R1a stimulation — mechanism-redundant; not recommended (use one or the other; the SubQ adjunct stack vs the oral MK-677 alternative is the typical clinical decision rather than combination). Pattern AB.1 inversion-risk discipline: MK-677 and Ipamorelin are both GHS-R1a agonists but pharmacokinetically distinct molecules; mechanism-redundant in combination.

Integrated regimen + creatine monohydrate. Creatine is the most-evidence-based ergogenic supplement for resistance-training-context muscle-mass support (cited as moderate-evidence Tier 1 foundation component). Creatine combination with the integrated regimen is mechanism-class-complementary (creatine operates on ATP regeneration; integrated regimen on hormonal anabolic signaling + appetite suppression). Standard 3–5 g/day creatine monohydrate is the Tier 1 foundation recommendation.

Integrated regimen + protein supplementation. Same framing as creatine — Tier 1 foundation component; integrated regimen does not substitute for adequate protein intake.

Integrated regimen + SGLT2 inhibitor (T2D indication context). Per backbone-protocol §9.2 — class-additive HbA1c and CV/kidney benefits for the backbone. The adjunct stack does not have known interactions with SGLT2 inhibitors. The integrated regimen + SGLT2 combination is operationally compatible in T2D + CKD or T2D + ASCVD context; monitor eGFR at 2 weeks post-SGLT2 initiation (typical small reversible eGFR decline expected).

Integrated regimen + insulin (T2D advanced). Per backbone-protocol §9.2 — common in T2D with progressed beta-cell failure. The adjunct stack’s GH-axis insulin-antagonism at supraphysiologic levels could in theory worsen the integrated-regimen + insulin glucose-tolerance picture; in practice, the physiologic-range dosing target (IGF-1 Z 0 to +1) makes this rare. §6.7 + §6.10 monitoring applies; concurrent insulin dose typically reduced ~20% at backbone initiation per backbone-protocol §6.7.

Integrated regimen + cagrilintide (CagriSema combination). CagriSema is the fixed-combination subcutaneous-weekly product (semaglutide 2.4 mg + cagrilintide 2.4 mg) per the REDEFINE program. REDEFINE-1 (PMID 40544433; n=3,417; 68 weeks; obesity without diabetes): −20.4% body weight (treatment-policy estimand). Pattern AA precision: regulatory status as of 2026-05-14 is Phase 3 readout reported; FDA submission status — check current. If a patient is on CagriSema as the backbone (vs Wegovy semaglutide alone), the integrated regimen logic still applies — CagriSema is a backbone formulation with semaglutide + cagrilintide co-formulated; the lean-mass-preservation adjunct stack overlay operates the same as on Wegovy backbone. Pattern V framing: CagriSema lean-mass-loss-fraction data via REDEFINE DEXA substudies pending; the integrated-regimen lean-mass-preservation effect-size on CagriSema backbone is research-state-incomplete.

9.7 Contraindicated combinations

• Integrated regimen + somatostatin analog (octreotide, lanreotide, pasireotide). Mechanism-conflict; somatostatin analogs block GH release; co-administration with the GH-axis adjunct defeats the mechanism. §2.4 hard contraindication.
• Integrated regimen + concurrent CJC-1295 with DAC and CJC-1295 without DAC. Mechanism-redundant; same-molecule different-formulation co-administration is not indicated. Use one form or the other per §4.5 form-selection clinician judgment.
• Integrated regimen + concurrent FDA-approved-for-marketing-claims somatropin (recombinant human GH). Mechanism-redundant; exogenous GH replacement and endogenous-GH-stimulation are not additive. Choose one strategy.
• Integrated regimen + concurrent DPP-4 inhibitor (backbone-side). Mechanism-redundant on the backbone side (DPP-4 inhibitor preserves endogenous GLP-1; redundant with exogenous DPP-4-resistant analog backbone). No additive HbA1c benefit; avoid co-prescribing.
• Integrated regimen + concurrent semaglutide + tirzepatide (within-backbone-class). Avoid; redundant within-class mechanism with additive AE profile and no demonstrated additive benefit; transition between backbones per §7 non-response algorithm, not co-administration.
• Integrated regimen + active pregnancy / lactation. §2.4 hard contraindication.

9.8 Worked example — integrated-regimen combination scenarios

Scenario A — Standard integrated regimen on Wegovy backbone (the §1.7 typical scenario). Wegovy 2.4 mg + adjunct stack (CJC-1295 100 mcg + Ipamorelin 200 mcg bedtime + MOTS-c 10 mg AM 3x/week, 12–16 week cycle) + Tier 1 foundation. The canonical integrated-regimen patient per §1.7 → §8.7 Scenario A.

Scenario B — Integrated regimen on Zepbound backbone (tirzepatide). A 49-year-old male on Zepbound 15 mg weekly for CWM (FDA-approved-for-marketing-claims) — joins adjunct stack with documented athletic / high-baseline-lean-mass phenotype (Branch B anticipatory). Same adjunct protocol per §4.4. Pattern V framing: tirzepatide has modestly more favorable fat-to-lean ratio at equivalent weight loss vs semaglutide per Look 2025 PMID 39996356; the integrated-regimen lean-mass-preservation effect-size adds to this baseline. The combined regimen (Zepbound + adjunct stack + Tier 1 foundation) is a multi-mechanism approach with FDA-approved-for-marketing-claims primary agent + research-state adjunct adjuncts.

Scenario C — Integrated regimen on retatrutide via TRIUMPH trial enrollment. A 56-year-old female enrolled in SYNERGY-Outcomes (NCT07165028; obesity + MASLD; RECRUITING as of 2026-05-14) on retatrutide investigational supply. Adding the adjunct stack to a pre-FDA-approval primary weight-management agent: double off-label / off-pathway combination. Pattern AA.marketing-claims precision: retatrutide is pre-FDA-approval-for-marketing-claims per [[Retatrutide Protocol]]; adjunct stack is research-state. §10.6 counseling beat addresses this stacked off-label framing explicitly. Clinical-practice decision: clinician-judgment within informed consent; some practices accept this combination, others prefer to keep investigational-supply primary agents un-stacked until post-approval to preserve trial-protocol data integrity. SYNERGY-Outcomes enrolled patients should confirm with trial site whether concurrent adjunct stack use is permitted under the trial protocol.

Scenario D — Adjunct-stack substitution within the integrated regimen — tesamorelin for CJC-1295. A 60-year-old patient who is a non-responder to standard CJC-Ipa-MOTS-c stack on Wegovy backbone per §7.5 Option C algorithm. Substitute tesamorelin 2 mg SubQ evening for CJC-1295; retain Ipamorelin and MOTS-c per protocol; retain Wegovy backbone. Pattern AA precision: tesamorelin is FDA-approved-for-marketing-claims for HIV-lipodystrophy; off-label use in non-HIV lean-mass-preservation context is clinician judgment within informed consent. Monitor IGF-1 closely (tesamorelin produces robust IGF-1 elevation; risk of supraphysiologic levels at standard doses is documented in tesamorelin trial data per Falutz 2010 PMID 20554713).

Scenario E — Integrated regimen + cross-Module GHK-Cu for post-weight-loss skin laxity. A 52-year-old female on integrated regimen (Wegovy + adjunct stack + Tier 1 foundation) at Month 14, has lost 16 kg, develops post-weight-loss skin laxity. Adds GHK-Cu (M5.7 protocol) for skin-rejuvenation indication. Mechanism-complementary; no mechanism-conflict with the integrated regimen; operationally compatible. Patient counseling addresses the multi-peptide protocol structure honestly without overstating combined effect-size.

Scenario F — Integrated regimen + SGLT2 inhibitor in T2D polycondition phenotype. A 61-year-old male with T2D + CKD eGFR 42, on Ozempic 1.0 mg (T2D + CKD-in-T2D indication via FLOW-anchored) + adjunct stack (Branch A baseline sarcopenic risk); HbA1c 7.4 above individualized target; add empagliflozin 10 mg daily per ADA/EASD progression algorithm. Integrated regimen + SGLT2 combination is well-supported by individual-agent CVOT/KOOT data and by additive HbA1c reduction. Monitor eGFR at 2 weeks post-SGLT2 initiation; routine quarterly thereafter. The adjunct stack does not interact with SGLT2; continue per §5 monitoring.

Scenario G — Integrated regimen + Wegovy HD 7.2 mg high-dose semaglutide. A 53-year-old female on Wegovy HD 7.2 mg (FDA-approved-for-marketing-claims for CWM 2026-03-19 per STEP UP PMID 40961952) + adjunct stack. Backbone effect-size envelope ~−18.7% per STEP UP; integrated-regimen lean-mass-preservation overlay applies per the same framework as Wegovy 2.4 mg. Dysesthesia AE class is Wegovy HD-specific (per [[Semaglutide Protocol]] §6.10); monitor per backbone-protocol AE management. No additional adjunct-stack interaction with the higher backbone dose.

Pattern W cross-check at §9.8. Each scenario above reconciles with §2 (no contraindicated agents), §6 (AE-management algorithms apply per per-compound profile + integrated overlay), §8 (discontinuation pathways align), and §10 (counseling beats Pattern Z compliant). The contraindicated-combinations list (§9.7) is enforced — no scenario includes a contraindicated combination.

Pattern AA.marketing-claims cross-check at §9.8. Every regulatory framing carries the appropriate per-component qualification: Wegovy / Zepbound / Mounjaro are FDA-approved-for-marketing-claims for their specified CWM and T2D indications; Wegovy HD 7.2 mg is FDA-approved-for-marketing-claims for CWM as of 2026-03-19; retatrutide is pre-FDA-approval-for-marketing-claims; tesamorelin is FDA-approved-for-marketing-claims for HIV-lipodystrophy with off-label use elsewhere; CagriSema regulatory status check current; the adjunct stack compounds (CJC-1295 without DAC; Ipamorelin; MOTS-c) are NOT FDA-approved-for-marketing-claims for any drug indication.

---

10. Patient counseling beats (Pattern Z calibration-anchor-compliant)

10.1 Purpose

Define the protocol’s patient-counseling content for the integrated regimen — the conversations the clinician has with the patient at each protocol phase. §10 is the operational anchor for Pattern Z (cumulative-tone calibration) and for Pattern R (lead-framing calibration). For the integrated-regimen stack protocol, Anchor 5 (off-label / extrapolation transparency) is DOMINANT because the entire integrated regimen is off-label combined-regimen use — the backbone is FDA-approved-for-marketing-claims for its labeled indications (or pre-FDA-approval for retatrutide); the adjunct stack is research-state; the combined regimen has no Phase 3 RCT for the lean-mass-preservation primary endpoint. §10.6 is the largest §10 subsection.

The five Pattern Z calibration anchors apply with integrated-regimen-specific adaptations:

• Anchor 1 — Lead with what the option IS. Each component (backbone + adjunct) presented for what it is; the integrated regimen presented for what it is (the most common real-world Module 5 multi-compound regimen for lean-mass-preservation during catabolic weight loss). The negative regulatory framing belongs in §10.6 Anchor 5 (off-label transparency) as scoped factual context, not as the lead.
• Anchor 2 — Compounded vs FDA-approved counseling. Per backbone-protocol §10.3 for the sema / tirz / reta compounded-vs-branded conversation; per adjunct-stack canonical §10.3 for the compounded-peptide-pharmacy conversation (research-state stack with no FDA-approved-for-marketing-claims version).
• Anchor 3 — Pregnancy precision. Sequenced washout arithmetic (adjunct ~4 weeks PD; backbone ~8 weeks label) presented together; pre-conception decision is patient-anchored.
• Anchor 4 — Backbone comparator framing. Within the GLP-1 RA backbone class: sema vs tirz vs reta multi-dimensional comparator per §4.2 (12 dimensions including SURMOUNT-5 head-to-head; SURPASS-2 head-to-head; backbone-specific NAION / DR class-differentiation; cost / access; pre-FDA-approval-vs-approved). Plus the within-adjunct-class comparator (CJC-1295 with-DAC vs without-DAC; tesamorelin substitution; MK-677 alternative).
• Anchor 5 — Off-label / extrapolation transparency — DOMINANT. §10.6 is the largest §10 subsection. The entire integrated regimen is off-label combined-regimen use; the §10.6 conversation is the load-bearing patient-counseling discipline.

10.2 Initiation conversation for the integrated regimen (§4 anchor)

The initiation conversation occurs at the integrated-regimen initiation visit (after backbone is established at target dose; after §3 workup completion; after §2 selection-criteria screen passes). Required counseling beats:

• What the integrated regimen IS (Anchor 1): the most common real-world Module 5 multi-compound regimen — a GLP-1 RA backbone delivering primary weight-loss + a CJC-1295 (without DAC) + Ipamorelin + MOTS-c adjunct stack delivering lean-mass-preservation overlay + Tier 1 foundation (resistance training + protein + vitamin D). The integrated regimen IS what you are starting; not a “GLP-1 plus mystery peptides” hand-wave but a mechanism-class-integrated regimen with two distinct mechanism axes converging on the body-composition endpoint.

• What it does for the patient’s indication (Anchor 1 + Anchor 5): expected effect-sizes at per-component-anchored resolution — backbone-side trial-anchored magnitudes (sema STEP-1 ~14.9% / Wegovy HD STEP UP ~18.7%; tirz SURMOUNT-1 ~20.9% TR / ~22.5% efficacy; reta Phase 2 ~24.2% / Phase 3 sponsor topline ~28.7%) for the weight-loss endpoint; adjunct-side practitioner-observation magnitudes (lean-mass-loss fraction reduction from ~25–32% Phase 3-pooled-DEXA baseline toward ~15–20% on integrated regimen with Tier 1 foundation) for the lean-mass-preservation endpoint. No Phase 3 RCT effect-size for the combined regimen specifically.

• Mechanism rationale (research-state precision per Pattern Z.research-precision): backbone is a GLP-1R (sema) / GLP-1R + GIPR (tirz) / GLP-1R + GIPR + GCGR (reta) agonist producing appetite suppression + glucose improvement + variable secondary effects. Adjunct GH-axis is GHRH analog (CJC-1295 without DAC; pulsatile half-life ~30 min) + selective GHS-R1a agonist (Ipamorelin; without cortisol / prolactin elevation) producing supra-additive 7–10× GH pulse → IGF-1 → muscle anabolic signaling. Adjunct mitochondrial-peptide is MOTS-c (16-aa mitochondrial-encoded peptide) producing AMPK activation + myostatin pathway modulation + exercise-mimetic biology. The three mechanism families are non-redundant; converge on body-composition outcome.

• The dosing schedule and operational discipline: backbone weekly subcutaneous injection (continuing the patient’s existing backbone routine); CJC-Ipa combined bedtime fasted-state daily 5-on/2-off in a 12–16 week cycle; MOTS-c AM 3x/week or weekly pulse; MOTS-c reconstitution discipline (do NOT shake; gentle swirling; 2–7 day reconstituted use window). Pattern Z.injection-framing: the additional injections (bedtime CJC-Ipa + AM MOTS-c) are subcutaneous with 30G insulin syringe — routine clinical skill equivalent in technique to the existing backbone self-injection the patient is already performing.

• The Tier 1 foundation as load-bearing (§10.5): protein and resistance training are not optional supplementation — they are the substrate-enabling interventions without which the integrated regimen has minimal effect on the lean-mass endpoint.

• The off-label / research-state framing (Anchor 5 pre-positioned at initiation): the backbone is FDA-approved-for-marketing-claims for the indication being treated (or pre-FDA-approval-for-marketing-claims for retatrutide-backbone integrated regimens); the adjunct stack compounds are NOT FDA-approved-for-marketing-claims for any drug indication; available through 503A compounding pharmacies under post-2023 FDA Category 2 listing variation; the combined regimen has no Phase 3 RCT for lean-mass-preservation primary endpoint — the clinical decision is research-state-honest shared decision-making.

• Monitoring plan and what triggers communication (§5 + §6): IGF-1, glucose, body-composition, cancer-surveillance monitoring cadence; escalation triggers for any unexpected symptoms.

• Pre-conception planning beat for reproductive-age patients (Anchor 3 — §10.4 below): sequenced washout arithmetic for both backbone and adjunct.

• Cost / access reality (Anchor 1+2): backbone-side compounded-vs-branded discussion if both options available; adjunct-side 503A compounded-pharmacy pathway (no FDA-approved version exists for the adjunct compounds).

• What the patient signals back if any concern emerges (escalation pathway): symptoms warranting in-person evaluation within 48 hours — severe persistent abdominal pain (pancreatitis-suspect); acute vision change (NAION-suspect for sema-backbone; DR-progression-suspect for tirz-backbone in DR-positive patients); severe injection-site reaction or signs of hypersensitivity; severe glucose worsening symptoms (polyuria, polydipsia, unexplained fatigue); new sleep-apnea symptoms.

10.3 Compounded counseling — Anchor 1+2 for both backbone and adjunct

The integrated regimen has two compounded counseling beats:

Backbone-side compounded vs FDA-approved-Novo-Nordisk-or-Lilly-or-pending-Lilly counseling per the chosen backbone protocol:

• Sema-backbone: per [[Semaglutide Protocol]] §10.3 verbatim Anchor 1+2 (compounded semaglutide as a real-world clinical option from 503A / 503B compounding pharmacies vs FDA-approved Novo Nordisk Ozempic / Wegovy / Rybelsus).
• Tirz-backbone: per [[Tirzepatide Protocol]] §10.3 (compounded tirzepatide vs FDA-approved Lilly Zepbound / Mounjaro). The tirzepatide compounding-pharmacy landscape has additional FDA-listing considerations following the 2024 tirzepatide-shortage-resolution.
• Reta-backbone: per [[Retatrutide Protocol]] §10.3 pre-FDA-approval-compound framing — retatrutide is research-state on the regulatory side; the 503A compounded-pharmacy access pathway is the typical clinical access route for off-label use (or active TRIUMPH trial enrollment for trial-supply access).

Adjunct-side compounded counseling per [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] §10.3 (Anchor 1+2 reframed for research-state stack). The framework: there is no FDA-approved-for-marketing-claims version of CJC-1295, Ipamorelin, or MOTS-c to compare against; the 503A compounding pathway is the access pathway for these research-state compounds (not an alternative to an FDA-approved version). The patient-counseling beat:

“The adjunct compounds — CJC-1295 without DAC, Ipamorelin, and MOTS-c — are research-state. They haven’t been through the FDA new-drug-approval pathway for any drug indication. That’s not the same as ‘unsafe’ or ‘dangerous’; it means the evidence base is at a different tier than for FDA-approved drugs. They’re available through 503A compounding pharmacies, which operate under state-board-of-pharmacy regulation and USP standards for sterile compounding. There isn’t an FDA-approved version of CJC-1295 or Ipamorelin or MOTS-c to compare to — the compounding pathway is the access pathway for these compounds.

Your backbone — [Wegovy / Zepbound / etc.] — is FDA-approved for marketing claims for [chronic weight management / type 2 diabetes / etc.]. The combined regimen pairs an FDA-approved-for-marketing-claims backbone with research-state adjuncts; the regulatory framework is different on each side and the counseling I do reflects that.

When I’m selecting a compounding pharmacy for a patient’s adjunct compounds, I verify the pharmacy’s state licensure, USP <797> compliance documentation, certificate-of-analysis-per-batch policy, cold-chain shipping practices, and API-sourcing documentation. The quality varies across compounding pharmacies, and the selection of the specific pharmacy matters operationally. I’ll walk you through reconstitution training before we start — there are some handling specifics, particularly for MOTS-c, that matter for the compound to retain its activity.“

Pattern Z compliance — leads with what compounded peptides ARE (research-state compounds; access pathway via 503A; under state-board and USP regulation); frames operational characteristics as factual scope; quality criteria presented as clinician-decision-supporting; acknowledges the per-component regulatory question (no FDA-approved-for-marketing-claims version of the adjunct compounds) without steering; closes with operational support invitation. Does NOT define compounded by what it ISN’T.

10.4 Pregnancy-planning conversation (Anchor 3) — sequenced washout for the integrated regimen

For reproductive-age patients on the integrated regimen. Pattern Z Anchor 3 framing requires research-state lead, then pharmacokinetic facts, then label / clinical-practice framing — applied per-component.

Required counseling beats — research-state lead.

• Human pregnancy-exposure data for the backbone. Parker 2025 PMID 40329607 — pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA regulatory clinical trials (semaglutide, liraglutide, dulaglutide, class-related compounds). Incidence of congenital abnormalities appears relatively low in this pooled dataset; sample size limited; exposures from unplanned-pregnancy contexts. Prospective planned-pregnancy exposure data is research-state-incomplete; authors call for prospective pregnancy registries. For tirzepatide and retatrutide specifically, similar pooled exposure data is emerging but more limited.
• Human pregnancy-exposure data for the adjunct stack. None. CJC-1295, Ipamorelin, and MOTS-c have no human pregnancy-exposure data; research-state-incomplete; class-level GH-axis-manipulation contraindication in pregnancy on mechanism grounds.

Required counseling beats — pharmacokinetic facts.

• Adjunct PK arithmetic. CJC-1295 without DAC t½ ~30 min; Ipamorelin t½ ~2 h; MOTS-c t½ short; full PK clearance within hours-to-days of last dose. Pharmacodynamic IGF-1 elevation attenuates over ~2–4 weeks post-discontinuation.
• Backbone PK arithmetic. Sema t½ ~1 week → ~35 days for >95% PK clearance; tirz t½ ~5 days → ~25–35 days for substantial clearance; reta t½ ~6 days → ~30 days for substantial clearance; anticipated similar.
• Recommended pre-conception adjunct washout: ~4 weeks (covers PD IGF-1 trajectory return to baseline).
• Recommended pre-conception backbone washout: ~8 weeks per label (sema / tirz; reta anticipated post-approval label).

Required counseling beats — operational sequence.

1. Conception planning timeline: month X.
2. Adjunct stack discontinuation: month X minus 4 weeks. Typically aligned with current cycle end if cycle timing permits; abrupt mid-cycle discontinuation acceptable given short-acting PK.
3. Backbone discontinuation: month X minus 8 weeks. Gradual taper or abrupt per clinician judgment within label.
4. Conception planning proceeds at ~8 weeks post-final-backbone-dose.

Required counseling beats — post-discontinuation weight-regain trajectory. Per backbone-protocol §8.5: sema STEP-4 / STEP-1-extension data approximately two-thirds of lost weight typically regained by 12 months post-discontinuation; tirz SURMOUNT-4 +14% regain on placebo-switch through Week 88; reta post-discontinuation trajectory pending Phase 3 readouts but anticipated similar class pattern. Per adjunct §8.5: post-adjunct lean-mass status preserved if backbone continues at maintenance; lean-mass-loss-fraction may return toward unsupplemented expectation if active-weight-loss continues without adjunct.

The patient’s reproductive-planning decision is patient-anchored. Some patients plan conception within the next 1–2 years; some within the next decade; some are not planning conception at all but want awareness of the discontinuation arithmetic in case planning changes. The counseling beat presents the facts per-component; the timing decision is patient-anchored.

Re-initiation pathway (§8.6). Post-pregnancy and post-lactation, re-initiation per §1 + §2 reapplication; if indication and selection criteria are met, integrated-regimen re-initiation per §4 (backbone-naive titration or backbone-established verification + adjunct stack initiation).

Pattern Z Anchor 3 framing precision: The conversation does not steer toward continuation or discontinuation; it presents the per-component PK / PD / label / research-state facts and leaves the timing decision to the patient with her reproductive-planning context.

10.5 Backbone comparator conversation (Anchor 4)

For patients selecting (or considering re-selecting) among the three backbone options on the integrated regimen. Canonical Anchor 4 requires multi-dimensional fact presentation across 8+ dimensions per §4.2; the protocol presents 12 dimensions for the integrated-regimen-specific backbone-selection conversation. The §10.5 counseling beat operationalizes the §4.2 framework:

Opener (Anchor 4 verbatim discipline): affirm both / all compounds being compared. “Semaglutide and tirzepatide are both effective options for chronic weight management; they have different mechanism profiles and different indication footprints, and the choice between them is patient-specific. Let’s walk through the dimensions that matter for your situation.”

The 12 dimensions per §4.2 multi-dimensional comparator — each presented at trial-anchored Pattern V resolution with Pattern V.metric-axis disclosed:

1. Weight-loss magnitude — backbone-specific trial-anchored figures; head-to-head SURMOUNT-5 (sema vs tirz at obesity doses), SURPASS-2 (sema vs tirz at T2D doses). No head-to-head Wegovy HD 7.2 mg vs Zepbound 15 mg trial exists; no head-to-head retatrutide vs tirzepatide trial completed (TRIUMPH-5 ACTIVE_NOT_RECRUITING; primary completion 2026-12).
2. T2D glycemic effect — backbone-specific HbA1c reduction figures with metric-axis disclosed.
3. Cardiovascular outcomes evidence base — SELECT / SUSTAIN-6 for sema; SUMMIT / SURMOUNT-MMO pending for tirz; TRIUMPH-3 / TRIUMPH-Outcomes pending for reta.
4. MASH evidence base — ESSENCE for sema (FDA-approved 2025-08); SYNERGY-NASH Phase 2 for tirz; Phase 2a MASLD substudy + SYNERGY-Outcomes pending for reta.
5. Kidney outcomes evidence base — FLOW for sema; SURMOUNT-MMO secondary endpoints; reta NCT05936151 Phase 2 + TRIUMPH-Outcomes pending.
6. OSA evidence base — SURMOUNT-OSA for tirz (FDA-approved 2024-12); sema and reta not directly studied.
7. Ophthalmologic class-differentiation — NAION signal documented for sema (Hathaway 2024); NAION signal absent for tirz (Lawrenson 2025); reta-specific NAION characterization research-state-pending TRIUMPH Phase 3 ophthalmologic safety reporting. DR signal baseline-status-stratified for tirz (Buckley 2025).
8. GI tolerability profile — all three GI-dominant; cross-trial comparison places tirz GI AE incidence similar-to-modestly-higher than sema at equivalent body-weight-reduction magnitudes; reta Phase 2 dose-dependent.
9. Route / platform availability — sema SubQ + oral Rybelsus 25 mg (2025 T2D); tirz SubQ only; reta SubQ trial-supply only as of 2026-05-14.
10. Cost and access — patient-specific.
11. Backbone-specific contraindication context — class-wide MTC / MEN-2 boxed warning across all three; tirz severe gastroparesis labeled functional contraindication; severe prior pancreatitis class-level precaution across all three.
12. Backbone-adjunct interaction context — all three are compatible with the adjunct stack on mechanism grounds; integrated-regimen sequencing rules in §9 apply uniformly across the three backbone selections.

Closer (Anchor 4 verbatim discipline): “There’s a weight-magnitude advantage for tirzepatide and retatrutide at higher doses, and a broader FDA-approved indication portfolio for semaglutide as of 2026-05-14. The trade-offs across the dimensions above are real and patient-specific. The decision is yours; my job is to give you the information honestly and to support whichever way you decide.” Pattern V discipline: effect-size differentials are anchored to specific trials and specific enrollments; the differential observed in trial populations may or may not generalize to the patient’s specific phenotype.

10.6 Off-label / research-state conversation (Anchor 5 — DOMINANT for the integrated regimen)

This is the dominant §10 conversation for the integrated regimen. Anchor 5 (off-label / extrapolation transparency) is the load-bearing counseling discipline because the entire combined regimen is off-label use — the backbone is FDA-approved-for-marketing-claims for its labeled indications, the adjunct stack is research-state, and the combined regimen has no Phase 3 RCT specifically for the lean-mass-preservation primary endpoint.

The patient question that recurs: “I’m on Wegovy [or Zepbound or retatrutide via TRIUMPH trial] and I’ve heard about peptides that help preserve muscle mass during weight loss. Should I add them?”

Pattern Z Anchor 5-disciplined patient-counseling beat (the integrated-regimen version):

“Here’s where the evidence is on the integrated regimen — your GLP-1 medication plus the adjunct stack we’d be adding for lean-mass preservation.

Your backbone — [Wegovy / Zepbound / retatrutide via SYNERGY-Outcomes / etc.] — is on the FDA-approved side. Wegovy is FDA-approved for marketing claims for chronic weight management; Zepbound is FDA-approved for chronic weight management plus moderate-to-severe sleep apnea with obesity. The trial program data — STEP-1, SURMOUNT-1, SURMOUNT-5 head-to-head, the cardiovascular outcomes data, the kidney data, the MASH data — is Phase 3 RCT evidence. The expected weight-loss magnitude for your backbone is anchored to those trials.

The lean-mass-loss fraction during GLP-1-driven weight loss is documented across the Phase 3 program. On semaglutide, the lean-mass-loss fraction is approximately 28–32% of total weight loss. On tirzepatide, it’s modestly more favorable at approximately 20–25%. That’s pooled DEXA data across the STEP and SURMOUNT programs. The lean-mass that you lose during this process is the body-composition cost of the catabolic pressure your GLP-1 is creating.

The adjunct compounds — CJC-1295 without DAC and Ipamorelin for the growth-hormone axis, and MOTS-c for the mitochondrial AMPK pathway — have strong mechanism rationales for preserving lean mass during this kind of weight loss. The growth-hormone-axis biology is well-characterized in about five decades of endocrinology literature. CJC-1295 without DAC is a modified version of growth hormone–releasing hormone, slightly modified to extend its half-life from about 7 minutes to about 30 minutes — the short half-life is important because it preserves the natural pulsatile pattern of GH release rather than producing sustained elevation. Ipamorelin is a selective ghrelin-receptor agonist — the first selective growth hormone secretagogue, meaning it stimulates GH release without elevating cortisol or prolactin the way earlier compounds in its class did. When you combine the two, they engage two different receptor pathways on the same pituitary cell, and the combined GH pulse is about 7 to 10 times bigger than either compound alone — that’s documented in human pharmacokinetic and pharmacodynamic studies from the mid-2000s.

MOTS-c is a 16-amino-acid peptide that your mitochondria actually produce — it’s encoded in the mitochondrial 12S ribosomal RNA gene. It was discovered at USC in 2015 and published in Cell Metabolism. The mechanism is AMPK activation — the same metabolic switch that metformin activates, but through a different molecular trigger. The 2021 Nature Communications paper showed that exercise increases MOTS-c in human skeletal muscle, and that giving older mice exogenous MOTS-c late in life reversed age-related physical decline. There’s a 2021 paper showing MOTS-c reduces myostatin expression — myostatin is the dominant negative regulator of muscle mass, so suppressing it is mechanistically anabolic.

Practitioner-observation data from clinics doing multi-peptide weight management suggests that on the integrated regimen — your GLP-1 plus this adjunct stack plus resistance training and adequate protein — the lean-mass-loss fraction can be reduced from the trial-program-pooled 25–32% toward something more like 15–20%. That’s the practitioner-observation expectation; it’s not a Phase 3 RCT figure.

What we don’t have is a Phase 3 randomized controlled trial that specifically tests the combined regimen — CJC-Ipamorelin and MOTS-c as an adjunct to your GLP-1 for lean-mass preservation — at the primary endpoint level. That trial hasn’t been done. The adjunct compounds are not FDA-approved for marketing claims for any drug indication; they’re available through 503A compounding pharmacies as research-state compounds, with regulatory variation across jurisdictions following the post-2023 FDA Category 2 listing.

So the decision is not ‘is there a Phase 3 trial that says the combined regimen works’ — there isn’t one. The decision is ‘is the mechanism rationale plus the preclinical evidence plus the practitioner-observation pathway plus the per-component Phase 1 / Phase 2 evidence sufficient for you, in your specific clinical situation, to layer these adjuncts on top of the foundation we’re already doing — your GLP-1, your resistance training, your protein intake, your monitoring.’

I can tell you what we know, what we don’t know, what the monitoring looks like — IGF-1 in the upper-quartile-of-reference range; glucose-tolerance trajectory; body-composition follow-up at 12-week and 24-week DEXA timepoints; cancer surveillance baseline including PSA in men over 40 and mammography in women over 40. I can tell you what the safety considerations are — the IGF-1 elevation has a cancer-surveillance literature with two sides; the consensus practice is monitor and keep IGF-1 in the physiologic range. I can tell you what the costs are and what the regulatory status is in our jurisdiction. The decision is yours to make with the information; my job is to give you the information honestly and to support whichever way you decide.“

Why this passes Pattern Z Anchor 5:

• Acknowledges the patient’s question without dismissing.
• Presents the per-component mechanism rationale + per-component preclinical evidence + practitioner-observation pathway as real (not dismissed).
• Frames the per-component regulatory status accurately (backbone FDA-approved-for-marketing-claims for labeled indications; adjunct research-state).
• Frames the absence of Phase 3 RCT for the combined regimen explicitly (research-state-incomplete framing at the combined-regimen level).
• Names the specific compounds at research-state precision (CJC-1295 modification; Ipamorelin selectivity; MOTS-c discovery and Nat Commun + Cell Metab anchors; myostatin mechanism).
• Does NOT use “highly experimental” / “fringe” / “unproven” / “speculative” / “untested” bias vocabulary (Pattern Z.research-precision).
• Does NOT push toward “no” or toward “yes.”
• Closes with shared-decision-making invitation.

Anchor 5 secondary counseling beat — IGF-1 cancer-risk for the integrated regimen:

“The cancer-surveillance literature on the adjunct stack’s IGF-1 elevation is the load-bearing safety consideration for adding the adjuncts to your backbone. There’s a Lancet meta-analysis from 2004 — Renehan and colleagues — showing that elevated IGF-1, the growth factor downstream of growth hormone, is associated with higher rates of prostate cancer and premenopausal breast cancer in observational data. That’s the association signal — observational, not causal.

On the other side, there’s a 2022 cohort of about 15,800 adults treated with growth hormone — Child and colleagues — where the cancer incidence was comparable to the general population. The clinical interpretation: in the GH-replacement context, the IGF-1 elevation profile did not associate with elevated cancer incidence at the population level. And there’s a 2022 expert-consensus statement on GH replacement in cancer survivors — Boguszewski and colleagues — that says ‘no association with cancer recurrence’ in the post-cancer-treatment setting, while still recommending oncologist clearance and IGF-1 monitoring.

Your backbone side is reassuring on cancer-context — the 2026 cancer SR including 48 RCTs with 94,000+ patients across the GLP-1 RA class characterizes the class as having ‘little or no effect on risk for obesity-related cancers’ overall. Your GLP-1 medication itself is not adding to cancer-risk.

Practically, what we do on the integrated regimen: we monitor IGF-1, target the upper-quartile of the reference range — Z-score zero to plus one for your age and sex — and avoid pushing into supraphysiologic elevation. If IGF-1 trends above your age-specific reference range, we dose-reduce the GH-axis adjuncts. We don’t use the integrated regimen in active malignancy; we use it cautiously in cancer survivors with oncologist clearance. For prostate health in men over 40, we add PSA monitoring. For breast-cancer-history patients, we have a separate conversation with your oncologist before considering this.

The honest framing: the IGF-1-cancer-risk association in observational data is real; the GH-replacement cohort data is reassuring; the consensus practice is monitor and to keep IGF-1 in the physiologic range. The decision in your specific case depends on your personal cancer-risk profile, your IGF-1 monitoring trajectory, and our shared judgment about whether the lean-mass-preservation benefit is worth the monitoring discipline.“

Anchor 5 secondary counseling beat — pre-FDA-approval backbone (retatrutide) plus research-state adjunct:

“You’re considering the integrated regimen with retatrutide as your backbone. That’s a double off-label combination — the backbone is pre-FDA-approval-for-marketing-claims, and the adjunct stack is research-state. The TRIUMPH Phase 3 program for retatrutide is reading out: TRIUMPH-4 sponsor topline December 2025 reported 28.7% body-weight reduction at the 12 mg dose at 68 weeks vs placebo; the peer-reviewed primary publication and the FDA submission are pending as of today. The anticipated approval pathway is multi-indication — obesity, T2D, MASH, knee OA, cardiovascular outcomes — but the specific FDA-approved indications and labels emerge at FDA approval.

On top of that, the adjunct stack is research-state. So we have two layers of regulatory framing here, and I want to be precise about each:

Layer 1 — retatrutide as your backbone. Access is via active TRIUMPH trial enrollment (where the trial protocol governs the use), or via clinician-judgment off-label investigational-supply use where a research-protocol acquisition pathway exists. Some practices accept that combination; others prefer to keep investigational-supply primary agents un-stacked until post-approval to preserve trial-protocol data integrity. If you’re enrolled in SYNERGY-Outcomes or another TRIUMPH trial, confirm with the trial site whether concurrent adjunct stack use is permitted under the trial protocol.

Layer 2 — the adjunct stack overlay. The same Pattern Z Anchor 5 conversation applies as on a Wegovy or Zepbound backbone — research-state compounds, 503A compounded pharmacy access, no Phase 3 RCT for the combined regimen.

The clinical decision sits at the intersection. The mechanism rationale is the same; the regulatory framing is more constrained because of the pre-FDA-approval backbone. The decision is yours.“

Anchor 5 secondary counseling beat — “exercise in a pill” framing question:

Per adjunct-stack canonical §10.6 — MOTS-c is exercise-mimetic biology in mice; it does not substitute for resistance training in humans. The integrated regimen uses MOTS-c as a layer on top of resistance training, not instead of it; the Tier 1 foundation continues throughout.

10.7 Tier 1 foundation conversation — load-bearing patient education

This is the load-bearing patient education for the integrated regimen — the foundation is not optional supplementation but the substrate-enabling intervention without which the integrated regimen has minimal effect on the lean-mass endpoint.

Patient-counseling beat (per adjunct-stack canonical §10.5):

“Your GLP-1 RA is doing the appetite-suppression and metabolic-improvement work — that’s the largest piece of your weight-loss program. Protein and resistance training are doing the muscle-preservation work — that’s the piece your medication can’t do on its own. Without protein and resistance training, the weight you lose will include more muscle than fat, and your metabolic rate will fall faster than it has to. The science on this is strong: protein in the 1.2 to 1.6 g/kg range, distributed across the day at 25–30 g per meal across 3 to 4 meals, plus 2 to 3 resistance-training sessions a week with progressive overload — squat, hinge, push, pull, and loaded carry variants in compound movements. Vitamin D at ≥30 ng/mL is the fall-prevention foundation. Creatine monohydrate 3–5 g/day is the most-evidence-based ergogenic supplement and pairs naturally with the resistance training. We can layer the peptide adjuncts on top of that — but the foundation is what we start with, and the foundation is what continues even when the peptide adjuncts are discontinued. The peptide adjuncts amplify the foundation’s effect; they do not substitute for it.”

Delivered at integrated-regimen initiation (§4), reinforced at each monitoring visit (§5), reframed at discontinuation (§8) — the Tier 1 foundation is the durable lean-mass-preservation intervention; the adjunct stack is the time-bounded amplifier.

10.8 Discontinuation conversation (§8 anchor)

For goal-achieved, backbone-transition-to-maintenance, AE-driven, or patient-preference discontinuation. Required counseling beats:

• Reason for discontinuation framing. Goal-achieved (celebratory — the integrated regimen served its purpose; adjunct discontinues; backbone continues at maintenance dose); backbone-transition-to-maintenance (planned adjunct discontinuation aligned with the active-weight-loss phase ending); AE-driven (clinical decision per §6 + §8); patient-preference (legitimate; protocol informs but does not override).
• Operational sequence (§8.3): adjunct cycle structure builds in natural washout; no pharmacologic adjunct taper required. Backbone gradual taper (clinician-judgment within label) typically not applied at adjunct-discontinuation-only (backbone continues); applied at full-regimen-exit (pre-conception; patient preference for full discontinuation).
• Post-discontinuation framing (§8.5): Tier 1 foundation continues as the durable intervention; lean-mass status preserved during adjunct typically maintained if backbone is at maintenance; lean-mass-loss-fraction may return toward unsupplemented expectation if active-weight-loss continues without adjunct. Post-backbone-discontinuation weight-regain trajectory ~two-thirds regain by 12 months per STEP-4 / SURMOUNT-4 trial data.
• Re-initiation pathway (§8.6): available if clinical indication re-emerges; backbone re-titration if discontinued; adjunct abbreviated re-initiation (no protracted re-titration; per-compound tolerability mild and reproducible).
• Cancer surveillance continues (§6.10.3): PSA / mammography per standard intervals; IGF-1 reverts to baseline within ~2–4 weeks post-adjunct-discontinuation; no ongoing on-protocol IGF-1 monitoring required once adjunct discontinued.

10.9 Pattern Z self-audit on §10 counseling beats

The five Anchors above are the self-audit checklist. The integrated-regimen §10 is Pattern-Z-violation-positive if any of the following appear:

• Compounded options framed as default-suspect (Anchor 1+2 violation; opens with what it is not). → Not present in §10.3 — both backbone-side compounded framing and adjunct-side compounded framing lead with what the access pathway IS.
• Pregnancy-planning framed with asymmetric emphasis (Anchor 3 violation; steering through asymmetric emphasis between weight-regain risk and pregnancy-exposure risk; or between adjunct PK and backbone PK arithmetics). → Not present in §10.4 — both backbone-side label arithmetic and adjunct-side PD arithmetic presented; patient-anchored decision.
• Backbone comparator framing with verbatim trial effect-sizes generalized to the patient’s phenotype without trial-enrollment qualification (Anchor 4 violation; Pattern V cross-fail). → Not present in §10.5 — multi-dimensional 12-axis presentation with trial-population qualification per Pattern V.
• Off-label use dismissed (Anchor 5 violation). → Not present in §10.6 — research-state lead with practitioner-observation pathway acknowledged; per-component regulatory framing precise.
• Use of “highly experimental” / “fringe” / “speculative” / “untested” bias vocabulary applied to the adjunct stack or to the integrated regimen (Pattern Z.research-precision violation per Editorial Framework v1.2 §1.4). → Scrubbed throughout; replaced with research-state-precise descriptors.
• Use of “scary” / “daunting” / “intimidating” applied to self-injection (Pattern Z.injection-framing violation). → Scrubbed throughout; self-injection framed as routine clinical skill equivalent to existing backbone self-injection.
• Conflation of regulatory-claim-status with clinical-evidence-state (Pattern AA.marketing-claims violation). → Per-component regulatory framing precise throughout — Wegovy / Zepbound / Mounjaro / etc. FDA-approved-for-marketing-claims for specified indications; Wegovy HD FDA-approved 2026-03-19; retatrutide pre-FDA-approval-for-marketing-claims via TRIUMPH Phase 3; adjunct compounds NOT FDA-approved-for-marketing-claims for any drug indication.

The §10 production passes the five-Anchor self-audit before handoff to §11 source citations and the verification cycle.

---

11. Source citations

11.1 Purpose

Define the bibliography format, evidence-hierarchy tiers, and PMID-anchor / NCT-anchor / DOI-anchor identifier-integrity discipline for the stacked-regimen protocol. §11 is the protocol’s evidentiary spine — every mechanism claim, effect-size statement, and safety consideration traces to a §11 citation entry.

For this stacked-regimen protocol, the evidence-hierarchy structure is hybrid: Tier 1 Phase 3 RCT evidence anchors the backbone-side weight-loss / glycemic / CV / kidney / MASH / OSA effect-sizes (the per-component backbone canonicals carry the full Phase 3 RCT inventories at [[Semaglutide Protocol]] §11 / [[Tirzepatide Protocol]] §11 / [[Retatrutide Protocol]] §11); Tier 1/2 mechanism + Phase 1/2 PK/PD anchors the adjunct-side per-compound mechanism (per [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] §11.2); Tier 3 clinical-context anchor for the lean-mass-loss-fraction baseline expectation (Look 2025 pooled DEXA across STEP and SURMOUNT; Beavers 2025 meta-analysis; Mozaffarian 2025 multi-society advisory); and Tier 5 practitioner-consensus / multi-peptide-practice observation for the combined-regimen effect-size at the lean-mass-preservation primary endpoint (research-state-incomplete at Phase 3 RCT level). Pattern AB.1 + AB.4 identifier-integrity discipline applies to every PMID + NCT.

11.2 Backbone-side Phase 3 RCT and head-to-head citations

The integrated regimen relies on backbone-protocol §11 bibliography entries; the integrated-regimen §11 carries the load-bearing subset relevant to the combined-regimen framing.

Semaglutide-backbone Phase 3 RCT anchors:

• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989-1002. PMID 33567185. NCT03548935. STEP-1; CWM-indication anchor; non-diabetic obesity; ~14.9% weight reduction at 68 weeks vs ~2.4% placebo (treatment-policy estimand). Cited in §1.3 + §1.7 + §4.2 + §9.8 + §11.
• Wharton S, et al. Semaglutide 7.2 mg in adults with overweight or obesity (STEP UP): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Diabetes Endocrinol 2025. PMID 40961952. STEP UP; Wegovy HD 7.2 mg ~−18.7% weight reduction at 72 weeks; FDA approval 2026-03-19 for CWM. Cited in §1.3 + §4.2 + §9.8 + §11.
• Pratley R, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN-7). Lancet Diabetes Endocrinol 2018;6:275-286. PMID 29397376. NCT02648204. SUSTAIN-7; HbA1c reduction ~1.8 pp at 1.0 mg. Cited in §4.2 + §11.
• Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834-1844. PMID 27633186. NCT01720446. SUSTAIN-6; CV-risk-in-T2D anchor; 3-point MACE HR ~0.74. Cited in §4.2 + §11.
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-2232. PMID 37952131. NCT03574597. SELECT; CV-risk-in-non-diabetic-obesity anchor; 3-point MACE HR ~0.80. Cited in §1.3 + §4.2 + §11.
• Sanyal AJ, Newsome PN, et al. Phase 3 trial of semaglutide in MASH. N Engl J Med 2025;392:2089-2099. PMID 40305708. NCT04822181. ESSENCE; MASH F2/F3 anchor; both co-primary endpoints met — 62.9% MASH resolution / 36.8% fibrosis improvement at 72 weeks. FDA approval 2025-08-15. Cited in §3.4 + §4.2 + §11.
• Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121. PMID 38785209. NCT03819153. FLOW; CKD-in-T2D anchor; kidney composite + CV death HR ~0.76. Cited in §3.5 + §4.2 + §11.
• Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA 2021;325:1414-1425. PMID 33755728. NCT03548987. STEP-4; post-discontinuation weight-regain trajectory ~two-thirds regain by 12 months. Cited in §1.5 + §8.5 + §11.
• Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes Obes Metab 2022;24:1553-1564. PMID 35441470. STEP-1 extension; substantial weight regain post-discontinuation. Cited in §1.5 + §8.5 + §11.
• Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 2023;389:1069-1084. PMID 37622681. NCT04788511. STEP-HFpEF; KCCQ-CSS between-group treatment difference +7.8 points (per-arm +16.6 vs +8.7 — Pattern V.metric-axis disclosed); investigational extension. Cited in §4.2 + §11.

Tirzepatide-backbone Phase 3 RCT anchors:

• Jastreboff AM, Aronne LJ, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216. PMID 35658024. NCT04184622. SURMOUNT-1; tirzepatide 15 mg ~−20.9% TR / ~−22.5% efficacy estimand at 72 weeks (Pattern V.estimand-axis disclosed). Cited in §1.3 + §4.2 + §11.
• Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503-515. PMID 34170647. NCT03987919. SURPASS-2; tirz 15 mg HbA1c reduction ~−2.30 pp vs sema 1 mg ~−1.86 pp at 40 weeks. Cited in §4.2 + §11.
• Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for Weight Reduction in Adults with Overweight or Obesity. N Engl J Med 2025;392(20):1893-1904. PMID 40353578. NCT05822830. SURMOUNT-5; head-to-head tirzepatide −20.2% vs semaglutide −13.7% at week 72 max-tolerated-dose. Cited in §1.3 + §4.2 + §11.
• Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193-1205. PMID 38912654. NCT05412004. SURMOUNT-OSA; AHI reduction ~−25.3 / −29.3 events/hour. FDA approval 2024-12 for OSA + obesity. Cited in §4.2 + §11.
• Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 2025;392:427-437. PMID 39555826. NCT04847557. SUMMIT; HR 0.62; investigational extension HFpEF + obesity. Cited in §4.2 + §11.
• Loomba R, Sanyal AJ, et al. Tirzepatide in Adults with MASH and Moderate or Severe Fibrosis. N Engl J Med 2024;391:299-310. PMID 38856224. NCT04166773. SYNERGY-NASH Phase 2; MASH resolution 44% / 56% / 62% at 5 / 10 / 15 mg vs 10% placebo. Cited in §3.4 + §4.2 + §11.
• Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA 2024;331:38-48. PMID 38078870. NCT04660643. SURMOUNT-4; +14% regain on placebo-switch through Week 88. Cited in §1.5 + §8.5 + §11.

Retatrutide-backbone evidence anchors:

• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med 2023;389:514-526. PMID 37366315. NCT04881760. Phase 2 obesity; up to ~−24.2% body weight at 12 mg / 48 weeks (treatment-policy estimand). Cited in §1.3 + §4.2 + §11.
• Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet 2023;402:529-544. PMID 37385280. NCT04867785. Phase 2 T2D; HbA1c reductions across dose-response framework vs placebo and dulaglutide 1.5 mg. Cited in §4.2 + §11.
• Sanyal AJ, et al. Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial. Nat Med 2024;30:2037-2048. PMID 38858523. NCT04881760 substudy. Phase 2a MASLD substudy; ~−82% MRI-PDFF reduction at 12 mg / 48 weeks; 86% achieving normal liver fat. Cited in §1.3 + §3.4 + §4.2 + §11.
• Giblin H, et al. Design and Rationale of the TRIUMPH Trial Program of Retatrutide. Diabetes Obes Metab 2026. PMID 41090431. Design paper, not primary results; TRIUMPH Phase 3 program design framework; titration / surveillance / endpoint inventory. Cited in §3.7 + §4.2 + §11.

Class-level signal anchors:

• Wen J, Nadora D, et al. Pancreatitis and pancreatic cancer risk in GLP-1 receptor agonists: a systematic review and meta-analysis. Endocrinol Diabetes Metab 2025. PMID 40988099. 62 RCTs n=66,232 including tirzepatide; pooled RR 1.44 for acute pancreatitis. Cited in §2.3 + §6.4 + §11.
• Ko HHT, et al. Glucagon-like Peptide-1 Receptor Agonists and Cancer Risk: A Systematic Review and Network Meta-analysis. Ann Intern Med 2026. PMID 41359966. 48 RCTs n=94,245 including tirzepatide; “GLP-1 RAs may have little or no effect on risk for obesity-related cancers” overall. Cited in §2.3 + §6.10.3 + §11.
• Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol 2024;142:732-739. PMID 38958939. NAION-signal anchor for semaglutide; post-marketing pharmacovigilance retrospective cohort. Cited in §3.7 + §4.2 + §6.5 + §11.
• Lawrenson JG, et al. Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Across GLP-1 Receptor Agonists. Am J Ophthalmol 2025. PMID 40383360. NAION class-differentiation; signal absent for tirzepatide at same analytic threshold. Cited in §3.7 + §4.2 + §6.5 + §11.
• Buckley AJ, et al. Tirzepatide and the risk of new-onset proliferative diabetic retinopathy: a retrospective cohort study. Diabetologia 2025. PMID 40637847. Tirzepatide retinopathy baseline-status-stratified RWE; OR 2.15 overall multivariate; OR 0.73 protective in no-baseline-DR subgroup. Cited in §2.3 + §3.7 + §6.5 + §11.
• Parker VER, et al. Pregnancy outcomes in women with overweight or obesity exposed to GLP-1 receptor agonists: pooled analysis of clinical trial data. J Clin Endocrinol Metab 2025. PMID 40329607. Pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA regulatory trials. Cited in §10.4 + §11.

11.3 Adjunct-stack per-compound mechanism + PK/PD citations

Per [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] §11.2 — the integrated-regimen §11 carries the load-bearing subset.

CJC-1295 (without DAC; Mod-GRF 1-29):

• Jette L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005;146:3052-3058. PMID 15817669. DAC technology identification; foundational discovery paper for CJC-1295 series. Cited in §1.3 + §11.
• Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab 2006;91:799-805. PMID 16352683. Human Phase 1/2 PK/PD anchor; 2–10x GH increases and 1.5–3x IGF-1 increases over 6–11 days at acute-trial doses. Cited in §1.3 + §6.10.1 + §11.
• Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab 2006;91:4792-4797. PMID 17018654. Pulsatile GH persistence during chronic CJC-1295 stimulation; supports pulse-preserving mechanism rationale for without-DAC form. Cited in §1.3 + §6.10.1 + §11.

Ipamorelin:

• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139:552-561. PMID 9849822. Foundational paper; Ipamorelin selectivity without cortisol/prolactin/ACTH elevation. Cited in §1.3 + §3.9 + §11.
• Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus. Int J Colorectal Dis 2014;29:1527-1534. PMID 25331030. Phase 2 RCT for postoperative ileus; informs human safety profile context. Cited in §11.

MOTS-c:

• Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015;21:443-454. PMID 25738459. Foundational discovery paper; MOTS-c mechanism (AMPK activation via folate-cycle inhibition). Cited in §1.3 + §11.
• Kim KH, et al. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab 2018;28:516-524. PMID 29983246. AMPK-dependent nuclear translocation; mitochondria-to-nucleus retrograde signaling. Cited in §1.3 + §11.
• Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021;12:470. PMID 33473109. Exercise mimesis evidence; mouse + human observational; late-life MOTS-c reversal of age-dependent physical decline in mice. Cited in §1.3 + §11.
• Kong BS, Min SH, et al. Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. Cell Rep 2021;36:109447. PMID 33554779. MOTS-c myostatin pathway via CK2-PTEN-mTORC2-AKT-FOXO1; load-bearing for lean-mass mechanism. Cited in §1.3 + §11.

11.4 Clinical-context anchors — lean-mass-loss-fraction baseline expectation

• Look M, Dunn JP, Kushner RF, et al. Body composition changes with semaglutide and tirzepatide in adults with overweight or obesity: pooled analysis of phase 3 trial data. Obesity (Silver Spring) 2025;33(4):712-724. PMID 39996356. Pooled DEXA substudies across STEP and SURMOUNT Phase 3 programs; semaglutide ~28–32% lean-mass-loss fraction; tirzepatide ~20–25% lean-mass-loss fraction. Load-bearing for the §1.2 + §1.3 + §7 expected lean-mass-loss-fraction range. Cited in §1.2 + §1.3 + §1.7 + §7 + §11.
• Beavers DP, Beavers KM, Loeser RF, et al. The independent and combined effects of GLP-1 receptor agonist and resistance training on muscle and bone health in adults with obesity: meta-analysis of randomized trials. Obesity (Silver Spring) 2025;33(2):225-237. PMCID PMC11774015. Meta-analysis 9 placebo-controlled GLP-1 RA RCTs with 7 DEXA outcomes (n=659); absolute lean-mass loss greater with GLP-1 vs placebo; small DEXA BMD reductions documented. Cited in §1.2 + §3.8 + §11.
• Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab 2024;26(Suppl 4):16-27. PMID 38937282. LBM mitigation review covering Phase 3 GLP-1 RA program data and resistance-training-plus-protein foundation rationale. Cited in §1.2 + §11.
• Mozaffarian D, Aronne LJ, Castro MR, et al. Roundtable on glucagon-like peptide-1 receptor agonists and weight management: addressing muscle and bone loss. Obesity (Silver Spring) 2025;33(8):1475-1503. PMID 40445127. 2025 multi-society advisory (ACLM, ASN, OMA, TOS) on lean-mass and bone-loss management during GLP-1 RA therapy; protein 1.2–1.6 g/kg/day; structured resistance training; nutrition referral. Cited in §1.2 + §3.8 + §11.

11.5 IGF-1 cancer-surveillance 3-pillar framework citations

• Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-1353. PMID 15110491. Foundational meta-analysis; elevated IGF-1 with prostate cancer OR 1.49 and premenopausal breast cancer OR 1.65 in observational data. Cited in §2.3 + §6.10.3 + §10.6 + §11.
• Child CJ, Conroy D, Zimmermann AG, Woodmansee WW, Erfurth EM, Robison LL. Long-term safety of growth hormone replacement in adults: 15,809 patients enrolled in the HypoCCS observational study. J Clin Endocrinol Metab 2022;107:e1374-e1383. PMID 35368070. Large GH-replacement cohort; cancer incidence comparable to general population (SIR 0.92); counter-signal to Renehan 2004. Cited in §2.3 + §6.10.3 + §10.6 + §11.
• Boguszewski CL, Boguszewski MCDS, Higham CE, et al. Growth hormone replacement therapy in cancer survivors: 2022 consensus statement. Pituitary 2022;25:198-216. PMID 35319491. 2022 expert-consensus statement; “no association with cancer recurrence” with oncologist clearance and IGF-1 monitoring recommended. Cited in §2.3 + §6.10.3 + §10.6 + §11.

11.6 Sarcopenia operational definition + class-adjacent anchors

• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16-31. PMID 30312372. EWGSOP2 contemporary sarcopenia operational definition; grip strength and 5-STS cutoffs. Cited in §1.2 + §3.8 + §11.
• Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 trials. J Clin Endocrinol Metab 2010;95:4291-4304. PMID 20554713. Tesamorelin Phase 3 pooled analysis; FDA-approved-for-marketing-claims 2010 as Egrifta for HIV-lipodystrophy. Cited in §7.4 + §9.6 + §11.
• Bjerre Knudsen L, Madsen LW, et al. GLP-1R agonists and rodent C-cell tumorigenicity. Endocrinology 2010;151:1473-1486. PMID 20203154. Foundational rodent C-cell mechanism finding for the class-wide FDA boxed warning. Cited in §2.4 + §11.

11.7 Bibliography format and identifier-integrity discipline (Pattern AB.1 / AB.4)

Each citation entry above contains: first author last name + et al. (or full list for ≤3 authors); paper title (exact); journal (full or standard abbreviation); year; volume; pages; PMID; effect-size or load-bearing-fact summary; citation context (sections that cite this source).

Pattern AB.1 (identifier verification at draft step): every PMID above has been verified by content against the constituent backbone-protocol §11 bibliographies and the adjunct-stack canonical §11.2 — the integrated-regimen §11 carries the load-bearing subset, and the per-protocol §11 PSV verification cascades to this protocol’s §11.

Pattern AB.4 (cascade scan): when any identifier in this Bibliography is corrected at the constituent backbone-protocol level (e.g., a Tirzepatide Protocol §11 PMID correction) or at the adjunct-stack-canonical level, every occurrence of that identifier in this protocol document is updated in the same commit per the standing-scan discipline.

Note on identifier-integrity self-flagging. This protocol cites PMIDs sourced from the constituent backbone protocols (Semaglutide / Tirzepatide / Retatrutide) and the adjunct-stack canonical, all of which have undergone PSV iteration 1 verification per their respective §11 / Appendix A frameworks. The integrated-regimen §11 inherits those verifications. The PSV iteration 1 for this protocol verifies (a) that the cited PMIDs in this §11 match the source canonical bibliographies; (b) that the effect-size attributions in this protocol match the source canonical effect-size statements; (c) Pattern AB.4 cascade scan across the integrated-regimen document for identifier-cascade alignment with source canonicals.

11.8 Evidence hierarchy tiers (stacked-regimen-adapted)

The Module 5 evidence hierarchy is adapted for this integrated-regimen protocol:

• Tier 1 — Phase 3 RCT pivotal trials anchoring backbone-side effect-sizes. STEP-1 (sema-CWM); STEP UP (sema HD); SUSTAIN-6 (sema CV); SELECT (sema CV non-T2D); ESSENCE (sema MASH); FLOW (sema CKD); SURMOUNT-1 (tirz CWM); SURMOUNT-5 (tirz vs sema head-to-head); SURPASS-2 (tirz vs sema T2D head-to-head); SURMOUNT-OSA (tirz OSA); SUMMIT (tirz HFpEF); SYNERGY-NASH (tirz MASH Phase 2 with Phase 3 in development).
• Tier 1.5 — head-to-head Phase 3 within-class RCT. SURMOUNT-5; SURPASS-2; TRIUMPH-5 ACTIVE_NOT_RECRUITING (reta vs tirz head-to-head; primary completion 2026-12).
• Tier 2 — Phase 2 RCT for backbone (retatrutide pre-FDA-approval) + Phase 1/2 human PK/PD primary source for adjunct. Jastreboff 2023 (reta Phase 2 obesity); Rosenstock 2023 (reta Phase 2 T2D); Sanyal 2024 (reta Phase 2a MASLD); Teichman 2006 (CJC-1295 human PK); Ionescu & Frohman 2006 (CJC pulsatile GH); Raun 1998 (Ipamorelin selectivity); Lee 2015 (MOTS-c discovery); Kim 2018 (MOTS-c nuclear translocation); Reynolds 2021 (MOTS-c exercise mimesis).
• Tier 3 — clinical-context anchor. Look 2025 (GLP-1 RA pooled DEXA lean-mass-loss-fraction baseline); Beavers 2025 (meta-analysis); Mozaffarian 2025 (multi-society advisory); Renehan 2004 (IGF-1 cancer observational); Child 2022 (GH-replacement cohort); Boguszewski 2022 (consensus statement); Ko 2026 (backbone-side cancer SR); Hathaway 2024 (NAION sema); Lawrenson 2025 (NAION class-differentiation); Buckley 2025 (tirz DR RWE).
• Tier 5 — practitioner-consensus / multi-peptide-practice observation. Combined-regimen lean-mass-preservation effect-size expectation (~15–20% lean-mass-loss fraction with integrated regimen + Tier 1 foundation vs ~25–32% Phase 3-pooled-DEXA baseline) — practitioner observation, not RCT-anchored. §10.6 Anchor 5 counseling beat frames at this resolution.

For this protocol specifically, the structural feature is that Tier 1 carries the backbone-side weight-loss effect-sizes, Tier 2 carries the per-compound adjunct mechanism + PK/PD, Tier 3 carries the lean-mass-loss-fraction baseline expectation, and Tier 5 carries the combined-regimen lean-mass-preservation effect-size — the integrated-regimen has no Tier 1 Phase 3 RCT for the combined regimen at the lean-mass-preservation primary endpoint. Pattern Z.research-precision names this resolution honestly throughout §10 counseling beats.

---

12. Clinical decision tree — phenotype-guided integration

12.1 Purpose

Define a phenotype-guided decision tree that integrates §1–§11 into a single navigable clinical-workflow reference. §12 is the operational summary that a clinician reaches for at point-of-care to navigate the integrated-regimen decisions: should this patient be considered for the integrated regimen, what backbone selection, what phenotype branch sequencing, what is the dosing, what is the monitoring cadence, what are the off-ramps.

The decision tree is not authority — it summarizes the authoritative content in §1–§11; if the decision tree and a §1–§11 sub-block disagree, the §1–§11 content is canonical.

12.2 High-level decision flowchart

                PATIENT PRESENTS — Module 5 weight-management context
                                |
                                v
                  [§1.2 + §2.2 Inclusion #1]
                  Established or initiating on GLP-1 RA backbone?
                                |
                       NO --> [Backbone protocol §4 backbone-naive titration
                             OR transition out of Module 5 weight-management]
                                |
                       YES (backbone-established at target dose ≥3 mo)
                                |
                                v
                  [§4.2 Backbone selection / verification — Pattern Z Anchor 4]
                  Sema (Wegovy 2.4 / Wegovy HD 7.2) / Tirz (Zepbound 5-15) /
                  Reta (12 mg via TRIUMPH or research-protocol) — 12-axis
                  multi-dimensional comparator framework
                                |
                                v
                  [§1.5 Phenotype branch identification]
                  Branch A (sarcopenic baseline / older adult — anticipatory)
                  Branch B (athletic / high-baseline-lean-mass — anticipatory)
                  Branch C (post-50lb / DEXA-triggered / mid-trajectory — reactive)
                                |
                                v
                  [§2.2 Adjunct stack inclusion check]
                  - Tier 1 foundation adherent (protein 1.2-1.6 g/kg; RT 2-3x/wk;
                    vitamin D ≥30)
                  - Lean-mass-concern trigger present per §1.2
                  - Adult ≥18
                  - Not WADA-tested competitive athlete
                  --> NO  --> Reinforce Tier 1 foundation; defer adjunct
                                |
                                v
                  [§2.3 Relative exclusion check]
                  - T2D with advanced DR; pre-T2D; cancer survivor >5y;
                    severe renal/hepatic; OSA untreated; pituitary hx;
                    psychiatric adherence; pre-conception 1-2 mo
                  --> Clinician-judgment posture; proceed with enhanced
                      surveillance OR defer
                                |
                                v
                  [§2.4 Hard contraindication check]
                  - MTC / MEN-2; severe pancreatitis hx; severe hypersensitivity;
                    pregnancy / lactation; active or <5y cancer treatment;
                    acromegaly; active pituitary tumor; active proliferative DR;
                    somatostatin analog; pediatric; WADA-tested athlete
                  --> YES --> Out of integrated regimen
                                |
                                v (No contraindication)
                  [§3 Pre-treatment workup — integrated regimen]
                  - Standard metabolic + diabetes + MASH + kidney + CV-risk +
                    organ-baseline + body-composition baseline + stacked-regimen-
                    specific (IGF-1 + Z-score; PSA/mammography; TSH/cortisol/
                    prolactin; STOP-BANG)
                                |
                                v
                  [§10 Informed consent — Anchor 5 off-label DOMINANT +
                  Anchor 1+2 compounded (backbone + adjunct) + Anchor 3
                  pregnancy + Anchor 4 backbone comparator + Tier 1 foundation]
                                |
                                v (Consent obtained)
                  [§4 Initiation — Phase A backbone + Phase B adjunct]
                  Backbone target-dose verification OR backbone-naive titration
                  per backbone protocol §4. Adjunct stack at protocol doses:
                  CJC-1295 100 mcg + Ipamorelin 200 mcg bedtime fasted-state
                  5-on/2-off; MOTS-c 10 mg AM 3x/wk; 12-16 week cycle.
                  Week 1 / 2-4 / 8 / 12 contact cadence.
                                |
                                v
                  [§5 Maintenance — open-ended backbone + cyclical adjunct]
                  Backbone target dose held; quarterly Y1, biannual thereafter.
                  Adjunct cycle 12-16 weeks on; 4-8 weeks off; 2-3 cycles per
                  active-weight-loss arc; ~6-12 mo maximum total adjunct.
                  IGF-1 at Week 8-12 of each stack cycle (target Z 0 to +1).
                  DEXA + functional measures at Week 12 + Week 24 of each cycle.
                  PSA / mammography annual.
                                |
                                v
                  [§6 / §7 / §8 Branch points]
                  - Backbone-side AE? --> §6 backbone AE-class algorithm
                  - Adjunct-side AE? --> §6 adjunct AE-class algorithm
                  - IGF-1 above range? --> §6.10.1 dose-reduce CJC-1295
                  - Glucose worsening? --> §6.7 dose-reduce or hold GH-axis
                  - Backbone-side plateau/non-response? --> §7 backbone branches
                  - Adjunct-side plateau/non-response? --> §7 adjunct branches
                  - Goal achieved? --> §8 sequenced discontinuation
                                |
                                v
                  [§9 Combination context]
                  - Adjunct ON established backbone (not before / instead)
                  - Cross-Module additions (tesamorelin / AOD-9604 / GHK-Cu /
                    BPC-157 / SGLT2 / insulin / CagriSema) per indication
                  - Contraindicated combinations (somatostatin / dual-CJC-form /
                    concurrent backbone-class redundancy / pregnancy)
                                |
                                v
                  [§8 Discontinuation]
                  - Goal achieved --> adjunct cycle washout; backbone continues
                    at maintenance
                  - Backbone transition to maintenance --> adjunct discontinue
                    at next cycle washout
                  - AE-driven (backbone-side or adjunct-side) --> per-component
                    discontinuation; counterpart continuation per indication
                  - Pre-conception --> sequenced washout (adjunct ~4 wk PD;
                    backbone ~8 wk label)
                  - Patient preference --> per-component or regimen-level
                                |
                                v
                  [§10.7 + §10.8 Post-discontinuation framing]
                  Tier 1 foundation as durable intervention; backbone weight-
                  regain trajectory ~two-thirds by 12 mo; lean-mass status
                  preserved if backbone at maintenance; re-initiation pathway
                  available

12.3 Phenotype-guided integrated-regimen decision matrix

Patient phenotype	Backbone selection (Anchor 4)	Phenotype branch (§1.5)	Adjunct stack?	Integrated-regimen-specific considerations
Post-menopausal female, CWM, BMI ≥30, baseline lean-mass concern	Sema (Wegovy 2.4 mg or HD 7.2 mg) OR tirz (Zepbound 15 mg) — patient preference within Anchor 4 framework	Branch A baseline + (potentially Branch C DEXA-triggered)	Yes — strong indication match	Highest-sarcopenic-risk subpopulation per 2025 multi-society advisory; IGF-1 monitoring + mammography baseline + ongoing
Older adult ≥65 on GLP-1 RA with sarcopenic-risk profile	Sema or tirz; reta off-label via informed consent	Branch A anticipatory at backbone target dose	Yes — favored stacked candidate	Conservative dosing; enhanced cancer surveillance; functional-measure monitoring
Athletic / high-baseline-lean-mass adult on GLP-1 RA targeting >15% loss; non-WADA-tested	Tirz (higher weight-loss magnitude per SURMOUNT-1; SURMOUNT-5 head-to-head) OR reta (Phase 2 / TRIUMPH-4 sponsor topline)	Branch B anticipatory at backbone target dose	Yes — lean-mass preservation primary concern	High absolute lean-mass at risk; WADA-tested competitive athletes ineligible for adjunct
Documented elevated lean-mass-loss fraction (>30% sema-backbone; >25% tirz-backbone) at 12-wk DEXA	Existing backbone continues	Branch C reactive at DEXA-triggered timepoint	Yes — DEXA signal documents indication	Standard protocol; reassess Cycle 1 end
Polycondition phenotype (T2D + ASCVD + CKD ± MASH)	Sema-backbone strongly preferred (FDA-approved-for-marketing-claims indication portfolio across T2D / CV / MASH / CKD); tirz alternative with co-indications	Branch determined by lean-mass risk profile + age	Yes with enhanced glucose surveillance	T2D-specific monitoring (HbA1c at Week 8 of cycle); CKD-specific monitoring (eGFR + UACR)
OSA + obesity phenotype	Tirz (Zepbound 2024-12 SURMOUNT-OSA indication)	Branch determined by lean-mass risk profile	Yes with adjunct-side sleep-apnea exacerbation surveillance	Sleep-medicine co-management; CPAP-adherent OSA patients eligible
MASH F2/F3 phenotype	Sema-backbone (Wegovy ESSENCE FDA-approved 2025-08); tirz Phase 2 SYNERGY-NASH supportive; reta Phase 2a MASLD substudy + SYNERGY-Outcomes pending	Branch determined by lean-mass risk profile	Yes with hepatology co-management	MASH-indication weight-loss + adjunct lean-mass overlay; transaminase surveillance
Pre-FDA-approval willingness / trial enrollment	Reta (TRIUMPH program enrollment or research-protocol off-label)	Branch determined by lean-mass risk profile	Yes — double off-label / off-pathway combination; §10.6 stacked counseling	Trial protocol may govern adjunct use; site confirmation required
Patient interest in adjunct without lean-mass-concern trigger or Tier 1 adherence	N/A	N/A	No — inclusion criteria not met	Reinforce Tier 1 foundation; reassess at established adherence and emergent trigger
T2D with HbA1c >7.0 and lean-mass concern	Sema or tirz with T2D-indication formulation (Ozempic or Mounjaro); reta T2D via TRANSCEND-T2D	Branch determined by sarcopenic risk + DEXA	Yes with enhanced glucose surveillance	HbA1c monitoring at Week 8 + Week 16; dose-reduce GH-axis if glucose worsens
T2D with active proliferative DR	N/A	N/A	No — hard contraindication	Backbone alone with ophthalmology co-management may proceed per backbone protocol
Active malignancy or <5y treatment	N/A	N/A	No — hard contraindication	Backbone may proceed with oncology clearance; adjunct deferred until ≥5y from treatment with oncologist clearance
Cancer survivor ≥5y from treatment	Per backbone selection	Branch determined by lean-mass risk profile	Yes with oncologist clearance	IGF-1 monitoring at upper-quartile target only; oncologist co-management; family-history breast/prostate awareness
Pre-conception planning within 3-6 months	Existing backbone; plan discontinuation	N/A	Discontinue if on regimen; defer initiation if considering	Sequenced washout: adjunct ~4 wk; backbone ~8 wk label
Pre-conception planning within 1-2 months	N/A	N/A	No — backbone discontinuation already required pre-conception	Wait for post-pregnancy / post-lactation re-initiation per §8.6
GLP-1 RA at maintenance dose at target weight	Existing backbone continues at maintenance	N/A	Discontinue at next cycle washout if on regimen (indication-resolution per §8.2)	Tier 1 foundation continues
Backbone non-responder to sema	Transition sema → tirz (SURMOUNT-5 + SURPASS-2 head-to-head); transition sema → reta (TRIUMPH-4 sponsor topline higher magnitude pre-FDA-approval)	Branch reassessed post-transition	Adjunct continues across backbone transition if catabolic-pressure indication continues	Backbone transition discipline per §7 + per backbone protocol §7
WADA-tested competitive athlete	Per backbone selection; verify backbone WADA status	N/A	No — adjunct compounds WADA-prohibited	Backbone alone may proceed; adjunct deferred outside competitive context
Compounded-vs-branded preference	Patient-anchored within Anchor 1+2 framework	Branch determined by lean-mass risk profile	Per inclusion criteria	Both backbone-side compounded counseling and adjunct-side 503A compounded counseling apply

12.4 Worked decision-tree application — the §1.7 canonical patient

A 54-year-old post-menopausal female on Wegovy 2.4 mg Month 6 with ~12% weight loss, lean-mass-loss fraction ~33% on 12-week DEXA, Tier 1 adherent, no contraindications.

Step 1 — On established GLP-1 RA backbone? Yes — Wegovy 2.4 mg Month 6 ≥3 months on target dose.

Step 2 — Backbone selection / verification (Anchor 4). Wegovy selected and established; no backbone re-selection indicated at this integrated-regimen initiation timepoint. The Anchor 4 multi-dimensional comparator framework is referenced for context; the patient is already on the chosen backbone.

Step 3 — Phenotype branch identification. Dual Branch A baseline (post-menopausal sarcopenic-risk per 2025 multi-society advisory) + Branch C reactive (documented elevated lean-mass-loss fraction ~33% on 12-week DEXA). The dual-branch identification is favorable for stacked-regimen initiation.

Step 4 — Adjunct stack inclusion check. Tier 1 adherent (1.4 g/kg protein; 3 sessions/week resistance training; vitamin D >30); lean-mass-concern trigger present (post-menopausal + DEXA-elevated); adult; not WADA-tested. Inclusion met.

Step 5 — Relative exclusion check. No T2D; no DR concern (T2D-negative); not cancer survivor; no severe renal / hepatic impairment; no OSA; no prior pituitary surgery; no psychiatric adherence concern; post-menopausal (pre-conception planning not applicable). Proceed.

Step 6 — Hard contraindication check. No personal / family MTC; no MEN-2; no severe pancreatitis history; no known peptide hypersensitivity; post-menopausal (pregnancy / lactation not applicable); no active malignancy; no recent (5y) cancer treatment; no acromegaly; no active pituitary tumor; no active proliferative DR; no concurrent somatostatin analog; adult; not WADA-tested competitive athlete. Proceed.

Step 7 — Pre-treatment workup (§3.11). Workup consolidation context — most backbone-protocol §3 work already in progress; integrated-regimen workup adds §3.9 stacked-regimen-specific additions (IGF-1 + Z-score; TSH/T4 + cortisol + prolactin; mammography confirmation; baseline grip strength + 5-STS at integrated-regimen initiation visit; STOP-BANG sleep-apnea screen).

Step 8 — Informed consent (§10). Anchor 5 off-label (DOMINANT — the integrated regimen is off-label combined-regimen use) + Anchor 1+2 compounded (backbone-side per Wegovy compounded-vs-Novo Nordisk + adjunct-side per 503A compounded-pharmacy access) + Anchor 3 pregnancy (n/a post-menopausal) + Anchor 4 backbone comparator (for context — Wegovy already chosen; tirz alternative presented as future option if non-response) + §10.5 Tier 1 foundation framing. Patient elects to proceed.

Step 9 — Initiation (§4.7). Phase A backbone target-dose verification (Wegovy 2.4 mg stable Month 6); Phase B adjunct stack initiation per §4.4 with reconstitution training. Day 0 initiation visit; Week 1 / 2-4 / 8 / 12 contact cadence.

Step 10 — Maintenance (§5.6). Cycle 1 at protocol doses. Week 12 monitoring: IGF-1 198 ng/mL Z ~+0.8 (on target); glucose / HbA1c stable on improving Wegovy trajectory; DEXA shows lean-mass-loss fraction ~22% (improved from pre-stack ~33%); grip strength stable. Continue Cycle 1 through Week 16.

Step 11 — Branch points (§6 / §7 / §8). No backbone-side AE; no adjunct-side AE; no IGF-1 above range; no glucose worsening; no plateau / non-response. Continue to cycle end.

Step 12 — Combination context (§9). Adjunct stack ON established Wegovy backbone (§9.2 sequencing rule satisfied); timing within weight-loss arc is mid-trajectory Branch C (§9.3 active-weight-loss phase); duration discipline 12-16 weeks on / 4-8 weeks off (§9.4); discontinuation pathway after lean-mass-preservation goal achieved (§9.5 — anticipated at Cycle 2 or Cycle 3 end as patient approaches target weight on Wegovy).

Step 13 — Discontinuation (§8.7 Scenario A). End of Cycle 2 (Month 18 on Wegovy), patient at target weight (18 kg total loss ~19%), body-composition favorable (lean-mass-loss fraction ~18%), functional measures stable. Plan adjunct stack discontinuation at end of Cycle 2 washout; Tier 1 foundation continues; Wegovy transitions to maintenance dose per backbone-protocol §5 / §8.

Pattern Z calibration audit at §12.4. The decision-tree walkthrough presents the patient’s integrated-regimen pathway factually with per-component evidence-state precision; the lean-mass-concern phenotype is anchored to specific triggers without inflating effect-size expectations; the IGF-1 monitoring target is explicit; the backbone comparator framing (Anchor 4) is presented without steering; the off-label / extrapolation transparency (Anchor 5 — DOMINANT) is explicit; the Tier 1 foundation is presented as load-bearing throughout.

12.5 Worked decision-tree application — high-target-weight-loss athletic patient on tirz-backbone (Branch B)

A 49-year-old male, baseline BMI 36, athletic / strength-training history, on Zepbound 15 mg Month 4 on target dose, has lost 9 kg (~8% of starting weight, on-trajectory SURMOUNT-1), plans target weight loss ~25% of starting weight (well above the 15% threshold for high-target-weight-loss phenotype). DEXA at Month 3 on Zepbound: lean-mass-loss fraction ~23% (within tirz-pooled-DEXA expected range; not elevated above expectation; but absolute lean-mass-loss magnitude across the planned 25% target weight-loss range will be operationally meaningful). Tier 1 adherent; no contraindications. Not WADA-tested.

Decision walkthrough. Backbone selection: tirz-backbone established (Anchor 4 dimension-1 high-magnitude advantage at SURMOUNT-1 anchored 22.5% efficacy). Phenotype branch: Branch B (athletic / high-baseline-lean-mass; anticipatory deployment at backbone target dose). Inclusion: met. No contraindications. Workup: per §3.11 framework. Counseling: §10 with Anchor 4 backbone-comparator beat (tirz already chosen; reta alternative presented for context — TRIUMPH-4 sponsor topline 28.7% pre-FDA-approval is the higher-magnitude alternative under explicit informed consent for trial enrollment or research-protocol). Initiation: §4.7 Branch B anticipatory adjunct deployment at Month 4 on Zepbound target dose; protocol doses; Week 1 / 2-4 / 8 / 12 cadence. Maintenance: Cycle 1 → Cycle 2 → potentially Cycle 3 aligned with the planned 25% target weight-loss arc on Zepbound. Discontinuation: planned at end of Cycle 3 at target weight attainment; Zepbound transitions to maintenance dose.

12.6 Worked decision-tree application — polycondition T2D + ASCVD + CKD on sema-backbone

A 56-year-old male with T2D HbA1c 8.2, prior MI 4 years ago on statin and antiplatelet, UACR 180 mg/g, eGFR 68, BMI 33, no MTC / MEN-2, on Ozempic 1.0 mg Month 6 (FLOW-anchored T2D + CKD indication via FDA-approved-for-marketing-claims Ozempic for CKD-in-T2D 2024 approval) with HbA1c trending down to 7.4 and weight ~8% reduction. DEXA at Month 6 shows lean-mass-loss fraction ~28% (within sema-pooled-DEXA expected range); age 56 with sarcopenic-risk profile. Tier 1 adherent.

Decision walkthrough. Backbone selection: Ozempic (sema-T2D-indication formulation) is the polycondition-anchored choice given the FDA-approved-for-marketing-claims indication portfolio (T2D Ozempic + CV-risk SUSTAIN-6 + CKD-in-T2D FLOW). Anchor 4 dimensions: sema has the broadest indication portfolio for this polycondition phenotype; tirz alternative supported by SURPASS-2 head-to-head for higher HbA1c reduction but lacks the FDA-approved-for-marketing-claims CKD-in-T2D indication. Phenotype branch: Branch A (age 56 sarcopenic-risk anticipatory at backbone target dose). Inclusion: met (T2D-indication backbone + Tier 1 adherent + lean-mass concern). Relative exclusion: T2D + UACR 180 with no documented advanced DR — proceed with ophthalmology baseline dilated exam per §3.7. Hard contraindication: clear. Workup: §3.11 framework with diabetes-specific panel (§3.3) + kidney-specific panel (§3.5) + CV-risk panel (§3.6). Counseling: §10 with Anchor 4 backbone-comparator and enhanced glucose-surveillance discussion (§6.7 + §6.10.2). Initiation: §4.7 with Branch A anticipatory adjunct deployment. Maintenance: §5 with HbA1c at Week 8-12 of each cycle (enhanced surveillance for T2D-positive integrated regimen); UACR + eGFR per FLOW-anchored CKD monitoring. Combination: §9 — SGLT2 inhibitor (empagliflozin 10 mg daily) added per polycondition T2D + ASCVD + CKD standard of care; integrated regimen + SGLT2 operationally compatible. Discontinuation: long-term integrated regimen anticipated; chronic-relapsing T2D + CKD context.

12.7 §12 Pattern compliance summary

The decision tree (§12.2 flowchart + §12.3 matrix + §12.4–§12.6 worked applications) presents integrated-regimen pathways factually with:

• Pattern R compliance: every decision branch leads with what the option IS (inclusion criteria + backbone selection + phenotype branch + adjunct stack inclusion) before exclusions and contraindications.
• Pattern V compliance: effect-size anchors at trial-population resolution with metric-axis disclosed.
• Pattern W compliance: every workup panel reconciled with monitoring intervals and AE-trigger labs (Pattern W table at §3.10).
• Pattern Z compliance: Anchor 1 (lead with what option IS), Anchor 2 (compounded counseling factual), Anchor 3 (pregnancy sequenced arithmetic), Anchor 4 (backbone comparator 12-dimensional), Anchor 5 (off-label / extrapolation transparency — DOMINANT for the integrated regimen).
• Pattern AA.marketing-claims compliance: per-component regulatory framing precise (Wegovy / Wegovy HD / Zepbound / Mounjaro / Ozempic / Rybelsus FDA-approved-for-marketing-claims for specified indications; retatrutide pre-FDA-approval; adjunct compounds NOT FDA-approved-for-marketing-claims for any drug indication).
• Pattern AB.1 / AB.4 compliance: identifier-integrity discipline per §11.7.

---

Appendix A. Verification gate

A.1 Cycle overview

This stacked-regimen integration protocol passes through the standard four-step verification cycle before delivery to clinicians: Production agent → Primary-Source-Verification (PSV) agent → Independent-Adversarial-Reviewer (IAR) agent → Dr. Gross clinical-judgment gate. The cycle is the operational discipline that prevents the failure modes documented in the AC2-26 System Observations log from reaching the clinician-facing deliverable.

A.2 Step 1 — Production agent (this draft)

This draft is the production-agent output, produced against the Module 5 Protocol Template structural authority and the constituent canonical content authority ([[Semaglutide Protocol]], [[Tirzepatide Protocol]], [[Retatrutide Protocol]], [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]]). Production-agent responsibilities discharged in this draft:

• Twelve-section structure (§1–§12) populated with stacked-regimen integration content.
• Pattern R.1 / R.2 framing discipline applied at section-architecture-design step before content generation; section-ordering locked; opening-content posture of each section established with research-state lead.
• Pattern V direction-of-effect anchoring on every effect-size claim — backbone-side trial-anchored magnitudes with Pattern V.metric-axis and Pattern V.estimand-axis disclosed (SURMOUNT-1 TR vs efficacy; STEP-HFpEF per-arm vs between-group; SURMOUNT-5 head-to-head); adjunct-side per-compound mechanism + PK/PD evidence; combined-regimen lean-mass-preservation practitioner-observation framing.
• Pattern V.metric-axis applied to KCCQ-CSS, weight, and other dual-axis endpoint citations.
• Pattern W cross-section consistency: structural-count claims (three backbone options; three phenotype branches; twelve sections; eight workup panels including stacked-regimen-specific addition; ten+ AE classes integrating backbone-side and adjunct-side; five Pattern Z anchors) reconciled end-to-end. §3.10 workup-to-monitoring reconciliation table.
• Pattern Z 5-anchor compliance in §10 with Anchor 5 DOMINANT designation; Pattern Z.research-precision and Pattern Z.injection-framing applied throughout.
• Pattern AA.marketing-claims precision on every regulatory claim — FDA-approved-for-marketing-claims (sema for T2D/CWM/CV/MASH/CKD/adolescent CWM; tirz for T2D/CWM/OSA + obesity; Wegovy HD CWM 2026-03; tesamorelin for HIV-lipodystrophy 2010); pre-FDA-approval-for-marketing-claims (retatrutide via TRIUMPH program); NOT FDA-approved-for-marketing-claims for any drug indication (CJC-1295 with or without DAC; Ipamorelin; MOTS-c; BPC-157; AOD-9604; GHK-Cu).
• Pattern AB.1 identifier integrity at draft-step (production-agent self-check) on every PMID — citations sourced from constituent backbone-protocol §11 + adjunct-stack canonical §11 with verified-identifier inheritance.
• Pattern AB.4 cascade scan discipline — when any identifier is corrected at constituent level, every occurrence in this protocol updated in the same commit.

Handoff to Step 2 with explicit declaration: draft complete; ready for primary-source verification.

A.3 Step 2 — Primary-Source-Verification (PSV) agent iteration 1

PSV agent mechanical responsibilities at iteration 1:

• For every PMID in §11 Bibliography, verify the citation entry’s title, authors, journal, year, and study type / intervention / population against PubMed via E-utilities — including the load-bearing trial anchors (STEP-1 PMID 33567185; STEP UP PMID 40961952; SUSTAIN-6 PMID 27633186; SELECT PMID 37952131; ESSENCE PMID 40305708; FLOW PMID 38785209; STEP-4 PMID 33755728; SURMOUNT-1 PMID 35658024; SURPASS-2 PMID 34170647; SURMOUNT-5 PMID 40353578; SURMOUNT-OSA PMID 38912654; SUMMIT PMID 39555826; SYNERGY-NASH PMID 38856224; SURMOUNT-4 PMID 38078870; Jastreboff 2023 reta PMID 37366315; Rosenstock 2023 reta PMID 37385280; Sanyal 2024 reta PMID 38858523; Giblin 2026 design paper PMID 41090431; Jette 2005 CJC PMID 15817669; Teichman 2006 CJC PMID 16352683; Ionescu 2006 CJC PMID 17018654; Raun 1998 Ipa PMID 9849822; Lee 2015 MOTS-c PMID 25738459; Kim 2018 MOTS-c PMID 29983246; Reynolds 2021 MOTS-c PMID 33473109; Kong 2021 MOTS-c myostatin PMID 33554779; Look 2025 PMID 39996356; Mozaffarian 2025 PMID 40445127; Cruz-Jentoft 2019 EWGSOP2 PMID 30312372; Renehan 2004 PMID 15110491; Child 2022 PMID 35368070; Boguszewski 2022 PMID 35319491; Wen 2025 PMID 40988099; Ko 2026 PMID 41359966; Hathaway 2024 NAION PMID 38958939; Lawrenson 2025 NAION class-differentiation PMID 40383360; Buckley 2025 tirz DR PMID 40637847; Parker 2025 pregnancy pooled PMID 40329607; Falutz 2010 tesamorelin PMID 20554713; Bjerre Knudsen 2010 PMID 20203154; Beck 2014 Ipa Phase 2 PMID 25331030).
• For every effect-size claim, confirm match against primary source’s reported value with trial-enrollment population qualification. SURMOUNT-1 TR vs efficacy estimand axis disclosed (Pattern V.estimand-axis); STEP-HFpEF KCCQ-CSS per-arm vs between-group axis disclosed (Pattern V.metric-axis); SURMOUNT-5 head-to-head ~6.5 pp differential at week 72.
• For every regulatory claim, verify against FDA label or sponsor disclosure date (Wegovy 2021; Wegovy HD 2026-03-19; Zepbound CWM 2023; Zepbound OSA 2024-12; Ozempic 2017 + 2020 CV + 2024 CKD; Wegovy MASH 2025-08-15; Wegovy CV-non-T2D 2024; retatrutide pre-FDA-approval per TRIUMPH Phase 3 program; tesamorelin Egrifta 2010).
• Run Pattern AB.4 standing scan across the protocol document for identifier-cascade alignment with constituent canonicals (verify NCT05929066 = TRIUMPH-1 obesity Phase 3, NOT NCT05608252; verify SURMOUNT-2 PMID 37385275 vs Rosenstock reta Phase 2 T2D PMID 37385280 — different trials with consecutive PMIDs).

Handoff to Step 3 with explicit declaration: “primary-source verification complete; cascade-report attached if applicable.”

A.4 Step 3 — Independent-Adversarial-Reviewer (IAR) agent iteration 1

IAR agent six-axis scrutiny at iteration 1:

1. Framing (Pattern R / R.1 / R.2). Does every section open with research-state content before regulatory / cautionary / contraindication framing? Specifically: §1 leads with what the integrated regimen IS; §2 leads with inclusion criteria; §6 AE-class sub-blocks lead with anticipatory framing; §7 leads with diagnostic distinctions; §8 leads with discontinuation triggers as legitimate clinical pathway; §10.6 leads with per-component mechanism rationale before absence-of-Phase-3-RCT-for-combined-regimen honest framing. Pattern Z 5-anchor compliance in §10 with Anchor 5 DOMINANT?
2. Completeness. Are all twelve sections substantively populated? Are stacked-regimen-specific calibrations applied throughout — §4.2 backbone selection 12-axis multi-dimensional comparator; §4.4 three-phenotype-branch sequencing framework; §6.10 IGF-1 + glucose + cancer-surveillance 3-pillar framework; §8.4 sequenced pre-conception washout arithmetic (adjunct ~4 wk PD + backbone ~8 wk label); §9 stack-combination operational core load-bearing; §10.6 Anchor 5 DOMINANT? Pattern AB.1 inversion-risk discipline at CJC-1295 with-DAC vs without-DAC (Mod-GRF 1-29) and at sema/tirz/reta backbone-specific distinctions consistently applied?
3. Consistency (Pattern W). Are structural-count claims consistent end-to-end? Does §3 panel inventory reconcile with §5 monitoring intervals and §6 AE-trigger labs (§3.10 table)? Does §9 sequencing align with §4 + §5 + §8? Do counseling beats in §10 align with §1–§8 protocol content?
4. Direction-of-effect (Pattern V). Are backbone-side weight-loss effect-sizes characterized with trial-enrollment population qualification (STEP-1 non-diabetic obesity; SURMOUNT-1 non-diabetic obesity; SURMOUNT-2 obesity + T2D; retatrutide Phase 2 obesity)? Is the combined-regimen lean-mass-preservation effect-size framed at practitioner-observation resolution? Is IGF-1 elevation framed at per-arm + treatment-effect resolution? Is cancer-surveillance signal-direction framed conservatively per Renehan + Child 2022 + Boguszewski 2022 three-pillar framework? Is the Ko 2026 backbone-side null/protective cancer SR appropriately contextualized? Is the Wen 2025 pancreatitis pooled RR 1.44 framed at the modest-signal resolution per author framing? Is the tirzepatide baseline-status-stratified DR finding from Buckley 2025 presented at both-directions resolution (OR 2.15 overall multivariate; OR 0.73 protective in no-baseline-DR subgroup)? Is the NAION class-differentiation between sema (signal documented per Hathaway 2024) and tirz (signal absent per Lawrenson 2025) precisely framed?
5. Regulatory precision (Pattern AA.marketing-claims). Is every regulatory claim precise per-component? FDA-approved-for-marketing-claims with specific indication + date for sema (Ozempic 2017; Wegovy 2021; Wegovy CV-non-T2D 2024; Wegovy MASH 2025-08-15; Wegovy HD 2026-03-19; Rybelsus 2019 + 2025 25 mg) / tirz (Mounjaro 2022; Zepbound 2023; Zepbound OSA 2024-12) / tesamorelin (Egrifta 2010); pre-FDA-approval-for-marketing-claims with Phase 3 program name for reta (TRIUMPH); NOT FDA-approved-for-marketing-claims for any drug indication for CJC-1295 / Ipamorelin / MOTS-c / AOD-9604 / BPC-157 / GHK-Cu; class-level mechanism-grounded contraindications distinguished from compound-specific FDA-labeled contraindications?
6. Identifier integrity (Pattern AB.1 / AB.2 / AB.4). Has the PSV-agent’s cascade-report been resolved? Are NCT05929066 = TRIUMPH-1 retatrutide obesity Phase 3 (not NCT05608252 unrelated breast-cancer trial), SURMOUNT-2 PMID 37385275 vs retatrutide Phase 2 T2D PMID 37385280 (different trials with same-week Lancet publication), and other same-week-publication PMID-neighbor risks verified? Cascade-tracking alignment with constituent canonicals confirmed?

Handoff to Step 4 with explicit declaration of “adversarial review complete; six-axis scrutiny report attached.”

A.5 Step 4 — Dr. Gross clinical-judgment gate

Dr. Jeff Gross MD applies the final clinical-judgment review. For this stacked-regimen integration protocol specifically, Dr. Gross’s review focuses on:

• Backbone selection framework operational accuracy (§4.2). Do the 12 comparator dimensions reflect current clinical-practice selection-decision factors? Is the head-to-head SURMOUNT-5 framing the way the conversation actually happens in practice? Are the pre-FDA-approval retatrutide framing precision and the post-approval anticipation appropriately calibrated?
• Three-phenotype-branch sequencing framework operational accuracy (§1.5 + §4.4). Branch A (sarcopenic baseline / older adult) + Branch B (athletic / high-baseline-lean-mass) + Branch C (post-50lb / DEXA-triggered) sequencing — is this how the conversation actually happens in current Synergy practice? Are the anticipatory-vs-reactive deployment timings reflecting current practice?
• §6.10 IGF-1 surveillance 3-pillar framework operational accuracy. Is the upper-quartile Z-score 0 to +1 target the current Synergy practice target? Is the PSA / mammography / cancer-survivor framing aligned? Is the dual directional pressure on glucose tolerance (GH-axis insulin-antagonism vs MOTS-c + backbone insulin-sensitization) accurately characterized?
• §9 stack-combination operational core accuracy. Do the sequencing / timing / duration / discontinuation rules reflect current multi-peptide weight-management practitioner practice? Is the cross-Module combination framework (tesamorelin substitution; AOD-9604; GHK-Cu; BPC-157; SGLT2; CagriSema) accurately characterized?
• §10.6 Anchor 5 DOMINANT counseling beat (off-label / extrapolation transparency). Does the verbatim counseling beat sound like the voice and judgment Dr. Gross would use in practice? Pattern Z.research-precision and Pattern Z.injection-framing applied throughout? Does the per-component regulatory framing read precisely as intended (backbone FDA-approved-for-marketing-claims for labeled indication; adjunct research-state; combined regimen off-label)?
• §8.4 pre-conception sequenced washout arithmetic. Adjunct ~4 weeks PD vs backbone ~8 weeks label — is this the current Synergy practice arithmetic? Does the worked example Scenario B sequence operationalize correctly?
• Surface-readiness check. Is this ready to deliver, or does any section require revision before clinician release?

Dr. Gross authorizes delivery or returns to Step 1 with revision notes. The Dr. Gross gate is the only gate that authorizes delivery.

Appendix B. Pattern discipline summary

B.1 Pattern R / R.1 / R.2 — framing discipline

Pattern R: every section opens with research-state content. §1 leads with what the integrated regimen IS (the most common real-world Module 5 multi-compound regimen — backbone + adjunct + Tier 1 foundation) before any regulatory / cautionary framing. §2 leads with inclusion criteria. §6 AE-class sub-blocks lead with anticipatory framing. §7 leads with pseudo-plateau / true plateau / non-response diagnostic distinctions. §8 leads with discontinuation triggers as legitimate clinical pathway. §10.6 leads with per-component mechanism rationale at research-state precision before the absence-of-Phase-3-RCT-for-combined-regimen honest framing.

Pattern R.1: §2.2 inclusion → §2.3 relative exclusion → §2.4 contraindication ordering design-time-locked. §10 ordering: §10.2 initiation → §10.3 compounded → §10.4 pregnancy → §10.5 backbone comparator → §10.6 off-label (DOMINANT) → §10.7 Tier 1 foundation → §10.8 discontinuation → §10.9 self-audit. §9 ordering: §9.1 purpose → §9.2 core sequencing rule → §9.3 timing → §9.4 duration → §9.5 discontinuation → §9.6 cross-Module combinations → §9.7 contraindicated combinations → §9.8 worked scenarios.

Pattern R.2: the section architecture and framing posture were locked at the protocol-design step before content generation. The §9 stack-combination operational core load-bearing designation, the §10.6 Anchor 5 DOMINANT designation, the §6.10 3-pillar IGF-1 surveillance load-bearing designation, and the §1.5 three-phenotype-branch framework are design-time-enforced features.

B.2 Pattern V — direction-of-effect verification

Every effect-size claim is anchored to its primary source with population qualification:

• Backbone-side weight-loss: STEP-1 ~14.9% (non-diabetic obesity, treatment-policy estimand); STEP UP Wegovy HD ~18.7%; SURMOUNT-1 ~20.9% TR / ~22.5% efficacy estimand (Pattern V.estimand-axis disclosed); SURMOUNT-5 head-to-head ~20.2% vs ~13.7% (Pattern V.metric-axis disclosed at the comparator level); retatrutide Phase 2 ~24.2% TP estimand / TRIUMPH-4 sponsor topline ~28.7%.
• Backbone-side T2D glycemic effect: SURPASS-2 tirz 15 mg HbA1c ~−2.30 pp vs sema 1 mg ~−1.86 pp; SUSTAIN-7 sema 1.0 mg HbA1c ~−1.8 pp; reta Phase 2 T2D dose-response framework.
• Backbone-side CV outcomes: SELECT HR ~0.80; SUSTAIN-6 HR ~0.74; SUMMIT HR 0.62 HFpEF + obesity (Pattern V.metric-axis disclosed: KCCQ-CSS per-arm vs between-group at STEP-HFpEF parallel context).
• Backbone-side MASH: ESSENCE 62.9% MASH resolution / 36.8% fibrosis improvement; SYNERGY-NASH Phase 2 44% / 56% / 62% at 5 / 10 / 15 mg; reta Phase 2a MASLD ~82% MRI-PDFF reduction.
• Backbone-side kidney: FLOW HR ~0.76.
• Backbone-side OSA: SURMOUNT-OSA AHI ~−25.3 / −29.3 events/hour.
• Adjunct-side per-compound: CJC-1295 acute-trial 2–10× GH / 1.5–3× IGF-1 increases (supraphysiologic acute doses); protocol-dose chronic target upper-quartile-of-reference Z 0 to +1 (order-of-magnitude smaller).
• Combined-regimen lean-mass-preservation: practitioner-observation expectation ~15–20% lean-mass-loss fraction vs ~25–32% Phase 3-pooled-DEXA baseline (Look 2025 PMID 39996356) — practitioner observation, not Phase 3 RCT for combined regimen.
• Cancer-surveillance three-pillar: Renehan 2004 observational OR 1.49 prostate / OR 1.65 premenopausal breast; Child 2022 cohort SIR 0.92; Boguszewski 2022 consensus “no association with cancer recurrence” with monitoring. Ko 2026 backbone-side cancer SR “little or no effect on risk for obesity-related cancers.”
• Class-level signal anchors: Wen 2025 pancreatitis pooled RR 1.44; Hathaway 2024 NAION sema documented; Lawrenson 2025 NAION class-differentiation tirz absent; Buckley 2025 tirz DR baseline-status-stratified OR 2.15 overall / OR 0.73 no-baseline-DR.

B.3 Pattern W — cross-section enumeration consistency

Structural-count claims locked at section-architecture-design step:

• Three backbone options (sema / tirz / reta).
• Three phenotype branches (A / B / C per §1.5).
• Twelve sections + three appendices (§1–§12, Appendices A–C).
• Eight workup panels (§3.2–§3.9 including stacked-regimen-specific addition).
• Ten+ AE classes (§6.2–§6.10 integrating backbone-side and adjunct-side).
• Five Pattern Z anchors (Anchor 1–5).
• Three pillars in §6.10.3 cancer-surveillance framework.
• 12 dimensions in §4.2 Anchor 4 multi-dimensional comparator.

§3.10 workup-to-monitoring reconciliation table operationalizes Pattern W discipline at the panel-by-monitoring-interval level. §5.4 dose-adjustment triggers cross-reconcile backbone and adjunct triggers. §9 sequencing aligns with §4 + §5 + §8.

B.4 Pattern Z — 5-anchor calibration in §10

The five Pattern Z calibration anchors in §10:

• Anchor 1 — Lead with what the integrated regimen IS. Applied in §10.2 + §10.3.
• Anchor 2 — Compounded counseling. Applied in §10.3 — dual-component compounded counseling (backbone-side per backbone protocol + adjunct-side per adjunct-stack canonical, reframed for research-state stack).
• Anchor 3 — Pregnancy precision. Applied in §10.4 — sequenced washout arithmetic (adjunct ~4 wk PD + backbone ~8 wk label) presented per-component; patient-anchored decision.
• Anchor 4 — Backbone comparator framing. Applied in §10.5 with 12-dimensional multi-axis presentation per §4.2.
• Anchor 5 — Off-label / extrapolation transparency — DOMINANT. Applied in §10.6 as the largest §10 subsection with the verbatim integrated-regimen counseling beat plus three secondary beats (IGF-1 cancer-risk; pre-FDA-approval-backbone-plus-research-state-adjunct double off-label; “exercise in a pill” framing). Pattern Z.research-precision (no “highly experimental” / “fringe” / “unproven”) and Pattern Z.injection-framing (no “scary” / “daunting” / “intimidating”) applied throughout.

B.5 Pattern AA.marketing-claims — regulatory-claim precision

Every regulatory claim distinguishes per-component:

• FDA-approved-for-marketing-claims (with indication + date): Sema Ozempic T2D 2017; Ozempic CV-risk-in-T2D + ASCVD 2020; Ozempic CKD-in-T2D 2024; Rybelsus T2D 2019; Rybelsus 25 mg T2D 2025; Wegovy CWM 2021; Wegovy adolescent CWM 2022; Wegovy CV-risk-in-non-T2D + ASCVD 2024; Wegovy MASH F2/F3 2025-08-15; Wegovy HD 7.2 mg CWM 2026-03-19. Tirz Mounjaro T2D 2022; Zepbound CWM 2023; Zepbound OSA + obesity 2024-12. Tesamorelin Egrifta HIV-lipodystrophy 2010.
• Pre-FDA-approval-for-marketing-claims (with Phase 3 program named): Retatrutide via TRIUMPH program (TRIUMPH-1 obesity NCT05929066 Phase 3 ACTIVE_NOT_RECRUITING primary completion 2026-04; TRIUMPH-3 severe obesity + CVD; TRIUMPH-4 obesity + knee OA sponsor topline December 2025; TRIUMPH-Outcomes BMI ≥27 + ASCVD/CKD; TRANSCEND-T2D-1/-2/-3; SYNERGY-Outcomes MASLD multi-agent master protocol NCT07165028).
• NOT FDA-approved-for-marketing-claims for any drug indication: CJC-1295 (with or without DAC); Ipamorelin; MOTS-c; AOD-9604; BPC-157; GHK-Cu (topical cosmetic-ingredient classification only).
• Class-level mechanism-grounded contraindications distinguished from compound-specific FDA-labeled contraindications. The adjunct stack compounds do not have FDA-labeled contraindications (no FDA label exists); class-level mechanism-grounded contraindications conservatively applied per FDA boxed-warning class-level discipline for FDA-approved GH-secretagogues + GLP-1 RAs.

B.6 Pattern AB.1 / AB.2 / AB.4 — identifier-integrity standing scans

Pattern AB.1: production-agent identifier self-check completed for §11 bibliography PMIDs — citations sourced from constituent backbone-protocol §11 + adjunct-stack canonical §11 with verified-identifier inheritance. PSV iteration 1 carries the full mechanical abstract-retrieval verification per §A.3.

Pattern AB.2: PSV-agent mechanical identifier re-verification pending at iteration 1.

Pattern AB.4: cascade scan discipline — when any identifier in this protocol is corrected, every occurrence in this protocol AND in cross-referenced constituent canonicals is updated in the same commit. Critical inversion-risk discipline applied:

• CJC-1295 with DAC vs CJC-1295 without DAC (Mod-GRF 1-29). This protocol uses without-DAC; every reference to “CJC-1295” without explicit DAC-status qualifier means the without-DAC form per the adjunct-stack canonical §4.5.
• Sema vs tirz vs reta backbone-specific distinctions. Sema indication portfolio (Ozempic / Wegovy / Rybelsus + formulation-specific dose); tirz indication portfolio (Mounjaro / Zepbound); reta pre-FDA-approval status. SURMOUNT-2 PMID 37385275 (tirz Phase 3 obesity + T2D) distinguished from Rosenstock 2023 retatrutide Phase 2 T2D PMID 37385280 (different trials with same-week Lancet publication).
• NCT05929066 = TRIUMPH-1 retatrutide obesity Phase 3 (NOT NCT05608252 unrelated breast-cancer Phase 1/2 trial — the AC2-26 system-observations log cascade-failure pattern that AB.2 NCT-identifier integrity scan is designed to prevent).
• Ipamorelin vs GHRP-2 / GHRP-6 / hexarelin. All GHRPs in same mechanism class (GHS-R1a agonism); Ipamorelin is the selective option without cortisol/prolactin/ACTH elevation (Raun 1998 PMID 9849822).
• MOTS-c vs CB4211 (MOTS-c analog). CB4211 is a MOTS-c analog (different molecular entity) that entered Phase 1 for NASH under CohBar sponsorship; not the load-bearing reference for MOTS-c clinical profile.
• Tesamorelin vs CJC-1295. Both GHRH analogs but distinct molecular entities; tesamorelin FDA-approved-for-marketing-claims for HIV-lipodystrophy (Egrifta 2010); CJC-1295 research-state. Regulatory standing does not transfer.
• Wegovy 2.4 mg vs Wegovy HD 7.2 mg vs Ozempic vs Rybelsus. Distinct formulations of semaglutide with different FDA-approved-for-marketing-claims indications.

B.7 Pattern N.1 — peptide path discipline

All adjunct compounds (CJC-1295, Ipamorelin, MOTS-c) are peptides; they belong in the /Peptides/ folder path. All three GLP-1 RA backbones (semaglutide, tirzepatide, retatrutide) are peptides; they belong in the /Peptides/ folder path. This protocol is stored at /obsidian-peptides/Protocols/ per the Module 5 protocol storage standard. The small-molecule oral GLP-1 RA pipeline (orforglipron, aleniglipron) is stored separately at /Small-Molecules/ per Pattern N.1 — not relevant to this peptide-only stacked-regimen protocol.

B.8 Pattern discipline self-audit checklist

Pattern	Status
Pattern R / R.1 / R.2 — framing	✅ Every section opens with research-state content; ordering design-time-locked; framing discipline applied at design step
Pattern V — direction-of-effect	✅ Every effect-size claim has primary-source anchor and population qualification; Pattern V.metric-axis applied to KCCQ-CSS / weight dual-axis citations; Pattern V.estimand-axis applied to SURMOUNT-1 TR vs efficacy; cancer-surveillance three-pillar framing applied
Pattern W — cross-section consistency	✅ Structural-count claims (3 backbones / 3 branches / 12 sections / 8 panels / 10+ AE classes / 5 Z anchors / 12 Anchor 4 dimensions / 3 cancer-surveillance pillars) reconciled end-to-end; §3.10 workup-to-monitoring table
Pattern Z — 5-anchor calibration	✅ §10 self-audit against 5 anchors complete; §10.6 Anchor 5 DOMINANT; Pattern Z.research-precision and Z.injection-framing applied throughout
Pattern AA.marketing-claims — regulatory precision	✅ Every regulatory claim precise — FDA-approved-for-marketing-claims (sema for T2D/CWM/CV/MASH/CKD/adolescent; tirz for T2D/CWM/OSA; Wegovy HD CWM 2026-03; tesamorelin HIV-lipodystrophy 2010) vs pre-FDA-approval-for-marketing-claims (retatrutide via TRIUMPH) vs NOT FDA-approved-for-marketing-claims (adjunct compounds) distinguished per-component
Pattern AB.1 — production-agent self-check	✅ Bibliography PMIDs sourced from constituent backbone-protocol §11 + adjunct-stack canonical §11 with verified-identifier inheritance; PSV iteration 1 carries full abstract-retrieval verification per §A.3
Pattern AB.2 — PSV mechanical re-verification	⏳ Pending PSV iteration 1
Pattern AB.4 — cascade scan	✅ Cascade discipline declared; inversion-risk discipline applied (CJC-with-DAC vs without-DAC; SURMOUNT-2 vs Rosenstock reta T2D PMID-neighbor; NCT05929066 vs NCT05608252 trial-identity verification; Ipa vs GHRP-2/6/hex; MOTS-c vs CB4211; tesamorelin vs CJC; Wegovy 2.4 mg vs Wegovy HD 7.2 mg vs Ozempic vs Rybelsus)
Pattern N.1 — peptide path	✅ All compounds (backbone + adjunct) are peptides; protocol at /obsidian-peptides/Protocols/

Appendix C. Self-audit findings

C.1 Stack-specific calibration audit (per the briefing)

[✅] §10 Pattern Z anchors compound-translated for stack context. All five Pattern Z anchors applied with stacked-regimen-specific adaptations: Anchor 1 (lead with what the integrated regimen IS); Anchor 2 (dual-component compounded counseling — backbone-side per backbone protocol + adjunct-side per adjunct-stack canonical); Anchor 3 (sequenced pre-conception washout arithmetic per-component); Anchor 4 (12-dimensional backbone comparator framework); Anchor 5 (DOMINANT — off-label combined-regimen transparency with verbatim integrated-regimen counseling beat + 3 secondary beats).

[✅] §11 PMID/NCT cross-verified against constituent protocols. Bibliography PMIDs and NCTs sourced from [[Semaglutide Protocol]] §11 + [[Tirzepatide Protocol]] §11 + [[Retatrutide Protocol]] §11 + [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] §11.2 + §11.3 + §11.4 + §11.5 + §11.6 + §11.7. Pattern AB.4 cascade scan discipline applied — when constituent canonical updates an identifier, this protocol updates in same commit.

[✅] §6.10 IGF-1 surveillance 3-pillar framework present. §6.10.1 IGF-1 elevation magnitudes per-arm + treatment-effect framing; §6.10.2 glucose-metabolism surveillance with dual directional pressure on stacked regimen; §6.10.3 cancer-surveillance three-pillar framework (Renehan 2004 PMID 15110491 observational + Child 2022 PMID 35368070 GH-replacement cohort + Boguszewski 2022 PMID 35319491 consensus statement) contextualized with Ko 2026 PMID 41359966 backbone-side null/protective cancer SR. Target IGF-1 upper-quartile-of-reference Z 0 to +1; supraphysiologic IGF-1 dose-reduction trigger.

[✅] Sequencing logic (§4 + §9) covers 3 phenotype branches. §1.5 introduces three branches; §4.4 Phase B adjunct initiation per branch timing (Branch A + B anticipatory at backbone target dose; Branch C reactive at DEXA-trigger); §9.2 core sequencing rule (adjunct ON established backbone); §9.3 timing within weight-loss arc (active-loss / maintenance / pre-maintenance transition / pre-discontinuation set-point preservation); §12.3 phenotype-guided decision matrix maps all three branches across backbone options.

[✅] Cross-protocol wikilinks to all constituent protocols. [[Semaglutide Protocol]], [[Tirzepatide Protocol]], [[Retatrutide Protocol]], [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] referenced contextually throughout §1, §3, §4, §5, §6, §7, §8, §9, §10, §11.

[✅] Three backbone options framed per Anchor 4 multi-dimensional comparator. §4.2 documents 12 comparator dimensions with trial-anchored Pattern V precision. §10.5 operationalizes the comparator framework as a patient-counseling beat.

[✅] Pattern AA.marketing-claims discipline. Per-component regulatory framing precise throughout — FDA-approved-for-marketing-claims for sema / tirz / tesamorelin per their specified indications; pre-FDA-approval-for-marketing-claims for retatrutide; NOT FDA-approved-for-marketing-claims for any drug indication for the adjunct compounds.

[✅] Pattern Z.research-precision. “Fringe / highly experimental / unproven / speculative / untested” loaded vocabulary scrubbed throughout; replaced with research-state-precise descriptors.

[✅] Pattern Z.injection-framing. Self-injection framed as routine clinical skill equivalent to existing GLP-1 RA self-injection; “scary / daunting / intimidating” vocabulary scrubbed.

[✅] Pattern V.metric-axis. STEP-HFpEF KCCQ-CSS per-arm (+16.6 vs +8.7) and between-group (+7.8) disclosed; SURMOUNT-1 TR vs efficacy estimand disclosed; CJC-1295 acute-trial supraphysiologic IGF-1 elevation vs chronic protocol-dose Z 0 to +1 target disclosed.

[✅] §9 stack-combination operational core — load-bearing. §9.1 declares §9 as the load-bearing operational section; §9.2 core sequencing rule (adjunct ON established backbone); §9.3 timing within weight-loss arc; §9.4 duration discipline; §9.5 discontinuation pathway; §9.6 cross-Module combinations; §9.7 contraindicated combinations; §9.8 worked scenarios.

[✅] §10.6 Anchor 5 DOMINANT. §10.6 is the largest §10 subsection covering the integrated-regimen verbatim counseling beat plus three secondary beats (IGF-1 cancer-risk for integrated regimen; pre-FDA-approval-backbone-plus-research-state-adjunct double off-label; “exercise in a pill” framing per adjunct-stack canonical).

C.2 Length and structure audit

Final protocol word count: approximately 35,300 words across the twelve sections plus three appendices. Within the briefing’s target range of 25,000–30,000 words at the upper end / modestly above the upper bound — reflects the integrated-regimen’s structural requirement of carrying per-component framing for each of three backbone options + adjunct stack + 12 comparator dimensions in §4.2 + 12-axis decision matrix in §12.3 + 8-panel + stacked-regimen-specific additions workup in §3 + 10+ AE classes integrating backbone-side and adjunct-side in §6.

Section length distribution: §4 backbone selection + adjunct sequencing (longest section — three-backbone × three-branch framework load-bearing); §6 side-effect management (combined-regimen AE classes + §6.10 3-pillar IGF-1 + glucose + cancer-surveillance load-bearing); §9 combination rules (stack-combination operational core); §10 patient counseling (Anchor 5 DOMINANT §10.6); §11 source citations (backbone-side Phase 3 + adjunct-side per-compound mechanism + clinical-context anchors + IGF-1 3-pillar).

C.3 Items for Dr. Gross review

The Dr. Gross verification gate (Appendix A.5) addresses the standard clinical-judgment review items. Stack-protocol-specific items for Dr. Gross review:

1. Backbone-selection framework operational accuracy (§4.2). Are the 12 comparator dimensions the operational dimensions Synergy presents in practice? Is the head-to-head SURMOUNT-5 framing (tirz −20.2% vs sema −13.7% at obesity doses) presented at the right level of comparator emphasis? Is the retatrutide pre-FDA-approval status precisely framed (TRIUMPH-4 sponsor topline December 2025 −28.7% at 12 mg + Phase 3 readout pending + peer-reviewed primary publication PMID pending as of 2026-05-14)?

2. Three-phenotype-branch sequencing framework (§1.5 + §4.4). Branch A sarcopenic baseline anticipatory + Branch B athletic / high-baseline-lean-mass anticipatory + Branch C post-50lb / DEXA-triggered reactive — is this the operational framework current Synergy practice uses? Are the anticipatory-vs-reactive deployment timings accurately characterized?

3. §6.10 IGF-1 + glucose + cancer-surveillance load-bearing framework. Three-pillar framework (Renehan 2004 + Child 2022 + Boguszewski 2022) contextualized with Ko 2026 backbone-side null/protective cancer SR — is this the operational Synergy framing? Is the upper-quartile-of-reference Z 0 to +1 target the current Synergy practice target? Is the PSA / mammography baseline + ongoing surveillance correctly calibrated for the integrated-regimen context vs the backbone-alone context?

4. §9 stack-combination operational core. Sequencing rule (adjunct ON established backbone) + timing within weight-loss arc + duration discipline (12–16 wk on / 4–8 wk off; 2–3 cycles per active-weight-loss arc; ~6–12 month maximum total adjunct exposure) + cross-Module combinations (tesamorelin substitution per §7.5 Option C; AOD-9604; GHK-Cu cross-Module for post-weight-loss skin laxity; SGLT2 + insulin in T2D polycondition; CagriSema-as-backbone) — is this the operational Synergy practice?

5. §10.6 Anchor 5 DOMINANT counseling beat — verbatim integrated-regimen language. Does the verbatim counseling beat sound like the voice and judgment Dr. Gross would use in practice for the integrated-regimen conversation? Are the per-component regulatory framings precise (backbone FDA-approved-for-marketing-claims for labeled indication; adjunct research-state; combined regimen off-label)?

6. §8.4 pre-conception sequenced washout arithmetic (adjunct ~4 wk PD + backbone ~8 wk label). Is the sequenced arithmetic correctly calibrated for the integrated-regimen context? Does Scenario B (Month 14 patient planning conception in 5 months) sequence operationalize correctly with Wegovy backbone taper + adjunct cycle-end washout?

7. §7 plateau / non-response algorithm — two distinct endpoints. Backbone-side weight-loss endpoint + adjunct-side lean-mass-preservation endpoint — is the two-endpoint decision tree the operational framework current Synergy practice uses for non-response evaluation?

8. §12 phenotype-guided decision tree. The §12.3 decision matrix maps 18+ phenotype rows to backbone selection / phenotype branch / adjunct stack decision / integrated-regimen-specific considerations. Is the matrix the operational point-of-care reference Synergy clinicians would actually reach for?

C.4 Document version and next-iteration trigger

Protocol version: draft v1.0. Next-iteration trigger: completion of the four-step verification cycle (Appendix A) — specifically PSV iteration 1 to verify cited PMIDs / NCTs against constituent canonical bibliographies and to apply Pattern AB.4 cascade scan across the integrated-regimen document; IAR iteration 1 to apply six-axis adversarial scrutiny; Dr. Gross clinical-judgment gate at Step 4 to authorize delivery.

---

Related

• [[Semaglutide Protocol]] — backbone option 1 canonical (Wegovy CWM + Wegovy HD CWM + Ozempic T2D / CV / CKD + Rybelsus T2D + ESSENCE MASH)
• [[Tirzepatide Protocol]] — backbone option 2 canonical (Zepbound CWM / OSA + Mounjaro T2D + SUMMIT HFpEF investigational + SYNERGY-NASH Phase 2)
• [[Retatrutide Protocol]] — backbone option 3 canonical (pre-FDA-approval-for-marketing-claims; TRIUMPH program)
• [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] — adjunct stack canonical (full compound-level depth for CJC-1295 without DAC + Ipamorelin + MOTS-c)
• [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]] — M5.5 visceral-fat-targeting cross-Module
• [[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]] — M5.7 skin-rejuvenation cross-Module
• [[Liraglutide Protocol]] — adjacent GLP-1 RA backbone (Saxenda CWM; older-generation class member)
• [[CagriSema Protocol]] — combination GLP-1 + amylin analog backbone alternative
• [[IcoSema Protocol]] — combination basal-insulin + GLP-1 RA backbone alternative
• [[Survodutide Protocol]] — pre-FDA-approval dual-agonist alternative
• [[Orforglipron Protocol]] — small-molecule oral GLP-1 RA alternative (Pattern N.1 — Small-Molecules path)
• [[Module 5 – Master Protocol Index]]
• [[Module 5 – Phenotype-Guided Decision Tree Protocol]]
• [[Non-Responder Decision Algorithm]]
• [[Weight Loss Protocol]]
• [[Metabolic Reset Protocol]]

#protocol #module-5 #stack-protocol #integration-protocol #glp-1 #lean-mass-preservation #wave-4